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Motor Neuron Disease (MND) continues to be a progressive loss of structure and 
function of neurons in the cerebral cortex, brainstem, and the spinal cord. Usually 
the loss of specific functions precedes the death of affected neurons, and the related 
clinical features depend on localization and degree of neurodegeneration. Amyotrophic 
Lateral Sclerosis (ALS) is the more common clinical presentation and MND is also 
related to mitochondrial dysfunctions, increased oxidative stress and atypical protein 
assemblies. MND continues to be a serious health problem leading to death in few years’ 
times in most of the patients. Before death, patients suffer from weakness or paralysis, 
muscle wasting and fasciculation, dysphagia, dysarthria and several complications. 
There are two forms of this fatal disease: sporadic, with no known genetic component, 
and familial, which makes up about 5% of all ALS cases. Among the familial cases, 
approximately 20% are caused by dominantly inherited mutations in the Cu/Zn 
superoxide dismutase (SOD1) gene, with more than 100 known mutations.
This is the second book that we have edited on ALS/MND. To edit this book, we have 
provided the best, safest, most confident and novel science information to our readers 
after following a rigorous process. All chapters were screened and analysed by a strict 
peer-review process, followed by corrections made by authors and the Academic Editor. 
Then a second revision was made by authors and editors performed the final review. It 
is important to highlight that after the peer-review process, all chapters were reviewed 
twice or even more to be accepted for publication. The chapter written by the Editor was 
also screened by another peer-review team.
In this book, the readers will find a compilation of state-of-the-art reviews about 
aetiology, therapies, investigations, the molecular basis of disease progression and 
clinical manifestations, and the genetics familial ALS, as well as novel diagnostic criteria.
An update aspect on ALS sourced 5 chapters from some of the world’s top central 
nervous system researchers and neurologists to provide a timely review of the latest 
developments in MND/ALS, covering experimental animal models, genetics, clinical 
aspects and treatment options, amongst others.
Contributors from different countries have collaborated enthusiastically and efficiently 
to create this reader-friendly and comprehensive work covering the topics with many 
explanatory figures, tables and photos to enhance legibility and make the book clinically 
useful. Countless hours have gone into writing these chapters, precious free time to be 
dedicated to our family, relatives and friends have been sacrificed but at the end, we all 
are very proud of this book.
Every effort has been made to check the novel information given in this book but it is 
important for our readers to scrutinize other information arriving considering it is a 
dynamic process for learning. We all attempted to include valuable updated information 
for all issues mentioned in this book. Every effort has been made in the preparation and 
editing of this book to ensure that the information given is correct, but it is possible that 
errors have been overlooked. Finally, we would like to highlight that we reviewed all 
controversial matters and our medical criteria and scientist’s opinions have been expressed 
with modesty, honesty and respect but the reader is advised to refer to other published 
information from other editorial houses and other reference works to check accuracy.
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Introduction to Novel Aspects on 
Motor Neuron Disease
Humberto Foyaca Sibat and Lourdes de Fátima Ibañez Valdés
1. Introduction
Motor neuron disease (MND) represents a wide and heterogeneous expanding 
group of diseases affecting the upper or lower motor neurons, mainly represented 
by amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive 
muscular atrophy (PMA), and progressive bulbar palsy. ALS is a disease of motor 
neuron degeneration in the cerebral hemisphere, brainstem, and spinal cord with a 
fatal prognosis in most of the cases due to a progressive paralysis of the diaphragm 
and other respiratory muscles leading to respiratory dysfunction and failure. 
Another recently recognized hallmark of ALS pathogenesis is vascular pathology 
apart from central nervous system capillary injury and microvascular impairment 
outside of the CNS [1].
2. Comments
Our first chapter is about stem cell therapy as a novel and promising modality 
for the treatment of ALS/MND. Robust safety profiles, low risk to benefit ratio, 
and ease of access make this approach a strong contender in the race against ALS/
MND. Our authors concluded that this procedure is not a curative treatment, but 
a combinatorial approach integrating stem cell therapy, intensive neurorehabilita-
tion, and current pharmacotherapeutic agents (e.g., Riluzole, Lithium, etc.) may be 
the best way forward. This chapter was written early last year (2019), but unfor-
tunately, a prolonged editorial process impeded to publish this information at due 
time. However, we reviewed the medical literature and found that the abovemen-
tioned information has been confirmed recently (March 2020) by other authors [2].
In this book, we discussed about the pathogenic contribution of a subtype of 
aberrant glial phenotype into the progression and output of the neurodegenerative 
disease ALS and concluded that aberrant astrocytes or more generally aberrant 
glial cells are among the most important players in CNS damage causing deleterious 
effects through many potential pathological mechanisms, mostly sustained on their 
exacerbated proliferation together with their unprecedented neurotoxicity suggest 
that controlling these populations seems at least equally important than mainte-
nance or restoration of homeostatic astrocyte functions to achieve CNS protection 
and repair. Another authors also suggest that aberrant glial cells (AbGC) isolated 
from the spinal cords of adult paralytic SOD1G93A rats exhibit highly proliferative 
and neurotoxic properties and may contribute to disease progression [4]. Same 
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be reduced by dichloroacetate (DCA), a metabolic modulator that has been used in 
humans, show beneficial effects on disease outcome in SOD1G93A mice. They also 
highlight that DCA treatment of AbGC reduced extracellular lactate levels indi-
cating that the main recognized DCA action targets the pyruvate dehydrogenase 
kinase/pyruvate dehydrogenase complex, and the results confirmed that AbGC 
metabolic phenotype is related to their toxicity to MNs and indicated that its modu-
lation can reduce glial mediated pathology in the spinal cord [3]. At this point, it is 
important to emphasize that neuronal cell death is the main pathological feature of 
chronic neurodegenerative diseases (NDs) like ALS. A common hallmark of several 
NDs is the accumulation and aggregation of proteins; such proteins are thought to 
be primarily turned over by autophagy. Therefore, autophagy is considered a critical 
ND-protective pathway, which opens up potential new therapeutic interventions, 
and some authors have been considering the roles of autophagy and its contribution 
to neurodegeneration in neurons and concluded that little is known about the func-
tions and disease contribution of the autophagy machinery in glia cells [4].
The next chapter of this book is related to the structural and functional con-
sequences of the SMA-linked missense mutations of the survival motor neuron 
protein, where the authors deliver a brief update of the structural and functional 
consequences of the missense mutations of this SMA protein. There is another 
before published chapter where the same author investigates how SMA-linked 
mutations of SMN1 lead to structural/functional deficiency of SMN, and a set of 
computational analysis of SMN-related structures was conducted, described, and 
highlighted three residues of SMN (Asp44, Glu134, and Gln136), and the electro-
static basis of how the SMA-linked missense mutations of the three residues cause 
structural/functional deficiency of SMN and also a possibility of SMN’s Lys45 and 
Asp36 acting as two electrostatically stabilizing clips at the SMN-Gemin2 complex 
structure interface [5].
Mutations to the gene encoding superoxide dismutase-1 (SOD1) were the first 
genetic elements discovered that cause motor neuron disease (MND). Around 10 
years back, the unique way to test ALS-related gene was SOD1 sequencing. Based 
on this postulate, we approved to include into this project a novel review about 
the current understanding of ALS-related genes, summarize the worldwide ALS 
distribution feature by frequency of occurrence in different regions, and outline the 
genetic testing consideration, within many advances in the field of ALS genetics. In 
this chapter, the author highlights the recent advances in ALS gene map, genome-
wide association study on ALS, genetic testing, and gene therapy.
Finally, we made a bibliography research about MND and the most recent 
advances on treatment and reviewed the most relevant papers published on the 
first trimester of 2019, but as was before-mentioned, this chapter is going to be 
published more than 1 year later when some of our information is already old-
fashioned. Last year, we reviewed on novel information about edaravone, riluzole 
(already approved by Food and Drug Administration), nusinersen, EH301, 
5Fluoroucil, Tryptophan, RNS60, Rasagiline, Tirasemtiv, Aquaporin, Fasudil, 
and Lunasil. In order to deliver to our reader community, more novel information 
about MND/ALS is important to highlight other procedure that has been proposed 
for treatment such as the multifaceted role of kinases in ALS. The comprehensive 
regulation of kinases, however, a better understanding of the disturbances in the 
kinome network in ALS, is needed to properly target specific kinases in the clinic. 
Different kinases have been recently involved in TDP-43 phosphorylation. Among 
these, protein casein kinase-1 is the first kinase identified to phosphorylate TDP-43 
in vivo, followed by tau tubulin kinase 1 and cell division cycle kinase 7. Currently, it 
is recognized that TDP-43 proteinopathy characterized by truncation, ubiquitina-
tion, hyperphosphorylation, and/or nuclear depletion in neurons is the prominent 
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and common pathological feature of sporadic and familiar ALS [6]. Some authors 
explored the effects of a chronic treatment with the compound IGS-2.7 in the TDP-
43 (A315T) transgenic mouse model and found a significant decrease in the levels of 
phosphorylation of TDP-43 in sporadic ALS lymphoblast, while no differences were 
observed in control group, and they arrived to the following conclusion: prolonged 
treatment with IGS-2.7 prevents the phosphorylation of TDP-43 in vivo in the cord 
of TDP-43 transgenic mice, being this effect associated with an attenuation of 
most of the events that reflect the worsening of the pathological phenotype, then 
the inhibition of CK-1δ with the benzothiazole derivative IGS-2.7 may modulate 
TDP-43 toxicity in vivo by limiting TDP-43 phosphorylation, which could explain 
the benefits obtained with this drug candidate in the preservation of spinal motor 
neurons. Therefore, benzothiazole IGS-2.7 has neuroprotective properties and not 
only decreases TDP-43 phosphorylation in cells derived from ALS patients but also 
corrects the subcellular localization of TDP-43, preventing the abnormal cytosolic 
TDP-43 accumulation in ALS lymphoblasts [6].
For another hand, other authors reported that 185 miRNAs in serum of 
affected patients and controls confirmed a downregulation of miR-335-5p in ALS 
patients [7].
Because we are under obligation to deliver the most recent information about 
MND/ALS therapy to our reader’s community, then we would like to comment 
about clinically used ebselen and related analogues to promote thermal stabil-
ity of A4V SOD1 when binding to Cys111 only [8]. Ebselen is an organoselenium 
compound with activity similar to glutathione peroxidase [9]. Several studies have 
demonstrated the neuroprotective activity of ebselen, possibly via its anti-oxidant 
properties [10, 11]. The capacity of ebselen to decrease mitochondrial cellular toxic-
ity caused by mutant SOD1 confirmed that this compound plays an important role 
in alleviating familial ALS [12].
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and common pathological feature of sporadic and familiar ALS [6]. Some authors 
explored the effects of a chronic treatment with the compound IGS-2.7 in the TDP-
43 (A315T) transgenic mouse model and found a significant decrease in the levels of 
phosphorylation of TDP-43 in sporadic ALS lymphoblast, while no differences were 
observed in control group, and they arrived to the following conclusion: prolonged 
treatment with IGS-2.7 prevents the phosphorylation of TDP-43 in vivo in the cord 
of TDP-43 transgenic mice, being this effect associated with an attenuation of 
most of the events that reflect the worsening of the pathological phenotype, then 
the inhibition of CK-1δ with the benzothiazole derivative IGS-2.7 may modulate 
TDP-43 toxicity in vivo by limiting TDP-43 phosphorylation, which could explain 
the benefits obtained with this drug candidate in the preservation of spinal motor 
neurons. Therefore, benzothiazole IGS-2.7 has neuroprotective properties and not 
only decreases TDP-43 phosphorylation in cells derived from ALS patients but also 
corrects the subcellular localization of TDP-43, preventing the abnormal cytosolic 
TDP-43 accumulation in ALS lymphoblasts [6].
For another hand, other authors reported that 185 miRNAs in serum of 
affected patients and controls confirmed a downregulation of miR-335-5p in ALS 
patients [7].
Because we are under obligation to deliver the most recent information about 
MND/ALS therapy to our reader’s community, then we would like to comment 
about clinically used ebselen and related analogues to promote thermal stabil-
ity of A4V SOD1 when binding to Cys111 only [8]. Ebselen is an organoselenium 
compound with activity similar to glutathione peroxidase [9]. Several studies have 
demonstrated the neuroprotective activity of ebselen, possibly via its anti-oxidant 
properties [10, 11]. The capacity of ebselen to decrease mitochondrial cellular toxic-
ity caused by mutant SOD1 confirmed that this compound plays an important role 
in alleviating familial ALS [12].
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Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable paralyzing disease character-
ized by motor neuron death and glial reactivity. Superoxide dismutase 1 (SOD1) are 
among the most frequent alterations found in around 15–20% of ALS inheritable 
forms. Mutant SOD1 murine models mimic main human ALS features and allow 
purposing that pathological mechanisms include defective communication between 
neural cells together with astrocyte preponderant roles in disease progression. Years 
ago, a subset of the most neurotoxic aberrant astrocytes (AbAs) was obtained from 
spinal cords of SOD1G93A rats. AbA cultures show an exponential growing yield 
since the early symptoms of the disease up to the terminal stages. In cultures, AbAs 
present unprecedented toxicity to motor neurons, increased proliferation, loss of 
mature astrocyte markers, as well as extreme ER stress and abundant extracellular 
matrix components. Strikingly, AbA phenotype seems to be changing along few 
passages suggesting its signaling and features may accompany disease progression. 
However, the link between main AbA features and their highest motor neuron 
toxicity is not yet completely understood. Here, we reviewed ALS underlying 
pathological mechanisms in association to AbA phenotype, to collaborate with 
identification of the most relevant processes that seem crucially involved in the 
triggering or maintenance of neurotoxicity.
Keywords: aberrant astrocytes, motor neuron death, non-cell autonomous disease
1. Introduction
This chapter will discuss the pathogenic contribution of a subtype of aberrant 
glial phenotype into the progression and output of the neurodegenerative disease 
amyotrophic lateral sclerosis (ALS). Complete understanding of neuronal and 
glial cells roles and communication is necessary to unravel disease processes and 
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1. Introduction
This chapter will discuss the pathogenic contribution of a subtype of aberrant 
glial phenotype into the progression and output of the neurodegenerative disease 
amyotrophic lateral sclerosis (ALS). Complete understanding of neuronal and 
glial cells roles and communication is necessary to unravel disease processes and 
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mechanisms. This will further allow the improvement of more focused therapeutic 
interventions aimed at reducing disease severity and positively impact on diagnosis, 
therapeutic management, and patients’ care.
2. ALS
ALS is an adult onset neurodegenerative disease characterized by progressive loss 
of spinal, brain stem, and cortical motor neurons, leading to fatal paralysis within 
1–5 years since the onset of symptoms that include tremor, muscle weakness, and 
spasticity [1–3]. ALS affects up to 2:100,000 persons per year; has a life risk around 
1:500–1:1000; and exhibits a little predominance of men over women affected [4]. 
Although ALS is a sporadic multifactorial disease resulting from yet unknown inter-
actions among environment, genes, and epigenetic modifications, genetics seemed 
to be the predominant factor for the risk of developing the disease [5], and more 
than 10% of ALS patients are linked to inheritable genetic abnormalities. Dominant 
mutations in the mitochondrial enzyme Cu/Zn superoxide dismutase-1 (SOD1) seem 
responsible for up to 1% of the total ALS cases and about 20% of the familial types 
[4, 6, 7]. Missense mutations in the 43 kDa transactive response DNA/RNA-binding 
protein (TDP-43) [8] and in fused in sarcoma/translocated in liposarcoma (FUS/
TLS) accounted each one for up to 5% of dominantly inherited familial ALS cases 
[9, 10]. Mutations in the open reading frame 72 on chromosome 9 (C9ORF72) that 
results in up to thousands of G4C2 hexanucleotide repeats in one allele are found in 
up to 40 and 7% of the ALS familial and sporadic cases, respectively [11]. There are 
other genes involved in ALS familial subtypes, but its contribution to the disease 
is significantly lower in terms of the affected individual number. Regarding to the 
pathological pathways linking genetic abnormalities to ALS, SOD1 mutations seem to 
be related to neuronal damage because of abnormal protein folding causes unstable 
conformations, intracellular inclusion bodies or toxic oligomers, as well as pathologi-
cal interactions with several proteins [3]. TDP-43 and FUS/TLS mutations are linked 
to altered RNA processing, transport, and quality control; whereas, G4C2 repeats 
might sequestrate RNA-binding proteins impairing the regulation of the RNA targets 
[12, 13] or causing epigenetic changes that decreased C9ORF72 expression [14, 15]. 
However, up to now, it is not completely understood how single mutations in one 
protein could elicit the ALS pathological cascades and how these cascades may finally 
cause a common neuropathological hallmark that is characterized by aggregation 
and accumulation of neuronal proteinaceous inclusions that in addition, are found in 
other neurodegenerative conditions including Alzheimer disease.
2.1 Animal models and non-cell autonomous mechanisms in ALS
To understand the different pathological mechanisms involved in ALS, many 
experimental models from yeast to rodents have been developed. Whereas, models 
in lower animals are powerful genetic tools and offer advantages related to short 
life span and easy handling, distance with mammal nervous systems constitute 
major limitations when studying human neurodegeneration [16, 17]. Mice and rats 
are closer to human brain anatomy and complexity, but are not good genetic tools 
and their lifespan makes necessary the over-expression of mutant human proteins 
several-fold times to mimic the disease [4], causing the risk that the number of 
copies over-expressed influence the model by itself. In spite of this, animal models 
appear as the best approaches to study ALS patho-mechanisms, at least until the 
employment of inducible pluripotent cells obtained from human patients becomes a 
well-known and controlled technology.
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The first successful ALS models, yet under current extensive use, were devel-
oped over-expressing different single mutations of human SOD1 (SOD1G93A, 
SOD1G37R, and SOD1G85R) in mice or rats [18–20]. Most of the models that 
overexpress SOD1 present an age-dependent progressive motor syndrome that 
mimics some pathological features of the human disease [4, 20]. In addition, it 
seems that pathological features elicited do not derive from the loss of SOD1 cata-
lytic activity but from a yet unknown gain-of-function [4, 20]. Among the highest 
contributions of murine SOD1 models to the ALS knowledge is the introduction 
of the non-cell autonomous mechanism concept in which the exclusive neuronal 
presence of mutant SOD1 did not cause motor neuron death. This implies that 
motor neuron disease results from the involvement of at least two different cell 
types. Therefore, a defective cell-cell communication between motor neurons and 
surrounding glial cells seems actively participating in motor neuron death through 
not completely understood mechanisms. Pioneer works made in LoxSOD1G37R/
GFAP-Cre+ mice [21] or specifically excising the mutant SOD1 transgene from dif-
ferent glial cell types in mice [22, 23] showed that astrocytes [21] and microglial 
cells [22] play active roles in ALS progression. In support of the non-cell autono-
mous mechanisms in SOD1 models, reactive astrocytes obtained from transgenic 
rats or mice [24–26], and from patients of sporadic and familial motor neuron 
diseases [27, 28] caused neurotoxicity to motor neurons even in cases in which 
SOD1 is not involved [28].
Other ALS models in rodents were not as clear as those over-expressing 
mutated SOD1. Transgenic animals expressing mutations of TDP-43-, FUS/TLS-, 
or C9ORF72-linked ALS produced controversial results without a clear associa-
tion between each mutation and motor neuron disease, in spite of having motor 
neuron damage, proteinaceous inclusions, and astrogliosis [29, 30]. Despite these 
drawbacks, ALS models valuably contribute to make the concept that disruption at 
systemic, cellular, and molecular levels likely result in many different interacting 
mechanisms and multiple factors, and that a particular combination of factors and 
mechanisms likely determine the singularity of each case thus explains the hetero-
geneity of the human disease.
3. Contribution of aberrant glial phenotypes to ALS pathogenesis
SOD1 models support the concept of ALS as a non-cell autonomous disease 
in which the reactive astrocyte phenotypes that are produced in the injuring 
environment greatly contribute to motor neuron death. Astrocytes are the most 
abundant glial cells in the mammal brain and those responsible for the main-
tenance of CNS homeostasis [31–34]. During injury, CNS homeostasis is lost 
and astrocytes respond in a process usually called astrogliosis, in which cells 
became reactive, highly proliferative and with morphological and functional 
changes that usually result in decreased protection together with activation of 
injuring cascades to neurons and oligodendrocytes, further affecting the whole 
CNS [31–37]. Depending on the injury type and context, astrocyte response can 
become chronic causing a long lasting state characterized by glial scar, structural 
tissue rearrangement and impeded repair, as well as a permanent imbalance 
among homeostatic supportive and gain of neurotoxic functions, all potentially 
participating in the triggering and progression of several neurological diseases 
[3, 31–35, 37, 38]. Remarkably, astrocytes also contribute to maintain astrogliosis 
through autocrine and paracrine signaling [35, 38, 39], thus causing a positive 
feedback that widespread reactivity and dependent injuring cascades perpetuat-
ing CNS damage.
Novel Aspects on Motor Neuron Disease
8
mechanisms. This will further allow the improvement of more focused therapeutic 
interventions aimed at reducing disease severity and positively impact on diagnosis, 
therapeutic management, and patients’ care.
2. ALS
ALS is an adult onset neurodegenerative disease characterized by progressive loss 
of spinal, brain stem, and cortical motor neurons, leading to fatal paralysis within 
1–5 years since the onset of symptoms that include tremor, muscle weakness, and 
spasticity [1–3]. ALS affects up to 2:100,000 persons per year; has a life risk around 
1:500–1:1000; and exhibits a little predominance of men over women affected [4]. 
Although ALS is a sporadic multifactorial disease resulting from yet unknown inter-
actions among environment, genes, and epigenetic modifications, genetics seemed 
to be the predominant factor for the risk of developing the disease [5], and more 
than 10% of ALS patients are linked to inheritable genetic abnormalities. Dominant 
mutations in the mitochondrial enzyme Cu/Zn superoxide dismutase-1 (SOD1) seem 
responsible for up to 1% of the total ALS cases and about 20% of the familial types 
[4, 6, 7]. Missense mutations in the 43 kDa transactive response DNA/RNA-binding 
protein (TDP-43) [8] and in fused in sarcoma/translocated in liposarcoma (FUS/
TLS) accounted each one for up to 5% of dominantly inherited familial ALS cases 
[9, 10]. Mutations in the open reading frame 72 on chromosome 9 (C9ORF72) that 
results in up to thousands of G4C2 hexanucleotide repeats in one allele are found in 
up to 40 and 7% of the ALS familial and sporadic cases, respectively [11]. There are 
other genes involved in ALS familial subtypes, but its contribution to the disease 
is significantly lower in terms of the affected individual number. Regarding to the 
pathological pathways linking genetic abnormalities to ALS, SOD1 mutations seem to 
be related to neuronal damage because of abnormal protein folding causes unstable 
conformations, intracellular inclusion bodies or toxic oligomers, as well as pathologi-
cal interactions with several proteins [3]. TDP-43 and FUS/TLS mutations are linked 
to altered RNA processing, transport, and quality control; whereas, G4C2 repeats 
might sequestrate RNA-binding proteins impairing the regulation of the RNA targets 
[12, 13] or causing epigenetic changes that decreased C9ORF72 expression [14, 15]. 
However, up to now, it is not completely understood how single mutations in one 
protein could elicit the ALS pathological cascades and how these cascades may finally 
cause a common neuropathological hallmark that is characterized by aggregation 
and accumulation of neuronal proteinaceous inclusions that in addition, are found in 
other neurodegenerative conditions including Alzheimer disease.
2.1 Animal models and non-cell autonomous mechanisms in ALS
To understand the different pathological mechanisms involved in ALS, many 
experimental models from yeast to rodents have been developed. Whereas, models 
in lower animals are powerful genetic tools and offer advantages related to short 
life span and easy handling, distance with mammal nervous systems constitute 
major limitations when studying human neurodegeneration [16, 17]. Mice and rats 
are closer to human brain anatomy and complexity, but are not good genetic tools 
and their lifespan makes necessary the over-expression of mutant human proteins 
several-fold times to mimic the disease [4], causing the risk that the number of 
copies over-expressed influence the model by itself. In spite of this, animal models 
appear as the best approaches to study ALS patho-mechanisms, at least until the 
employment of inducible pluripotent cells obtained from human patients becomes a 
well-known and controlled technology.
9
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
The first successful ALS models, yet under current extensive use, were devel-
oped over-expressing different single mutations of human SOD1 (SOD1G93A, 
SOD1G37R, and SOD1G85R) in mice or rats [18–20]. Most of the models that 
overexpress SOD1 present an age-dependent progressive motor syndrome that 
mimics some pathological features of the human disease [4, 20]. In addition, it 
seems that pathological features elicited do not derive from the loss of SOD1 cata-
lytic activity but from a yet unknown gain-of-function [4, 20]. Among the highest 
contributions of murine SOD1 models to the ALS knowledge is the introduction 
of the non-cell autonomous mechanism concept in which the exclusive neuronal 
presence of mutant SOD1 did not cause motor neuron death. This implies that 
motor neuron disease results from the involvement of at least two different cell 
types. Therefore, a defective cell-cell communication between motor neurons and 
surrounding glial cells seems actively participating in motor neuron death through 
not completely understood mechanisms. Pioneer works made in LoxSOD1G37R/
GFAP-Cre+ mice [21] or specifically excising the mutant SOD1 transgene from dif-
ferent glial cell types in mice [22, 23] showed that astrocytes [21] and microglial 
cells [22] play active roles in ALS progression. In support of the non-cell autono-
mous mechanisms in SOD1 models, reactive astrocytes obtained from transgenic 
rats or mice [24–26], and from patients of sporadic and familial motor neuron 
diseases [27, 28] caused neurotoxicity to motor neurons even in cases in which 
SOD1 is not involved [28].
Other ALS models in rodents were not as clear as those over-expressing 
mutated SOD1. Transgenic animals expressing mutations of TDP-43-, FUS/TLS-, 
or C9ORF72-linked ALS produced controversial results without a clear associa-
tion between each mutation and motor neuron disease, in spite of having motor 
neuron damage, proteinaceous inclusions, and astrogliosis [29, 30]. Despite these 
drawbacks, ALS models valuably contribute to make the concept that disruption at 
systemic, cellular, and molecular levels likely result in many different interacting 
mechanisms and multiple factors, and that a particular combination of factors and 
mechanisms likely determine the singularity of each case thus explains the hetero-
geneity of the human disease.
3. Contribution of aberrant glial phenotypes to ALS pathogenesis
SOD1 models support the concept of ALS as a non-cell autonomous disease 
in which the reactive astrocyte phenotypes that are produced in the injuring 
environment greatly contribute to motor neuron death. Astrocytes are the most 
abundant glial cells in the mammal brain and those responsible for the main-
tenance of CNS homeostasis [31–34]. During injury, CNS homeostasis is lost 
and astrocytes respond in a process usually called astrogliosis, in which cells 
became reactive, highly proliferative and with morphological and functional 
changes that usually result in decreased protection together with activation of 
injuring cascades to neurons and oligodendrocytes, further affecting the whole 
CNS [31–37]. Depending on the injury type and context, astrocyte response can 
become chronic causing a long lasting state characterized by glial scar, structural 
tissue rearrangement and impeded repair, as well as a permanent imbalance 
among homeostatic supportive and gain of neurotoxic functions, all potentially 
participating in the triggering and progression of several neurological diseases 
[3, 31–35, 37, 38]. Remarkably, astrocytes also contribute to maintain astrogliosis 
through autocrine and paracrine signaling [35, 38, 39], thus causing a positive 
feedback that widespread reactivity and dependent injuring cascades perpetuat-
ing CNS damage.
Novel Aspects on Motor Neuron Disease
10
A striking question that remained unanswered until recently was to know 
if all of the astrocytes that share the same injuring environment respond in the 
same way or if some of them adopt the worse aberrant phenotypes that account 
for most of the neurotoxic effects. Trying to unravel this question, when we 
were studying spinal cord astrocyte phenotypes along the symptomatic phase 
of the rat SOD1G93A ALS experimental model, we isolated a novel type of aber-
rant astrocyte-like cells (AbAs) from the spinal cord of paralytic animals whose 
number exponentially increased toward the terminal stages of the disease [40]. 
AbAs proliferated faster than astrocytes from neonates or adult wild-type rats and 
were exceptionally toxic to embryonic motor neurons grown in culture, sug-
gesting a link between their emergence and progression of the paralysis that is a 
characteristic in the SOD1G93A ALS rat model. Moreover, AbAs did not express 
distinctive markers that clearly allow distinguishing from typical astrocytes; but 
present peculiar functional and ultrastructural features that suggest a distinctive 
phenotype. Among the most remarkable features that AbAs possess, Jiménez-
Riani et al. [41] describe their permanent absence of contact inhibition that 
allowed them to grow in multiple layers and arrange in 3D-cell aggregates that 
adopt a helicoidal pattern with a central core of extracellular matrix surrounded 
by cells. In addition, AbAs cytoskeleton does not have intermediate filaments but 
a significant abundance of microtubules and mitochondria, and ER stress have a 
restricted perinuclear location suggesting disturbed organelle trafficking that may 
be associated to alteration in microtubule network or Golgi fragmentation [42]. 
Furthermore, mitochondria from AbAs are small, electron dense matrix and with 
few crests; all, comparable to what was described early in models and human ALS 
[43, 44]. AbAs also have prominent ER with extremely swollen cisternae, some of 
them degenerating, and express high levels of some ER stress markers [45–47], as 
well as abundant lipid droplets close to ER and to mitochondria. Their cytoplasm 
is enriched in diverse vesicles with abundant signs of secretion including extracel-
lular vesicles that can be distinguished by MET and SEM in cultures as well as 
expression of protein that marks secretion granules [41, 48, 49]. AbAs are also 
highly positive to the autophagy marker LC3B [50] and present cells’ autophagic 
vesicles and residual bodies [51, 52], likely showing signs of increased autophagy 
that may allow cells coping with ER stress by favoring the clearance of misfolded 
proteins [53].
Recently, we confirmed that AbAs were not isolated from the cervical spinal 
cord of paralytic animals. Instead, the cultures obtained from the cervical spinal 
cord were similar to the age-matched wild type non-transgenic rats, sharing a 
low rate of proliferation and resembling a phagocytic microglia morphology that 
persists throughout the cell culture. Similarities also include low survival along few 
passages together with absence of complete phenotypic transition to flat cells like 
astrocytes (Figure 1). Therefore, AbAs might result as a local lumbar response to 
damage, acting similar to astrocytes when react stereotypically depending on injury 
type, location, and signaling [32].
In addition, we have found that some AbAs critical features are changing 
during few passages, as occurring with their most prominent markers S100β and 
glial glutamate transporter GLT1. Meanwhile, there were no evident morpho-
logical differences between low (LP) (~4–7) and high passages (HP) (~14–18) 
(Figure 2A), since cultured AbAs proliferated without replicative senescence, 
S100β expression levels decreased ≅98% (Figure 2B), suggesting that this aberrant 
phenotype may exhibit some plasticity along time. S100β is a well-known danger-
associated molecular pattern (DAMP) which downstream trigger the transcription 
of nuclear factor NFKB that further may elicit increased expression and release of 
pro- inflammatory cytokines [54, 55]. Given that S100β appears to integrate AbAs 
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cytoskeletal elements, we cannot discard that S100β downregulated expression may 
cause cytoskeleton instability, a characteristic that is linked to exacerbated prolif-
erative capacity as found in AbAs [56]. Thus, decreasing S100β might constitute a 
reinforcing proliferation feedback that may underlie AbAs invasive properties as 
disease progressed. We have also found that GLT1 expression levels also decreased 
strongly along AbAs passages (≅94%, Figure 2B), worsening its poor expression 
which can also aggravated excitotoxic damage [31].
Concurrence of all of the features makes AbAs a unique aberrant phenotype 
with unprecedented neurotoxicity, which may rely in the yet unknown combina-
tion of ER stress, lipid droplet accumulation, abundant extracellular matrix, 
secretory granules, and exacerbated proliferation. Likely, all these events causing 
the active production of proteinaceous or lipidic soluble factors that act by itself 
or reinforce the defective cell-contact properties produced by loss of contact 
inhibition [41].
Figure 1. 
Morphological appearance of AbAs throughout the cell culture. Light microscopy examination of cells isolated 
from symptomatic cervical and lumbar spinal cord of transgenic (Tg cervical SC and Tg lumbar SC) or 
age-matched non-transgenic animals (No Tg lumbar SC) at 48 h, 5 days and 2 weeks after dissection. Note that 
AbA cells are recovered only from the lumbar spinal cord of transgenic animals whereas the cultures obtained 
from the cervical spinal cord of the same animals have similar characteristics to the age-matched wild type non-
transgenic rats. Adherent cell population is heterogenous with very bright cells that resemble microglial cells and 
others elongated similar to astrocytes. Scale bar = 150 μm (first line) and 100 μm (second and third lines).
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3.1 Mechanisms that might link AbA to ALS pathogenesis
The most important cellular processes implicated in ALS pathophysiology 
include ER stress and protein clearance, neuron-glia metabolic coupling, and 
energy homeostasis [57, 58]. Among their most remarkable features, AbAs 
exhibit a hardly coping extreme ER stress, as well as lipid droplets and disturbed 
mitochondrial morphology and trafficking [41]. ER stress is produced by the 
lack of balance between protein synthesis, folding, and degradation rates [59]. 
To recover ER homeostasis, cells activate the unfolded protein response (UPR) 
that orchestrates pro-adaptive and pro-death cellular responses that include 
protein synthesis decrease except for the effectors that mediates UPR [59–61]. 
ER stress’s final outcome depends on stress duration, strength, and cell targets, 
and if not resolved, it becomes chronic and as one of the earliest perturbations in 
several neurodegenerative diseases [59]. Interestingly, ER stress is present in ALS 
Figure 2. 
Morphology and gene expression in AbAs at low and high cell passages. A. Representative light microscopy 
images of low (LP, left) and high (HP, right) passage cells from transgenic lumbar spinal cords showing their 
distinctive appearance of flatted elongated cells that appear very similar to astrocytes. Note the low number 
of bright microglial-like cells. Scale bar = 100 μm. B. Gene expression analysis in AbA cell cultures showing a 
down-regulation of S100β (left) and glutamate transporter GLT1 (right) in HP cells compared with LP cells 
(control). The expression levels for each gene were obtained by SYBR green qPCR and normalized to the actin 
transcripts. Data represent the mean ± the standard deviation for each group.
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experimental models, and is described as a predominant mechanism underlying 
motor neuron death in patients from sporadic and familial cases [46, 59, 62–66]. 
Furthermore, active UPR in AbAs may down regulate the expression of peptides 
and proteins that collaborate with neuron survival such as the most important 
cellular antioxidant defense glutathione or neurotrophins [3, 32]. Thus, although 
ER stress in AbAs did not cause their own death, it is highly probable that it affects 
neuron and oligodendrocyte survival in view of their high dependence on astro-
cyte support.
In close relationship with ER stress, AbAs are also much enriched in lipid drop-
lets that appear near to mitochondria or ER cisternae [41]. Lipid droplets originate 
from the ER and are described as having a role in ER stress and clearance of protein 
aggregates as well as in energy homeostasis [67]. Protein turnover is critical for 
ALS because a number of mutations linked to ALS affect genes directly involved in 
protein clearance and homeostasis [58]. Lipid droplets appear associated with some 
of these proteins into the cytoplasm or the nucleus [67, 68], where they appear close 
and likely associated with the nuclear-naked organelles that control transcriptional 
activity, cell senescence, and protein degradation named as promyelocytic leukemia 
nuclear bodies [67, 69, 70], which in addition are found in cell nuclei of ALS patient 
brains co-localizing with ubiquitin and proteasome components in nuclear inclu-
sions [71].
In brain, lipid droplets are found mainly in glial cells and help to provide 
fuel for neurons when energy is needed and glucose is scarce. At this time, lipid 
droplets turned over by cytoplasmic lipases and autophagy, providing fatty 
acid fuel for ATP production [67], thus playing a crucial role in the anaplerotic 
support [72]. However, overabundance of lipid droplets as seen in AbAs may 
suggest a disrupted lipid metabolism in which lipid droplets may not be digested 
thus decreasing the energy intermediate shuttle to neurons, which can influence 
motor neuron survival through limited anaplerosis. Lipidic dysfunction could 
also indirectly impact motor neuron survival as shown in mice over-expressing 
TDP-43, that beside displaying neurological symptoms and motor deficits, also 
present increased fat accumulation and adipocyte hypertrophy [73]. Conversely, 
TDP-43 depletion causes body fat reduction, increased fatty acid consumption, 
and rapid death [74], likely, because TDP-43 depletion blocks insulin-induced 
trafficking of glucose transporter Glut4 to the plasma membrane thus impairing 
glucose uptake and inducing a metabolic switch toward lipids for energy produc-
tion. This has also been reported in SOD1 mouse models in which spinal cord 
neurons display decreased glucose usage [75], and a fat-rich diet restores body 
mass, delays disease onset, and extends life expectancy [57]. Moreover, excessive 
accumulation of lipid droplets in glial cells is a hallmark in many models of neu-
rodegeneration, and it is usually linked to mitochondrial dysfunction and disease 
progression [72, 76, 77]. It also seemed enough to promote neurodegeneration by 
itself [76], therefore indicating that overabundance of lipid droplets in AbAs may 
have dual functions: for one side not only helping to the clearance of abnormal 
proteins, but also impairing anaplerotic support to neurons or even having direct 
neurotoxicity.
AbAs also show evidences of a high secretory activity, which also is described 
as being crucial to ALS neuronal damage. Although secretory granules seem a 
conserved protective response to conserve energy and allow recovery under stress 
conditions, sustained secretory activity of stress granules seems crucial to ALS 
pathogenesis [78]. Moreover, it has been demonstrated that chromogranins inter-
act and co-localize with mutated misfolded SOD1 [79]; and can eventually act as 
chaperones to promote secretion of SOD1 mutants that once released may trigger 
microgliosis and neuronal death [79].
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Absence of contact inhibition and exacerbated proliferation are other of the 
relevant features related to AbAs neurotoxic capacity. Contact inhibition that 
occurs when dividing normal cells contact adjacent ones is crucial to maintain 
tissue homeostasis [80, 81], thus constituting an important anticancer mechanism 
which lack unleashes cells to proliferate virtually unchecked. Although underly-
ing mechanisms are mostly unknown, cell contact inhibition seems to occur when 
injury disrupts intercellular contacts achieving a proliferative status leading to 
an aggressive state associated with neoplasia [82] and malignant transformation 
[81]. Thus, AbAs, absence of contact inhibition seemed directly related to their 
exacerbated proliferation and invasive behavior during the final stages of the 
disease. In addition, abundance of EM components secreted by AbA cells may 
create a non- permissive microenvironment that potentiates invasive behavior apart 
from having a direct neurotoxic influence to motor neurons, as described in ALS 
astrocytes [83–85]. No one of each proposed mechanisms seem enough to explain 
AbAs unprecedented neurotoxicity. Instead, it likely results from the concurrence 
of many pathological pathways. However, it is also possible that one or two underly-
ing mechanisms prevail over the rest and elicit most of AbAs deleterious effects. 
Identification of these prevalent mechanisms will be a valuable aid to design the 
best ALS treatment (Table 1 and Figure 3).
(i) Absence of contact inhibition
• Invasive phenotype [40, 41]
• Lack of replicative senescence [40, 86]
• Exacerbated proliferation [40, 86, 87]
(ii) Immature phenotype
• Lack of gliofilaments [40, 41]
• Defective differentiation [40, 41, 88]
(iii) Oxidative and ER stress
• Mitochondrial dysfunction [89, 90]
• Mitochondrial morphological alterations [41]
• Defective oxidative phosphorylation [89, 90]
• Dysfunction in energy homeostasis [24, 89, 91]
• Dilated ER and degenerating ER cisternae [41]
• Elevated expression of ER stress markers [41]
(iv) Altered lipid metabolism
• Abundant lipid droplets close to mitochondria & ER [41]
• Altered anaplerotic support [88]
(v) Intracellular inclusions
• Intranuclear and intramitochondrial deposits [41]
• Abundance of autophagic bodies [41]
(vi) Aberrant signaling
• Extremely neurotoxic conditioned media [40]
• Neurotoxic exosomes [90]
• Abundance of secretory vesicles and secretory body markers [41]
Table 1. 
A summary of AbAs potential pathogenic contribution to the main ALS hallmark. All of ALS main features 
are listened as (i)–(vi) together with each specific AbAs potential participation.
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4. ALS therapeutics focused on aberrant astrocytes
ALS is an old disease with a narrow offer of pharmacological approaches. 
Riluzole, an anti-glutamatergic drug, was the first compound authorized to be used 
in ALS, providing around of 3-month improvement in survival [92]. Recently, FDA 
approved the free radical scavenger edaravone, as the second compound to treat 
ALS, that seemed to have beneficial effects only on patients in an early stages of the 
disease that in addition satisfy a number of restricted criteria. In that population, 
edavarone showed a significantly smaller decline of Revised ALS Functional Rating 
Scale score compared with placebo [93]. A randomized phase III clinical trial that 
tested the effect of the tyrosine kinase inhibitor masitinib in ALS patients showed 
an improving in the functioning of ALS patients, and the combination with riluzole 
caused a delayed disease progression without adverse effects [94]. However, the 
narrow temporal windows that the two compounds approved offer obligates to 
search alternative avenues to treat the disease.
As astrocytes and microglial cells develop both protective and pathological 
functions its pharmacological targeting must be carefully evaluated. However, in 
view of the distinctive phenotype of AbAs, it seems rational to direct therapeutic 
treatments toward the control of this population during disease progression 
and ideally trying to inhibit their emergence during asymptomatic stages. AbAs 
expression of S100β at levels higher than wild type astrocytes may imply that 
they have a role in the amplification of the inflammatory response, therefore new 
anti-inflammatory drugs targeting the production of pro-inflammatory cytokines 
Figure 3. 
AbAs: Cytotoxic effects and pathological events. AbAs present mitochondrial dysfunction associated to 
oxidative stress and ER stress as well as accumulation of lipid droplets, all causing a positive feedback that elicit 
and perpetuate cell damage (red and black arrows). Mitochondrial abnormalities together with cytoskeletal 
alterations are also involved in AbAs exacerbated proliferation and cytoskeleton instability both likely 
underlying the absence of contact inhibition and invasive phenotype as well as S100β-dependent inflammation 
cascades (green and yellow arrows). Progressive loss of the glutamate transporter GLT1 causes decreased 
glutamate uptake becoming neurons more expose to glutamate excitoxicity. Altered signaling and disturbed 
autophagia and proteasome functions caused the release of stress granules and soluble neurotoxins as well as the 
accumulation of cell detritus and inclusion bodies (violet and blue arrows). Finally, the lack of mitochondrial 
potential (represented as Ψ) caused increased glycolysis and deficient anaplerosis that alters the trophic and 
energetic support to neurons and oligodendrocytes (light blue).
Novel Aspects on Motor Neuron Disease
14
Absence of contact inhibition and exacerbated proliferation are other of the 
relevant features related to AbAs neurotoxic capacity. Contact inhibition that 
occurs when dividing normal cells contact adjacent ones is crucial to maintain 
tissue homeostasis [80, 81], thus constituting an important anticancer mechanism 
which lack unleashes cells to proliferate virtually unchecked. Although underly-
ing mechanisms are mostly unknown, cell contact inhibition seems to occur when 
injury disrupts intercellular contacts achieving a proliferative status leading to 
an aggressive state associated with neoplasia [82] and malignant transformation 
[81]. Thus, AbAs, absence of contact inhibition seemed directly related to their 
exacerbated proliferation and invasive behavior during the final stages of the 
disease. In addition, abundance of EM components secreted by AbA cells may 
create a non- permissive microenvironment that potentiates invasive behavior apart 
from having a direct neurotoxic influence to motor neurons, as described in ALS 
astrocytes [83–85]. No one of each proposed mechanisms seem enough to explain 
AbAs unprecedented neurotoxicity. Instead, it likely results from the concurrence 
of many pathological pathways. However, it is also possible that one or two underly-
ing mechanisms prevail over the rest and elicit most of AbAs deleterious effects. 
Identification of these prevalent mechanisms will be a valuable aid to design the 
best ALS treatment (Table 1 and Figure 3).
(i) Absence of contact inhibition
• Invasive phenotype [40, 41]
• Lack of replicative senescence [40, 86]
• Exacerbated proliferation [40, 86, 87]
(ii) Immature phenotype
• Lack of gliofilaments [40, 41]
• Defective differentiation [40, 41, 88]
(iii) Oxidative and ER stress
• Mitochondrial dysfunction [89, 90]
• Mitochondrial morphological alterations [41]
• Defective oxidative phosphorylation [89, 90]
• Dysfunction in energy homeostasis [24, 89, 91]
• Dilated ER and degenerating ER cisternae [41]
• Elevated expression of ER stress markers [41]
(iv) Altered lipid metabolism
• Abundant lipid droplets close to mitochondria & ER [41]
• Altered anaplerotic support [88]
(v) Intracellular inclusions
• Intranuclear and intramitochondrial deposits [41]
• Abundance of autophagic bodies [41]
(vi) Aberrant signaling
• Extremely neurotoxic conditioned media [40]
• Neurotoxic exosomes [90]
• Abundance of secretory vesicles and secretory body markers [41]
Table 1. 
A summary of AbAs potential pathogenic contribution to the main ALS hallmark. All of ALS main features 
are listened as (i)–(vi) together with each specific AbAs potential participation.
15
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
4. ALS therapeutics focused on aberrant astrocytes
ALS is an old disease with a narrow offer of pharmacological approaches. 
Riluzole, an anti-glutamatergic drug, was the first compound authorized to be used 
in ALS, providing around of 3-month improvement in survival [92]. Recently, FDA 
approved the free radical scavenger edaravone, as the second compound to treat 
ALS, that seemed to have beneficial effects only on patients in an early stages of the 
disease that in addition satisfy a number of restricted criteria. In that population, 
edavarone showed a significantly smaller decline of Revised ALS Functional Rating 
Scale score compared with placebo [93]. A randomized phase III clinical trial that 
tested the effect of the tyrosine kinase inhibitor masitinib in ALS patients showed 
an improving in the functioning of ALS patients, and the combination with riluzole 
caused a delayed disease progression without adverse effects [94]. However, the 
narrow temporal windows that the two compounds approved offer obligates to 
search alternative avenues to treat the disease.
As astrocytes and microglial cells develop both protective and pathological 
functions its pharmacological targeting must be carefully evaluated. However, in 
view of the distinctive phenotype of AbAs, it seems rational to direct therapeutic 
treatments toward the control of this population during disease progression 
and ideally trying to inhibit their emergence during asymptomatic stages. AbAs 
expression of S100β at levels higher than wild type astrocytes may imply that 
they have a role in the amplification of the inflammatory response, therefore new 
anti-inflammatory drugs targeting the production of pro-inflammatory cytokines 
Figure 3. 
AbAs: Cytotoxic effects and pathological events. AbAs present mitochondrial dysfunction associated to 
oxidative stress and ER stress as well as accumulation of lipid droplets, all causing a positive feedback that elicit 
and perpetuate cell damage (red and black arrows). Mitochondrial abnormalities together with cytoskeletal 
alterations are also involved in AbAs exacerbated proliferation and cytoskeleton instability both likely 
underlying the absence of contact inhibition and invasive phenotype as well as S100β-dependent inflammation 
cascades (green and yellow arrows). Progressive loss of the glutamate transporter GLT1 causes decreased 
glutamate uptake becoming neurons more expose to glutamate excitoxicity. Altered signaling and disturbed 
autophagia and proteasome functions caused the release of stress granules and soluble neurotoxins as well as the 
accumulation of cell detritus and inclusion bodies (violet and blue arrows). Finally, the lack of mitochondrial 
potential (represented as Ψ) caused increased glycolysis and deficient anaplerosis that alters the trophic and 
energetic support to neurons and oligodendrocytes (light blue).
Novel Aspects on Motor Neuron Disease
16
by a blockade of NFkB activation may have positive results, moreover because 
NFkB is downstream to S100β [54]. For example, FDA has been approved a drug 
called mitoxantrone for multiple sclerosis treatment because it inhibited produc-
tion of IL-12 and IL-23 and suppressed the expression of C-reactive protein by 
astrocytes in culture and LPS induction of NFkB DNA-binding activity in primary 
astrocytes, suggesting a novel mechanism that suppresses the expression of 
astrocytic pro-inflammatory molecules helping to modulate inflammatory diseases 
[95]. However, as AbAs seem to loss S100β at higher passages, neuroprotection by 
targeting this via might be successful only during asymptomatic stages. Targeting 
neuroinflammation, recently, it has been shown that the tyrosine kinase inhibitor 
(masitinib) that is used to control cancer cell proliferation reduced the emergence 
of aberrant glial cells in the degenerating spinal cord of SOD1G93A paralytic rats 
and delay disease progression [87]. Authors proposed that masitinib acts prevent-
ing the appearance of aberrant glial phenotypes, likely through the inhibition of 
CSF-1R kinase which activation potentiates inflammatory phenotypes and glial 
reactivity, and that are particularly effective on proliferating but not on post-
mitotic cells [96]. Furthermore, masitinib also prevented astrocyte-induced motor 
neuron death in cell cultures [97], suggesting that neuroprotection can be achieved 
through different pathways. In accordance, other report has shown that CSF-1R 
blockade with the drug GW2580 administered to ALS mice several weeks before 
paralysis onset decreased both microgliosis and slowed disease progression [98], 
thus opening a wider avenue to treat aberrant glial phenotypes. Finally, although 
molecular genetic techniques devoted to switch genes on or off, or to edit their 
nucleotide sequences, once developed and approved can be effective therapeutic 
tools to the inherited ALS forms, pharmacological approaches directed against 
aberrant glial phenotypes may help to control disease progression in a wider range 
of patients.
5. Conclusions
All data reviewed here suggest that aberrant astrocytes or more generally, 
aberrant glial cells, are among the most important players in CNS damage causing 
deleterious effects through many potential patho-mechanisms, mostly sustained 
on their exacerbated proliferation together with their unprecedented neurotoxic-
ity. Therefore, controlling these populations seems at least equally important than 
maintenance or restoration of homeostatic astrocyte functions to achieve CNS 
protection and repair. Moreover, AbAs seemed a better pharmacological target than 
astrocytes, since therapeutic approaches focused on astrocytes have to be carefully 
tailored taking into account their multiple faces, moreover in the context of neuro-
degeneration where several cell types are involved. Future investigation should aim 
to elucidate if AbAs can indeed be feasible targets to avoid initiation, progression or 
outcome of neurodegeneration.
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by a blockade of NFkB activation may have positive results, moreover because 
NFkB is downstream to S100β [54]. For example, FDA has been approved a drug 
called mitoxantrone for multiple sclerosis treatment because it inhibited produc-
tion of IL-12 and IL-23 and suppressed the expression of C-reactive protein by 
astrocytes in culture and LPS induction of NFkB DNA-binding activity in primary 
astrocytes, suggesting a novel mechanism that suppresses the expression of 
astrocytic pro-inflammatory molecules helping to modulate inflammatory diseases 
[95]. However, as AbAs seem to loss S100β at higher passages, neuroprotection by 
targeting this via might be successful only during asymptomatic stages. Targeting 
neuroinflammation, recently, it has been shown that the tyrosine kinase inhibitor 
(masitinib) that is used to control cancer cell proliferation reduced the emergence 
of aberrant glial cells in the degenerating spinal cord of SOD1G93A paralytic rats 
and delay disease progression [87]. Authors proposed that masitinib acts prevent-
ing the appearance of aberrant glial phenotypes, likely through the inhibition of 
CSF-1R kinase which activation potentiates inflammatory phenotypes and glial 
reactivity, and that are particularly effective on proliferating but not on post-
mitotic cells [96]. Furthermore, masitinib also prevented astrocyte-induced motor 
neuron death in cell cultures [97], suggesting that neuroprotection can be achieved 
through different pathways. In accordance, other report has shown that CSF-1R 
blockade with the drug GW2580 administered to ALS mice several weeks before 
paralysis onset decreased both microgliosis and slowed disease progression [98], 
thus opening a wider avenue to treat aberrant glial phenotypes. Finally, although 
molecular genetic techniques devoted to switch genes on or off, or to edit their 
nucleotide sequences, once developed and approved can be effective therapeutic 
tools to the inherited ALS forms, pharmacological approaches directed against 
aberrant glial phenotypes may help to control disease progression in a wider range 
of patients.
5. Conclusions
All data reviewed here suggest that aberrant astrocytes or more generally, 
aberrant glial cells, are among the most important players in CNS damage causing 
deleterious effects through many potential patho-mechanisms, mostly sustained 
on their exacerbated proliferation together with their unprecedented neurotoxic-
ity. Therefore, controlling these populations seems at least equally important than 
maintenance or restoration of homeostatic astrocyte functions to achieve CNS 
protection and repair. Moreover, AbAs seemed a better pharmacological target than 
astrocytes, since therapeutic approaches focused on astrocytes have to be carefully 
tailored taking into account their multiple faces, moreover in the context of neuro-
degeneration where several cell types are involved. Future investigation should aim 
to elucidate if AbAs can indeed be feasible targets to avoid initiation, progression or 
outcome of neurodegeneration.
Acknowledgements
We thank IIBCE (MEC), PEDECIBA, and UdelaR, URUGUAY.
Conflict of interest
There is no conflict of interest.
17
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
Author details
Gabriel Otero Damianovich1, Olga Cristina Parada2, Pablo Díaz-Amarilla1,  
Eugenia Eloísa Isasi1,2, Carmen Isabel Bolatto Pereira2 and Silvia Olivera-Bravo1*
1 Cell and Molecular Neurobiology, Institute of Biological Research Clemente 
Estable (IIBCE), Montevideo, Uruguay
2 Department of Histology and Embriology, School of Medicine (UdelaR), 
Montevideo, Uruguay
*Address all correspondence to: solivera@iibce.edu.uy
18
Novel Aspects on Motor Neuron Disease
[1] Cleveland DW, Rothstein 
JD. From Charcot to Lou Gehrig: 
Deciphering selective motor neuron 
death in ALS. Nature Reviews 
Neuroscience. 2001;2:806-819. DOI: 
10.1038/35097565
[2] Kiernan MC, Vucic S, Cheah BC, 
Turner MR, Eisen A, Hardiman O, et al. 
Amyotrophic lateral sclerosis. Lancet. 
2011;377(9769):942-955. DOI: 10.1016/
S0140-6736(10)61156-7
[3] Pehar M, Harlan BA, Killoy KM, 
Vargas MR. Role and therapeutic 
potential of astrocytes in amyotrophic 
lateral sclerosis. Current Pharmaceutical 
Design. 2017;23(33):5010-5021. DOI:  
10.2174/1381612823666170622095802
[4] Ilieva H, Maragakis NJ. Motoneuron 
disease: Basic science. In: Beart P, 
Robinson M, Rattray M, Maragakis 
NJ, editors. Advances in Neurobiology 
15; Neurodegenerative Diseases 
Pathology, Mechanisms, and 
Potential Therapeutic Targets. Cham: 
Springer; 2017. pp. 163-190. DOI: 
10.1007/978-3-319-57193-5
[5] Al-Chalabi A, Fang F, Hanby MF, 
Leigh PN, Shaw CE, Ye W, et al. An 
estimate of amyotrophic lateral sclerosis 
heritability using twin data. Journal 
of Neurology, Neurosurgery, and 
Psychiatry. 2010;81(12):1324-1326. DOI: 
10.1136/jnnp.2010.207464
[6] Cudkowicz ME, Warren L, Francis 
JW, Lloyd KJ, Friedlander RM, Borges 
LF, et al. Intrathecal administration 
of recombinant human superoxide 
dismutase 1 in amyotrophic lateral 
sclerosis: A preliminary safety and 
pharmacokinetic study. Neurology. 
1997;49:213-222. DOI: 10.1212/
WNL.49.1.213
[7] Rosen DR. Mutations in Cu/
Zn superoxide dismutase gene are 
associated with familial amyotrophic 
lateral sclerosis. Nature. 1993;364:362. 
DOI: 10.1038/362059a0
[8] Neumann M, Sampathu DM, Kwong 
LK, Truax AC, Micsenyi MC, Chou 
TT, et al. Ubiquitinated TDP-43 in 
frontotemporal lobar degeneration and 
amyotrophic lateral sclerosis. Science. 
2006;314(5796):130-133. DOI: 10.1126/
science.1134108
[9] Kwiatkowski TJ Jr, Bosco DA,  
Leclerc AL, Tamrazian E, Vanderburg 
CR, Russ C, et al. Mutations in the  
FUS/TLS gene on chromosome  
16 cause familial amyotrophic lateral 
sclerosis. Science. 2009;323(5918): 
1205-1208. DOI: 10.1126/science. 
1166066
[10] Vance C, Rogelj B, Hortobágyi T, 
De Vos KJ, Nishimura AL, Sreedharan 
J, et al. Mutations in FUS, an RNA 
processing protein, cause familial 
amyotrophic lateral sclerosis type 6. 
Science. 2009;323(5918):1208-1211. 
DOI: 10.1126/science.1165942
[11] Todd PK, Paulson HL. RNA-
mediated neurodegeneration in 
repeat expansion disorders. Annals of 
Neurology. 2010;67(3):291-300. DOI: 
10.1002/ana.21948
[12] Ling SC, Polymenidou M, Cleveland 
DW. Converging mechanisms in ALS 
and FTD: Disrupted RNA and protein 
homeostasis. Neuron. 2013;79(3): 
416-438. DOI: 10.1016/j.neuron. 
2013.07.033
[13] van Blitterswijk M, DeJesus-
Hernandez M, Rademakers R.  
How do C9ORF72 repeat expansions 
cause amyotrophic lateral sclerosis and 
frontotemporal dementia:  
Can we learn from other noncoding 
repeat expansion disorders? 





Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
[14] Mori K, Weng SM, Arzberger 
T, May S, Rentzsch K, Kremmer E, 
et al. The C9orf72 GGGGCC repeat is 
translated into aggregating dipeptide 
repeat proteins in FTLD/ALS. Science. 
2013;339(6125):1335-1338. DOI: 
10.1126/science.1232927
[15] Ash PE, Bieniek KF, Gendron 
TF, Caulfield T, Lin WL, Dejesus-
Hernandez M, et al. Unconventional 
translation of C9ORF72 GGGGCC 
expansion generates insoluble 
polypeptides specific to c9FTD/
ALS. Neuron. 2013;77(4):639-646. DOI: 
10.1016/j.neuron.2013.02.004
[16] Sulston JE, Horvitz HR. Post-
embryonic cell lineages of the 
nematode, Caenorhabditis 
elegans. Developmental Biology. 
1977;56(1):110-156. DOI: 
10.1016/0012-1606(77)90158-0
[17] Howe K, Clark MD, Torroja CF, 
Torrance J, Berthelot C, Muffato 
M, et al. The zebrafish reference 
genome sequence and its relationship 
to the human genome. Nature. 
2013;496(7446):498-503. DOI: 10.1038/
nature12111
[18] Gurney ME, Pu H, Chiu AY, Dal 
Canto MC, Polchow CY, Alexander 
DD, et al. Motor neuron degeneration 
in mice that express a human Cu, 
Zn superoxide dismutase mutation. 
Science. 1994;264:1772-1775. DOI: 
10.1126/science.8209258
[19] Howland DS, Liu J, She Y, Goad 
B, Maragakis NJ, Kim B, et al. Focal 
loss of the glutamate transporter 
EAAT2 in a transgenic rat model of 
SOD1 mutant-mediated amyotrophic 
lateral sclerosis (ALS). Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2002;99:1604-1609. DOI: 10.1073/
pnas.032539299
[20] Turner BJ, Talbot K. Transgenics, 
toxicity and therapeutics in rodent 
models of mutant SOD1 mediated 
familial ALS. Progress in Neurobiology. 
2008;85:94-134. DOI: 10.1016/j.
pneurobio.2008.01.001
[21] Yamanaka K, Chun SJ, Boillee 
S, Fujimori-Tonou N, Yamashita H, 
Gutmann DH, et al. Astrocytes as 
determinants of disease progression in 
inherited amyotrophic lateral sclerosis. 
Nature Neuroscience. 2008;11(3): 
251-253. DOI: 10.1038/nn2047
[22] Boillée S, Vande Velde C, 
Cleveland DW. ALS: A disease of 
motor neurons and their non neuronal 
neighbors. Neuron. 2006;52:39-59. DOI: 
10.3109/21678421.2013.778548
[23] Ilieva H, Polymenidou M, Cleveland 
DW. Non-cell autonomous toxicity in 
neurodegenerative disorders: ALS and 
beyond. The Journal of Cell Biology. 
2009;187:761-772. DOI: 10.1083/
jcb.200908164
[24] Cassina P, Cassina A, Pehar M, 
Castellanos R, Gandelman M,  
de León A, et al. Mitochondrial 
dysfunction in SOD1G93A-bearing 
astrocytes promotes motor neuron 
degeneration: Prevention by 
mitochondrial-targeted antioxidants. 
The Journal of Neuroscience. 
2008;28:4115-4122. DOI: 10.1523/
JNEUROSCI.5308-07.2008
[25] Di Giorgio FP, Boulting GL, 
Bobrowicz S, Eggan KC. Human 
embryonic stem cell-derived  
motor neurons are sensitive to the 
toxic effect of glial cells carrying an 
ALS-causing mutation. Cell Stem 
Cell. 2008;3:637-648. DOI: 10.1016/j.
stem.2008.09.017
[26] Nagai M, Re DB, Nagata T, 
Chalazonitis A, Jessell TM, Wichterle H, 
et al. Astrocytes expressing ALS-linked 
mutated SOD1 release factors selectively 
toxic to motor neurons. Nature 
Neuroscience. 2007;10:615-622. DOI: 
10.1038/nn1876
18
Novel Aspects on Motor Neuron Disease
[1] Cleveland DW, Rothstein 
JD. From Charcot to Lou Gehrig: 
Deciphering selective motor neuron 
death in ALS. Nature Reviews 
Neuroscience. 2001;2:806-819. DOI: 
10.1038/35097565
[2] Kiernan MC, Vucic S, Cheah BC, 
Turner MR, Eisen A, Hardiman O, et al. 
Amyotrophic lateral sclerosis. Lancet. 
2011;377(9769):942-955. DOI: 10.1016/
S0140-6736(10)61156-7
[3] Pehar M, Harlan BA, Killoy KM, 
Vargas MR. Role and therapeutic 
potential of astrocytes in amyotrophic 
lateral sclerosis. Current Pharmaceutical 
Design. 2017;23(33):5010-5021. DOI:  
10.2174/1381612823666170622095802
[4] Ilieva H, Maragakis NJ. Motoneuron 
disease: Basic science. In: Beart P, 
Robinson M, Rattray M, Maragakis 
NJ, editors. Advances in Neurobiology 
15; Neurodegenerative Diseases 
Pathology, Mechanisms, and 
Potential Therapeutic Targets. Cham: 
Springer; 2017. pp. 163-190. DOI: 
10.1007/978-3-319-57193-5
[5] Al-Chalabi A, Fang F, Hanby MF, 
Leigh PN, Shaw CE, Ye W, et al. An 
estimate of amyotrophic lateral sclerosis 
heritability using twin data. Journal 
of Neurology, Neurosurgery, and 
Psychiatry. 2010;81(12):1324-1326. DOI: 
10.1136/jnnp.2010.207464
[6] Cudkowicz ME, Warren L, Francis 
JW, Lloyd KJ, Friedlander RM, Borges 
LF, et al. Intrathecal administration 
of recombinant human superoxide 
dismutase 1 in amyotrophic lateral 
sclerosis: A preliminary safety and 
pharmacokinetic study. Neurology. 
1997;49:213-222. DOI: 10.1212/
WNL.49.1.213
[7] Rosen DR. Mutations in Cu/
Zn superoxide dismutase gene are 
associated with familial amyotrophic 
lateral sclerosis. Nature. 1993;364:362. 
DOI: 10.1038/362059a0
[8] Neumann M, Sampathu DM, Kwong 
LK, Truax AC, Micsenyi MC, Chou 
TT, et al. Ubiquitinated TDP-43 in 
frontotemporal lobar degeneration and 
amyotrophic lateral sclerosis. Science. 
2006;314(5796):130-133. DOI: 10.1126/
science.1134108
[9] Kwiatkowski TJ Jr, Bosco DA,  
Leclerc AL, Tamrazian E, Vanderburg 
CR, Russ C, et al. Mutations in the  
FUS/TLS gene on chromosome  
16 cause familial amyotrophic lateral 
sclerosis. Science. 2009;323(5918): 
1205-1208. DOI: 10.1126/science. 
1166066
[10] Vance C, Rogelj B, Hortobágyi T, 
De Vos KJ, Nishimura AL, Sreedharan 
J, et al. Mutations in FUS, an RNA 
processing protein, cause familial 
amyotrophic lateral sclerosis type 6. 
Science. 2009;323(5918):1208-1211. 
DOI: 10.1126/science.1165942
[11] Todd PK, Paulson HL. RNA-
mediated neurodegeneration in 
repeat expansion disorders. Annals of 
Neurology. 2010;67(3):291-300. DOI: 
10.1002/ana.21948
[12] Ling SC, Polymenidou M, Cleveland 
DW. Converging mechanisms in ALS 
and FTD: Disrupted RNA and protein 
homeostasis. Neuron. 2013;79(3): 
416-438. DOI: 10.1016/j.neuron. 
2013.07.033
[13] van Blitterswijk M, DeJesus-
Hernandez M, Rademakers R.  
How do C9ORF72 repeat expansions 
cause amyotrophic lateral sclerosis and 
frontotemporal dementia:  
Can we learn from other noncoding 
repeat expansion disorders? 





Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
[14] Mori K, Weng SM, Arzberger 
T, May S, Rentzsch K, Kremmer E, 
et al. The C9orf72 GGGGCC repeat is 
translated into aggregating dipeptide 
repeat proteins in FTLD/ALS. Science. 
2013;339(6125):1335-1338. DOI: 
10.1126/science.1232927
[15] Ash PE, Bieniek KF, Gendron 
TF, Caulfield T, Lin WL, Dejesus-
Hernandez M, et al. Unconventional 
translation of C9ORF72 GGGGCC 
expansion generates insoluble 
polypeptides specific to c9FTD/
ALS. Neuron. 2013;77(4):639-646. DOI: 
10.1016/j.neuron.2013.02.004
[16] Sulston JE, Horvitz HR. Post-
embryonic cell lineages of the 
nematode, Caenorhabditis 
elegans. Developmental Biology. 
1977;56(1):110-156. DOI: 
10.1016/0012-1606(77)90158-0
[17] Howe K, Clark MD, Torroja CF, 
Torrance J, Berthelot C, Muffato 
M, et al. The zebrafish reference 
genome sequence and its relationship 
to the human genome. Nature. 
2013;496(7446):498-503. DOI: 10.1038/
nature12111
[18] Gurney ME, Pu H, Chiu AY, Dal 
Canto MC, Polchow CY, Alexander 
DD, et al. Motor neuron degeneration 
in mice that express a human Cu, 
Zn superoxide dismutase mutation. 
Science. 1994;264:1772-1775. DOI: 
10.1126/science.8209258
[19] Howland DS, Liu J, She Y, Goad 
B, Maragakis NJ, Kim B, et al. Focal 
loss of the glutamate transporter 
EAAT2 in a transgenic rat model of 
SOD1 mutant-mediated amyotrophic 
lateral sclerosis (ALS). Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2002;99:1604-1609. DOI: 10.1073/
pnas.032539299
[20] Turner BJ, Talbot K. Transgenics, 
toxicity and therapeutics in rodent 
models of mutant SOD1 mediated 
familial ALS. Progress in Neurobiology. 
2008;85:94-134. DOI: 10.1016/j.
pneurobio.2008.01.001
[21] Yamanaka K, Chun SJ, Boillee 
S, Fujimori-Tonou N, Yamashita H, 
Gutmann DH, et al. Astrocytes as 
determinants of disease progression in 
inherited amyotrophic lateral sclerosis. 
Nature Neuroscience. 2008;11(3): 
251-253. DOI: 10.1038/nn2047
[22] Boillée S, Vande Velde C, 
Cleveland DW. ALS: A disease of 
motor neurons and their non neuronal 
neighbors. Neuron. 2006;52:39-59. DOI: 
10.3109/21678421.2013.778548
[23] Ilieva H, Polymenidou M, Cleveland 
DW. Non-cell autonomous toxicity in 
neurodegenerative disorders: ALS and 
beyond. The Journal of Cell Biology. 
2009;187:761-772. DOI: 10.1083/
jcb.200908164
[24] Cassina P, Cassina A, Pehar M, 
Castellanos R, Gandelman M,  
de León A, et al. Mitochondrial 
dysfunction in SOD1G93A-bearing 
astrocytes promotes motor neuron 
degeneration: Prevention by 
mitochondrial-targeted antioxidants. 
The Journal of Neuroscience. 
2008;28:4115-4122. DOI: 10.1523/
JNEUROSCI.5308-07.2008
[25] Di Giorgio FP, Boulting GL, 
Bobrowicz S, Eggan KC. Human 
embryonic stem cell-derived  
motor neurons are sensitive to the 
toxic effect of glial cells carrying an 
ALS-causing mutation. Cell Stem 
Cell. 2008;3:637-648. DOI: 10.1016/j.
stem.2008.09.017
[26] Nagai M, Re DB, Nagata T, 
Chalazonitis A, Jessell TM, Wichterle H, 
et al. Astrocytes expressing ALS-linked 
mutated SOD1 release factors selectively 
toxic to motor neurons. Nature 
Neuroscience. 2007;10:615-622. DOI: 
10.1038/nn1876
Novel Aspects on Motor Neuron Disease
20
[27] Haidet-Phillips AM, Hester ME, 
Miranda CJ, Meyer K, Braun L, Frakes 
A, et al. Astrocytes from familial and 
sporadic ALS patients are toxic to 
motor neurons. Nature Biotechnology. 
2011;29:824-828. DOI: 10.1038/nbt.1957
[28] Re DB, Le Verche V, Yu C, Amoroso 
MW, Politi KA, Phani S, et al. 
Necroptosis drives motor neuron death 
in models of both sporadic and familial 
ALS. Neuron. 2014;81:1001-1008. DOI: 
10.1016/j.neuron.2014.01.011
[29] Wegorzewska I, Bell S, Cairns 
NJ, Miller TM, Baloh RH. TDP-43 
mutant transgenic mice develop 
features of ALS and frontotemporal 
lobar degeneration. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2009;106(44):18809-18814. DOI: 
10.1073/pnas.0908767106
[30] Swarup V, Phaneuf D, Bareil C, 
Robertson J, Rouleau GA, Kriz J, et al. 
Pathological hallmarks of amyotrophic 
lateral sclerosis/frontotemporal lobar 
degeneration in transgenic mice 
produced with TDP-43 genomic 
fragments. Brain. 2011;134(9): 
2610-2626. DOI: 10.1093/brain/awr159
[31] Maragakis NJ, Rothstein JD. 
Mechanisms of disease: Astrocytes 
in neurodegenerative disease. 
Nature Clinical Practice. Neurology. 
2006;2(12):679-689. DOI: 10.1038/
ncpneuro0355
[32] Sofroniew MV, Vinters 
HV. Astrocytes: Biology and pathology. 
Acta Neuropathologica. 2010;119(1): 
7-35. DOI: 10.1007/s00401-009-0619-8
[33] Verkhratsky A, Sofroniew MV, 
Messing A, de Lanerolle NC, Rempe 
D, Rodríguez JJ, et al. Neurological 
diseases as primary gliopathies: A 
reassessment of neurocentrism. ASN 
Neuro. 2012;4(3):e00082. DOI: 10.1042/
AN20120010
[34] Sloan SA, Barres BA. Mechanisms 
of astrocyte development and their 
contributions to neurodevelopmental 
disorders. Current Opinion in 
Neurobiology. 2014;27:75-81. DOI: 
10.1016/j.conb.2014.03.005
[35] Barbeito LH, Pehar M, Cassina P, 
Vargas MR, Peluffo H, Viera L,  
et al. A role for astrocytes in motor 
neuron loss in amyotrophic lateral 
sclerosis. Brain Research. Brain  
Research Reviews. 2004;47 
(1-3):263-274. DOI: 10.1016/j.
brainresrev.2004.05.003
[36] Hostenbach S, Cambron M, 
D’haeseleer M, Kooijman R, De Keyser 
J. Astrocyte loss and astrogliosis 
in neuroinflammatory disorders. 
Neuroscience Letters. 2014;565:39-41. 
DOI: 10.1016/j.neulet.2013.10.012
[37] Pekny M, Wilhelmsson U, Pekna M.  
The dual role of astrocyte activation 
and reactive gliosis. Neuroscience 
Letters. 2014;565:30-38. DOI: 10.1016/j.
neulet.2013.12.071
[38] Olivera-Bravo S, Isasi E, 
Fernández A, Casanova G, Rosillo JC, 
Barbeito L. Astrocyte dysfunction in 
developmental neurometabolic diseases. 
Advances in Experimental Medicine 
and Biology. 2016;949:227-243. DOI: 
10.1007/978-3-319-40764-7_11
[39] Kuno R, Yoshida Y, Nitta A, 
Nabeshima T, Wang J, Sonobe Y, et al. 
The role of TNF-alpha and  
its receptors in the production of 
NGF and GDNF by astrocytes. Brain 
Research. 2006;1116(1):12-18. DOI: 
10.1016/j.brainres.2006.07.120
[40] Díaz-Amarilla P, Olivera-Bravo S, 
Trias E, Cragnolini A, Martínez-Palma 
L, Cassina P, et al. Phenotypically 
aberrant astrocytes that promote 
motoneuron damage in a model of 
inherited amyotrophic lateral sclerosis. 
Proceedings of the National Academy 
of Sciences of the United States of 
21
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
America. 2011;108:18126-18131. DOI: 
10.1073/pnas.1110689108
[41] Jiménez-Riani M, Díaz-Amarilla 
P, Isasi E, Casanova G, Barbeito L, 
Olivera-Bravo S. Ultrastructural features 
of aberrant glial cells isolated from the 
spinal cord of paralytic rats expressing 
the amyotrophic lateral sclerosis-linked 
SOD1G93A mutation. Cell and Tissue 
Research. 2017;370(3):391-401. DOI: 
10.1007/s00441-017-2681-1
[42] Yoshiyama Y, Zhang B, Bruce J, 
Trojanowski JQ , Lee VMY. Reduction 
of detyrosinated microtubules and 
Golgi fragmentation are linked to 
tau-induced degeneration in astrocytes. 
The Journal of Neuroscience. 
2003;23:10662-10671. DOI: 10.1523/
JNEUROSCI.23-33-10662.2003
[43] Kawamata H, Manfredi G. 
Mitochondrial dysfunction and 
intracellular calcium dysregulation 
in ALS. Mechanisms of Ageing and 
Development. 2010;131:517-526. DOI: 
10.1016/j.mad.2010.05.003
[44] Sasaki S, Iwata M. Dendritic 
synapses of anterior horn neurons 
in amyotrophic lateral sclerosis: 
An ultrastructural study. Acta 
Neuropathologica. 2006;91:278-283. 
DOI: 10.1016/0304-3940(96)12314-4
[45] Gallagher CM, Walter P. Ceapins 
inhibit ATF6a signaling by selectively 
preventing transport of ATF6a to the 
Golgi apparatus during ER stress. eLife. 
2016;5:e11880. DOI: 10.7554/eLife.11880
[46] Hetz C, Thielen P, Matus S, 
Nassif M, Court F, Kiffin R, et al. 
XBP-1 deficiency in the nervous system 
protects against amyotrophic lateral 
sclerosis by increasing autophagy. Genes 
& Development. 2009;23:2294-2306. 
DOI: 10.1101/gad.1830709
[47] Kondo S, Murakami T, Tatsumi K, 
Ogata M, Kanemoto S, Otori K, et al. 
OASIS, a CREB/ATF-family member, 
modulates UPR signalling in astrocytes. 
Nature Cell Biology. 2005;7:186-194. 
DOI: 10.1038/ncb1213
[48] Hur YS, Kim KD, Paek SH. Yoo SH 
(2010) evidence for the existence of 
secretory granule (dense-core vesicle)-
based inositol 1,4,5-trisphosphate-
dependent Ca2+ signaling system in 
astrocytes. PLoS ONE. 2010;5(8):e11973. 
DOI: 10.1371/journal.pone.0011973
[49] Ozawa H, Takata K. The Granin 
family-its role in sorting and secretory 
granule formation. Cell Structure 
and Function. 1995;20:415-420. DOI: 
10.1247/csf.20.415
[50] Kabeya Y, Mizushima N, Ueno T, 
Yamamoto A, Kirisako T, Noda T,  
et al. LC3, a mammalian homologue 
of yeast Apg8p, is localized in 
autophagosome membranes after 
processing. The EMBO Journal. 
2000;19:5720-5728. DOI: 10.1093/
emboj/19.21.5720
[51] Herrera F, Martin V, Carrera P, 
García-Santos G, Rodriguez-Blanco 
J, Rodriguez C, et al. Tryptamine 
induces cell death with ultrastructural 
features of autophagy in neurons 
and glia: Possible relevance for 
neurodegenerative disorders. The 
Anatomical Record. 2006;288: 
1026-1030. DOI: 10.1002/ar.a.20368
[52] Robert F, Hervor TK. Abnormal 
organelles in cultured astrocytes are 
largely enhanced by streptomycin 
and intensively by gentamicin. 
Neuroscience. 2007;144:191-197. DOI: 
10.1016/j.neuroscience.2006.08.059
[53] Nixon RA, Wegiel J, Kumar A,  
Yu WH, Peterhoff C, Cataldo A,  
et al. Extensive involvement of 
autophagy in Alzheimer disease:  
An immuno-electron microscopy  
study. Journal of Neuropathology  
and Experimental Neurology. 
2005;64:113-122. DOI: 10.1093/
jnen/64.2.113
Novel Aspects on Motor Neuron Disease
20
[27] Haidet-Phillips AM, Hester ME, 
Miranda CJ, Meyer K, Braun L, Frakes 
A, et al. Astrocytes from familial and 
sporadic ALS patients are toxic to 
motor neurons. Nature Biotechnology. 
2011;29:824-828. DOI: 10.1038/nbt.1957
[28] Re DB, Le Verche V, Yu C, Amoroso 
MW, Politi KA, Phani S, et al. 
Necroptosis drives motor neuron death 
in models of both sporadic and familial 
ALS. Neuron. 2014;81:1001-1008. DOI: 
10.1016/j.neuron.2014.01.011
[29] Wegorzewska I, Bell S, Cairns 
NJ, Miller TM, Baloh RH. TDP-43 
mutant transgenic mice develop 
features of ALS and frontotemporal 
lobar degeneration. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2009;106(44):18809-18814. DOI: 
10.1073/pnas.0908767106
[30] Swarup V, Phaneuf D, Bareil C, 
Robertson J, Rouleau GA, Kriz J, et al. 
Pathological hallmarks of amyotrophic 
lateral sclerosis/frontotemporal lobar 
degeneration in transgenic mice 
produced with TDP-43 genomic 
fragments. Brain. 2011;134(9): 
2610-2626. DOI: 10.1093/brain/awr159
[31] Maragakis NJ, Rothstein JD. 
Mechanisms of disease: Astrocytes 
in neurodegenerative disease. 
Nature Clinical Practice. Neurology. 
2006;2(12):679-689. DOI: 10.1038/
ncpneuro0355
[32] Sofroniew MV, Vinters 
HV. Astrocytes: Biology and pathology. 
Acta Neuropathologica. 2010;119(1): 
7-35. DOI: 10.1007/s00401-009-0619-8
[33] Verkhratsky A, Sofroniew MV, 
Messing A, de Lanerolle NC, Rempe 
D, Rodríguez JJ, et al. Neurological 
diseases as primary gliopathies: A 
reassessment of neurocentrism. ASN 
Neuro. 2012;4(3):e00082. DOI: 10.1042/
AN20120010
[34] Sloan SA, Barres BA. Mechanisms 
of astrocyte development and their 
contributions to neurodevelopmental 
disorders. Current Opinion in 
Neurobiology. 2014;27:75-81. DOI: 
10.1016/j.conb.2014.03.005
[35] Barbeito LH, Pehar M, Cassina P, 
Vargas MR, Peluffo H, Viera L,  
et al. A role for astrocytes in motor 
neuron loss in amyotrophic lateral 
sclerosis. Brain Research. Brain  
Research Reviews. 2004;47 
(1-3):263-274. DOI: 10.1016/j.
brainresrev.2004.05.003
[36] Hostenbach S, Cambron M, 
D’haeseleer M, Kooijman R, De Keyser 
J. Astrocyte loss and astrogliosis 
in neuroinflammatory disorders. 
Neuroscience Letters. 2014;565:39-41. 
DOI: 10.1016/j.neulet.2013.10.012
[37] Pekny M, Wilhelmsson U, Pekna M.  
The dual role of astrocyte activation 
and reactive gliosis. Neuroscience 
Letters. 2014;565:30-38. DOI: 10.1016/j.
neulet.2013.12.071
[38] Olivera-Bravo S, Isasi E, 
Fernández A, Casanova G, Rosillo JC, 
Barbeito L. Astrocyte dysfunction in 
developmental neurometabolic diseases. 
Advances in Experimental Medicine 
and Biology. 2016;949:227-243. DOI: 
10.1007/978-3-319-40764-7_11
[39] Kuno R, Yoshida Y, Nitta A, 
Nabeshima T, Wang J, Sonobe Y, et al. 
The role of TNF-alpha and  
its receptors in the production of 
NGF and GDNF by astrocytes. Brain 
Research. 2006;1116(1):12-18. DOI: 
10.1016/j.brainres.2006.07.120
[40] Díaz-Amarilla P, Olivera-Bravo S, 
Trias E, Cragnolini A, Martínez-Palma 
L, Cassina P, et al. Phenotypically 
aberrant astrocytes that promote 
motoneuron damage in a model of 
inherited amyotrophic lateral sclerosis. 
Proceedings of the National Academy 
of Sciences of the United States of 
21
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
America. 2011;108:18126-18131. DOI: 
10.1073/pnas.1110689108
[41] Jiménez-Riani M, Díaz-Amarilla 
P, Isasi E, Casanova G, Barbeito L, 
Olivera-Bravo S. Ultrastructural features 
of aberrant glial cells isolated from the 
spinal cord of paralytic rats expressing 
the amyotrophic lateral sclerosis-linked 
SOD1G93A mutation. Cell and Tissue 
Research. 2017;370(3):391-401. DOI: 
10.1007/s00441-017-2681-1
[42] Yoshiyama Y, Zhang B, Bruce J, 
Trojanowski JQ , Lee VMY. Reduction 
of detyrosinated microtubules and 
Golgi fragmentation are linked to 
tau-induced degeneration in astrocytes. 
The Journal of Neuroscience. 
2003;23:10662-10671. DOI: 10.1523/
JNEUROSCI.23-33-10662.2003
[43] Kawamata H, Manfredi G. 
Mitochondrial dysfunction and 
intracellular calcium dysregulation 
in ALS. Mechanisms of Ageing and 
Development. 2010;131:517-526. DOI: 
10.1016/j.mad.2010.05.003
[44] Sasaki S, Iwata M. Dendritic 
synapses of anterior horn neurons 
in amyotrophic lateral sclerosis: 
An ultrastructural study. Acta 
Neuropathologica. 2006;91:278-283. 
DOI: 10.1016/0304-3940(96)12314-4
[45] Gallagher CM, Walter P. Ceapins 
inhibit ATF6a signaling by selectively 
preventing transport of ATF6a to the 
Golgi apparatus during ER stress. eLife. 
2016;5:e11880. DOI: 10.7554/eLife.11880
[46] Hetz C, Thielen P, Matus S, 
Nassif M, Court F, Kiffin R, et al. 
XBP-1 deficiency in the nervous system 
protects against amyotrophic lateral 
sclerosis by increasing autophagy. Genes 
& Development. 2009;23:2294-2306. 
DOI: 10.1101/gad.1830709
[47] Kondo S, Murakami T, Tatsumi K, 
Ogata M, Kanemoto S, Otori K, et al. 
OASIS, a CREB/ATF-family member, 
modulates UPR signalling in astrocytes. 
Nature Cell Biology. 2005;7:186-194. 
DOI: 10.1038/ncb1213
[48] Hur YS, Kim KD, Paek SH. Yoo SH 
(2010) evidence for the existence of 
secretory granule (dense-core vesicle)-
based inositol 1,4,5-trisphosphate-
dependent Ca2+ signaling system in 
astrocytes. PLoS ONE. 2010;5(8):e11973. 
DOI: 10.1371/journal.pone.0011973
[49] Ozawa H, Takata K. The Granin 
family-its role in sorting and secretory 
granule formation. Cell Structure 
and Function. 1995;20:415-420. DOI: 
10.1247/csf.20.415
[50] Kabeya Y, Mizushima N, Ueno T, 
Yamamoto A, Kirisako T, Noda T,  
et al. LC3, a mammalian homologue 
of yeast Apg8p, is localized in 
autophagosome membranes after 
processing. The EMBO Journal. 
2000;19:5720-5728. DOI: 10.1093/
emboj/19.21.5720
[51] Herrera F, Martin V, Carrera P, 
García-Santos G, Rodriguez-Blanco 
J, Rodriguez C, et al. Tryptamine 
induces cell death with ultrastructural 
features of autophagy in neurons 
and glia: Possible relevance for 
neurodegenerative disorders. The 
Anatomical Record. 2006;288: 
1026-1030. DOI: 10.1002/ar.a.20368
[52] Robert F, Hervor TK. Abnormal 
organelles in cultured astrocytes are 
largely enhanced by streptomycin 
and intensively by gentamicin. 
Neuroscience. 2007;144:191-197. DOI: 
10.1016/j.neuroscience.2006.08.059
[53] Nixon RA, Wegiel J, Kumar A,  
Yu WH, Peterhoff C, Cataldo A,  
et al. Extensive involvement of 
autophagy in Alzheimer disease:  
An immuno-electron microscopy  
study. Journal of Neuropathology  
and Experimental Neurology. 
2005;64:113-122. DOI: 10.1093/
jnen/64.2.113
Novel Aspects on Motor Neuron Disease
22
[54] Donato R, Sorci G, Riuzzi F, 
Arcuri C, Bianchi R, Brozzi F, et al. 
S100B’s double life: Intracellular 
regulator and extracellular signal. 
Biochimica et Biophysica Acta. 
2009;1793(6):1008-1022. DOI: 10.1016/j.
bbamcr.2008.11.009
[55] Gonzalez-Reyes RE, Rubiano MG. 
Astrocyte’s RAGE: More than just a 
question of mood. Central Nervous 
System Agents in Medicinal Chemistry. 
2018;18(1):39-48. DOI: 10.2174/1871524
916999160505105121
[56] Fife CM, McCarroll JA, Kavallaris M. 
Movers and shakers: Cell cytoskeleton 
in cancer metastasis. British Journal of 
Pharmacology. 2014;171(24):5507-5523. 
DOI: 10.1111/bph.12704
[57] Schmitt F, Hussain G, Dupuis L,  
Loeffler JP, Henriques A. A plural 
role for lipids in motor neuron 
diseases: Energy, signaling and 
structure. Frontiers in Cellular 
Neuroscience. 2014;8:25. DOI: 10.3389/
fncel.2014.00025. eCollection 2014
[58] Taylor JP, Brown RH Jr, Cleveland 
DW. Decoding ALS: From genes to 
mechanism. Nature. 2016;539:197-206. 
DOI: 10.1038/nature20413
[59] Valenzuela V, Oñate M,  
Hetz C, Court FA. Injury to the  
nervous system: A look into the 
ER. Brain Research. 2016;1648: 
617-625. DOI: 10.1016/j.
brainres.2016.04.053
[60] Walter P, Ron D. The unfolded 
protein response: From stress pathway 
to homeostatic regulation. Science. 
2011;334:1081-1086. DOI: 10.1126/
science.1209038
[61] Oakes SA, Papa FR. The role  
of endoplasmic reticulum stress  
in human pathology. Annual  
Review of Pathology.2015;10: 
173-194. DOI: 10.1146/
annurev-pathol-012513-104649
[62] Halliday M, Mallucci 
GR. Modulating the unfolded protein 
response to prevent neurodegeneration 
and enhance memory. Neuropathology 
and Applied Neurobiology. 2015;41: 
414-427. DOI: 10.1111/nan.12211
[63] Lee S, Shang Y, Redmond SA, 
Urisman A, Tang AA, Li KH, et al. 
Activation of HIPK2 promotes ER 
stress-mediated neurodegeneration 
in amyotrophic lateral sclerosis. 
Neuron. 2016;91:41-55. DOI: 10.1016/j.
neuron.2016.05.021
[64] Suzuki H, Matsuoka M. TDP-43 
toxicity is mediated by the unfolded 
protein response-unrelated induction of 
C/EBP homologous protein expression. 
Journal of Neuroscience Research. 
2012;90:641-647. DOI: 10.1002/
jnr.22777
[65] Tsang KY, Chan D, Bateman JF, 
Cheah KSE. In vivo cellular adaptation 
to ER stress: Survival strategies with 
double-edged consequences. Journal of 
Cell Science. 2010;123:2145-2154. DOI: 
10.1242/jcs.068833
[66] Walker AK, Soo KY, 
Sundaramoorthy V, Parakh S, Ma Y, 
Farg MA, et al. ALS-associated TDP-
43 induces endoplasmic reticulum 
stress, which drives cytoplasmic 
TDP-43 accumulation and stress 
granule formation. PLoS ONE. 
2013;8(11):e81170. DOI: 10.1371/
journal.pone.0081170
[67] Pennetta G, Welte MA. Emerging 
links between lipid droplets and motor 
neuron diseases. Developmental Cell. 
2018;45:427-432. DOI: 10.1016/j.
devcel.2018.05.002
[68] Ernst WL, Shome K, Wu CC,  
Gong X, Frizzell RA, Aridor M. 
VAMP-associated proteins (VAP) as 
receptors that couple cystic fibrosis 
transmembrane conductance regulator 
(CFTR) proteostasis with lipid 
homeostasis. The Journal of Biological 
23
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
Chemistry. 2016;291:5206-5220. DOI: 
10.1074/jbc.M115.692749
[69] Janer A, Martin E, Muriel MP, 
Latouche M, Fujigasaki H, Ruberg 
M, et al. PML clastosomes prevent 
nuclear accumulation of mutant 
ataxin-7 and other polyglutamine 
proteins. The Journal of Cell Biology. 
2006;174(1):65-76. DOI: 10.1074/jbc.
M115.692749
[70] Zhu L, Brangwynne CP. Nuclear 
bodies: The emerging biophysics of 
nucleoplasmic phases. Current Opinion 
in Cell Biology. 2015;34:23-30. DOI: 
10.1016/j.ceb.2015.04.003
[71] Seilhean D, Takahashi J, El Hachimi 
KH, Fujigasaki H, Lebre AS, Biancalana 
V, et al. Amyotrophic lateral sclerosis 
with neuronal intranuclear protein 
inclusions. Acta Neuropathologica. 
2004;108:81-87. DOI: 10.1007/
s00401-004-0855-x
[72] Welte MA. Expanding roles 
for lipid droplets. Current Biology. 
2015;25:470-481. DOI: 10.1016/j.
cub.2015.04.004
[73] Stallings NR, Puttaparthi K, 
Dowling KJ, Luther CM, Burns DK, 
Davis K, et al. TDP-43, an ALS linked 
protein, regulates fat deposition and 
glucose homeostasis. PLoS ONE. 
2013;8:e71793. DOI: 10.1371/journal.
pone.0071793
[74] Chiang PM, Ling J, Jeong YH, 
Price DL, Aja SM, Wong PC. Deletion 
of TDP-43 down-regulates Tbc1d1, 
a gene linked to obesity, and alters 
body fat metabolism. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2010;107(37):16320-16324. DOI: 
10.1073/pnas.1002176107
[75] Miyazaki K, Masamoto K,  
Morimoto N, Kurata T, Mimoto T, 
Obata T, et al. Early and progressive 
impairment of spinal blood flow-glucose 
metabolism coupling in motor neuron 
degeneration of ALS model mice. 
Journal of Cerebral Blood Flow and 
Metabolism. 2012;32(3):456-467. DOI: 
10.1038/jcbfm.2011.155
[76] Liu L, Zhang K, Sandoval H, 
Yamamoto S, Jaiswal M, Sanz E, et al. 
Glial lipid droplets and ROS induced 
by mitochondrial defects promote 
neurodegeneration. Cell. 2015;160: 
177-190. DOI: 10.1016/j.cell.2014.12.019
[77] Yamamoto S, Jaiswal M, Charng 
WL, Gambin T, Karaca E, Mirzaa G, 
et al. A drosophila genetic resource 
of mutants to study mechanisms 
underlying human genetic diseases. 
Cell. 2014;159:200-214. DOI: 10.1016/j.
cell.2014.09.002
[78] Li YR, King OD, Shorter J, 
Gitler AD. Stress granules as crucibles 
of ALS pathogenesis. The Journal of 
Cell Biology. 2013;201:361-372. DOI: 
10.1083/jcb.201302044
[79] Urushitani M, Ezzi SA, Matsuo A, 
Tooyama I, Julien JP. The endoplasmic 
reticulum-Golgi pathway is a target 
for translocation and aggregation 
of mutant superoxide dismutase 
linked to ALS. The FASEB Journal. 
2006;22:2476-2487. DOI: 10.1096/
fj.07-092783
[80] Eagle H, Levine EM. Growth 
regulatory effects of cellular interaction. 
Nature. 1967;213:1102-1106. DOI: 
10.1038/2131102a0
[81] Choi EH, Dai Y. SIRT1 controls 
cell proliferation by regulating 
contact inhibition. Biochemical and 
Biophysical Research Communications. 
2016;478(2):868-872. DOI: 10.1016/j.
bbrc.2016.08.041
[82] Yang C, Iyer RR, Yu AC, Yong RL, 
Park DM, Weil RJ, et al. β-Catenin 
signaling initiates the activation 
of astrocytes and its dysregulation 
contributes to the pathogenesis 
Novel Aspects on Motor Neuron Disease
22
[54] Donato R, Sorci G, Riuzzi F, 
Arcuri C, Bianchi R, Brozzi F, et al. 
S100B’s double life: Intracellular 
regulator and extracellular signal. 
Biochimica et Biophysica Acta. 
2009;1793(6):1008-1022. DOI: 10.1016/j.
bbamcr.2008.11.009
[55] Gonzalez-Reyes RE, Rubiano MG. 
Astrocyte’s RAGE: More than just a 
question of mood. Central Nervous 
System Agents in Medicinal Chemistry. 
2018;18(1):39-48. DOI: 10.2174/1871524
916999160505105121
[56] Fife CM, McCarroll JA, Kavallaris M. 
Movers and shakers: Cell cytoskeleton 
in cancer metastasis. British Journal of 
Pharmacology. 2014;171(24):5507-5523. 
DOI: 10.1111/bph.12704
[57] Schmitt F, Hussain G, Dupuis L,  
Loeffler JP, Henriques A. A plural 
role for lipids in motor neuron 
diseases: Energy, signaling and 
structure. Frontiers in Cellular 
Neuroscience. 2014;8:25. DOI: 10.3389/
fncel.2014.00025. eCollection 2014
[58] Taylor JP, Brown RH Jr, Cleveland 
DW. Decoding ALS: From genes to 
mechanism. Nature. 2016;539:197-206. 
DOI: 10.1038/nature20413
[59] Valenzuela V, Oñate M,  
Hetz C, Court FA. Injury to the  
nervous system: A look into the 
ER. Brain Research. 2016;1648: 
617-625. DOI: 10.1016/j.
brainres.2016.04.053
[60] Walter P, Ron D. The unfolded 
protein response: From stress pathway 
to homeostatic regulation. Science. 
2011;334:1081-1086. DOI: 10.1126/
science.1209038
[61] Oakes SA, Papa FR. The role  
of endoplasmic reticulum stress  
in human pathology. Annual  
Review of Pathology.2015;10: 
173-194. DOI: 10.1146/
annurev-pathol-012513-104649
[62] Halliday M, Mallucci 
GR. Modulating the unfolded protein 
response to prevent neurodegeneration 
and enhance memory. Neuropathology 
and Applied Neurobiology. 2015;41: 
414-427. DOI: 10.1111/nan.12211
[63] Lee S, Shang Y, Redmond SA, 
Urisman A, Tang AA, Li KH, et al. 
Activation of HIPK2 promotes ER 
stress-mediated neurodegeneration 
in amyotrophic lateral sclerosis. 
Neuron. 2016;91:41-55. DOI: 10.1016/j.
neuron.2016.05.021
[64] Suzuki H, Matsuoka M. TDP-43 
toxicity is mediated by the unfolded 
protein response-unrelated induction of 
C/EBP homologous protein expression. 
Journal of Neuroscience Research. 
2012;90:641-647. DOI: 10.1002/
jnr.22777
[65] Tsang KY, Chan D, Bateman JF, 
Cheah KSE. In vivo cellular adaptation 
to ER stress: Survival strategies with 
double-edged consequences. Journal of 
Cell Science. 2010;123:2145-2154. DOI: 
10.1242/jcs.068833
[66] Walker AK, Soo KY, 
Sundaramoorthy V, Parakh S, Ma Y, 
Farg MA, et al. ALS-associated TDP-
43 induces endoplasmic reticulum 
stress, which drives cytoplasmic 
TDP-43 accumulation and stress 
granule formation. PLoS ONE. 
2013;8(11):e81170. DOI: 10.1371/
journal.pone.0081170
[67] Pennetta G, Welte MA. Emerging 
links between lipid droplets and motor 
neuron diseases. Developmental Cell. 
2018;45:427-432. DOI: 10.1016/j.
devcel.2018.05.002
[68] Ernst WL, Shome K, Wu CC,  
Gong X, Frizzell RA, Aridor M. 
VAMP-associated proteins (VAP) as 
receptors that couple cystic fibrosis 
transmembrane conductance regulator 
(CFTR) proteostasis with lipid 
homeostasis. The Journal of Biological 
23
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
Chemistry. 2016;291:5206-5220. DOI: 
10.1074/jbc.M115.692749
[69] Janer A, Martin E, Muriel MP, 
Latouche M, Fujigasaki H, Ruberg 
M, et al. PML clastosomes prevent 
nuclear accumulation of mutant 
ataxin-7 and other polyglutamine 
proteins. The Journal of Cell Biology. 
2006;174(1):65-76. DOI: 10.1074/jbc.
M115.692749
[70] Zhu L, Brangwynne CP. Nuclear 
bodies: The emerging biophysics of 
nucleoplasmic phases. Current Opinion 
in Cell Biology. 2015;34:23-30. DOI: 
10.1016/j.ceb.2015.04.003
[71] Seilhean D, Takahashi J, El Hachimi 
KH, Fujigasaki H, Lebre AS, Biancalana 
V, et al. Amyotrophic lateral sclerosis 
with neuronal intranuclear protein 
inclusions. Acta Neuropathologica. 
2004;108:81-87. DOI: 10.1007/
s00401-004-0855-x
[72] Welte MA. Expanding roles 
for lipid droplets. Current Biology. 
2015;25:470-481. DOI: 10.1016/j.
cub.2015.04.004
[73] Stallings NR, Puttaparthi K, 
Dowling KJ, Luther CM, Burns DK, 
Davis K, et al. TDP-43, an ALS linked 
protein, regulates fat deposition and 
glucose homeostasis. PLoS ONE. 
2013;8:e71793. DOI: 10.1371/journal.
pone.0071793
[74] Chiang PM, Ling J, Jeong YH, 
Price DL, Aja SM, Wong PC. Deletion 
of TDP-43 down-regulates Tbc1d1, 
a gene linked to obesity, and alters 
body fat metabolism. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2010;107(37):16320-16324. DOI: 
10.1073/pnas.1002176107
[75] Miyazaki K, Masamoto K,  
Morimoto N, Kurata T, Mimoto T, 
Obata T, et al. Early and progressive 
impairment of spinal blood flow-glucose 
metabolism coupling in motor neuron 
degeneration of ALS model mice. 
Journal of Cerebral Blood Flow and 
Metabolism. 2012;32(3):456-467. DOI: 
10.1038/jcbfm.2011.155
[76] Liu L, Zhang K, Sandoval H, 
Yamamoto S, Jaiswal M, Sanz E, et al. 
Glial lipid droplets and ROS induced 
by mitochondrial defects promote 
neurodegeneration. Cell. 2015;160: 
177-190. DOI: 10.1016/j.cell.2014.12.019
[77] Yamamoto S, Jaiswal M, Charng 
WL, Gambin T, Karaca E, Mirzaa G, 
et al. A drosophila genetic resource 
of mutants to study mechanisms 
underlying human genetic diseases. 
Cell. 2014;159:200-214. DOI: 10.1016/j.
cell.2014.09.002
[78] Li YR, King OD, Shorter J, 
Gitler AD. Stress granules as crucibles 
of ALS pathogenesis. The Journal of 
Cell Biology. 2013;201:361-372. DOI: 
10.1083/jcb.201302044
[79] Urushitani M, Ezzi SA, Matsuo A, 
Tooyama I, Julien JP. The endoplasmic 
reticulum-Golgi pathway is a target 
for translocation and aggregation 
of mutant superoxide dismutase 
linked to ALS. The FASEB Journal. 
2006;22:2476-2487. DOI: 10.1096/
fj.07-092783
[80] Eagle H, Levine EM. Growth 
regulatory effects of cellular interaction. 
Nature. 1967;213:1102-1106. DOI: 
10.1038/2131102a0
[81] Choi EH, Dai Y. SIRT1 controls 
cell proliferation by regulating 
contact inhibition. Biochemical and 
Biophysical Research Communications. 
2016;478(2):868-872. DOI: 10.1016/j.
bbrc.2016.08.041
[82] Yang C, Iyer RR, Yu AC, Yong RL, 
Park DM, Weil RJ, et al. β-Catenin 
signaling initiates the activation 
of astrocytes and its dysregulation 
contributes to the pathogenesis 
Novel Aspects on Motor Neuron Disease
24
of astrocytomas. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2012;109:6963-6968. DOI: 10.1073/
pnas.1118754109
[83] Baker DJ, Blackburn DJ, Keatinge M, 
Sokhi D, Viskaitis P, Heath PR, et al. 
Lysosomal and phagocytic activity 
is increased in astrocytes during 
disease progression in the SOD1G93A 
mouse model of amyotrophic lateral 
sclerosis. Frontiers in Cellular 
Neuroscience. 2015;9:410. DOI: 10.3389/
fncel.2015.00410
[84] Das MM, Svendsen CN. Astrocytes 
show reduced support of motor neurons 
with aging that is accelerated in a rodent 
model of ALS. Neurobiology of Aging. 
2015;36:1130-1139. DOI: 10.1016/j.
neurobiolaging.2014.09.020
[85] Song SW, Miranda CJ, Braun L, 
Meyer K, Frakes AE, Ferraiuolo L, et al. 
MHC class I protects motor neurons 
from astrocyte-induced toxicity in 
amyotrophic lateral sclerosis (ALS). 
Nature Medicine. 2016;22:397-403. DOI: 
10.1038/nm.4052
[86] Trias E, Díaz-Amarilla P, Olivera-
Bravo S, Isasi E, Drechsel DA, Lopez 
N, et al. Phenotypic transition of 
microglia into astrocyte-like cells 
associated with disease onset in a model 
of inherited ALS. Frontiers in Cellular 
Neuroscience. 2013;7:274. DOI: 10.3389/
fncel.2013.00274
[87] Trias E, Ibarburu S, Barreto-
Núñez R, Babdor J, Maciel TT, Guillo 
M, et al. Post-paralysis tyrosine 
kinase inhibition with masitinib 
abrogates neuroinflammation and 
slows disease progression in inherited 
amyotrophic lateral sclerosis. Journal 
of Neuroinflammation. 2016;13(1):177. 
DOI: 10.1186/s12974-016-0620-9
[88] Lamp J, Keyser B, Koeller DM, 
Ullrich K, Braulke T, Mühlhausen 
C. Glutaric aciduria type 1 metabolites 
impair the succinate transport from 
astrocytic to neuronal cells. The 
Journal of Biological Chemistry. 
2011;286(20):17777-17784. DOI: 
10.1074/jbc.M111.232744
[89] Miquel E, Cassina A, Martínez-
Palma L, Souza JM, Bolatto 
C, Rodríguez-Bottero S, et al. 
Neuroprotective effects of the 
mitochondria-targeted antioxidant 
MitoQ in a model of inherited 
amyotrophic lateral sclerosis. 
Free Radical Biology & Medicine. 
2014;70:204-213. DOI: 10.1016/j.
freeradbiomed.2014.02.019
[90] Díaz-Amarilla P, Miquel E, 
Trostchansky A, Trias E, Ferreira AM,  
Freeman BA, et al. Electrophilic 
nitro-fatty acids prevent astrocyte-
mediated toxicity to motor neurons in 
a cell model of familial amyotrophic 
lateral sclerosis via nuclear factor 
erythroid 2-related factor activation. 
Free Radical Biology & Medicine. 
2016;95:112-120. DOI: 10.1016/j.
freeradbiomed.2016.03.013
[91] Martínez-Palma L, Miquel E, 
Lagos-Rodríguez V, Barbeito L, Cassina 
A, Cassina P. Mitochondrial modulation 
by dichloroacetate reduces toxicity of 
aberrant glial cells and gliosis in the 
SOD1G93A rat model of amyotrophic 
lateral sclerosis. Neurotherapeutics. 
2018;16(1):203-215. DOI: 10.1007/
s13311-018-0659-7
[92] Miller RG, Mitchell JD, Moore DH. 
Riluzole for amyotrophic lateral  
sclerosis (ALS)/motor neuron 
disease (MND). Cochrane 
Database of Systematic Reviews. 
2012;14(3):CD001447. DOI: 
10.1002/14651858.CD001447.pub3
[93] Writing Group. Edaravone (MCI-
186) ALS 19 Study Group. Safety and 
efficacy of edaravone in well defined 
patients with amyotrophic lateral 
sclerosis: A randomised, double-
blind, placebo-controlled trial. Lancet 
25
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
Neurology. 2017;16(7):505-512. DOI: 
10.1016/S1474-4422(17)30115-1
[94] Scott A. On the treatment trail for 
ALS. Nature. 2017;550(7676):S120-S121. 
DOI: 10.1038/550S120a
[95] Burns SA, Lee Archer R, Chavis JA,  
Tull CA, Hensley LL, Drew 
PD. Mitoxantrone repression of 
astrocyte activation: Relevance to 
multiple sclerosis. Brain Research. 
2012;1473:236-241. DOI: 10.1016/j.
brainres.2012.07.054
[96] Kocic I, Kowianski P, Rusiecka I, 
Lietzau G, Mansfield C, Moussy A, et al. 
Neuroprotective effect of masitinib 
in rats with postischemic stroke. 
Naunyn-Schmiedeberg’s Archives of 
Pharmacology. 2015;388(1):79-86. DOI: 
10.1007/s00210-014-1061-6
[97] Rojas F, Gonzalez D, Cortes N, 
Ampuero E, Hernandez DE, Fritz E, 
et al. Reactive oxygen species trigger 
motoneuron death in non-cell-
autonomous models of ALS through 
activation of c-Abl signaling. Frontiers 
in Cellular Neuroscience. 2015;9:203. 
DOI: 10.3389/fncel.2015.00203
[98] Martínez-Muriana A, Mancuso R, 
Francos-Quijorna I, Olmos-Alonso A, 
Osta R, Perry VH, et al. CSF1R blockade 
slows the progression of amyotrophic 
lateral sclerosis by reducing microgliosis 
and invasion of macrophages into 
peripheral nerves. Scientific Reports. 
2016;6:25663. DOI: 10.1038/srep25663
Novel Aspects on Motor Neuron Disease
24
of astrocytomas. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2012;109:6963-6968. DOI: 10.1073/
pnas.1118754109
[83] Baker DJ, Blackburn DJ, Keatinge M, 
Sokhi D, Viskaitis P, Heath PR, et al. 
Lysosomal and phagocytic activity 
is increased in astrocytes during 
disease progression in the SOD1G93A 
mouse model of amyotrophic lateral 
sclerosis. Frontiers in Cellular 
Neuroscience. 2015;9:410. DOI: 10.3389/
fncel.2015.00410
[84] Das MM, Svendsen CN. Astrocytes 
show reduced support of motor neurons 
with aging that is accelerated in a rodent 
model of ALS. Neurobiology of Aging. 
2015;36:1130-1139. DOI: 10.1016/j.
neurobiolaging.2014.09.020
[85] Song SW, Miranda CJ, Braun L, 
Meyer K, Frakes AE, Ferraiuolo L, et al. 
MHC class I protects motor neurons 
from astrocyte-induced toxicity in 
amyotrophic lateral sclerosis (ALS). 
Nature Medicine. 2016;22:397-403. DOI: 
10.1038/nm.4052
[86] Trias E, Díaz-Amarilla P, Olivera-
Bravo S, Isasi E, Drechsel DA, Lopez 
N, et al. Phenotypic transition of 
microglia into astrocyte-like cells 
associated with disease onset in a model 
of inherited ALS. Frontiers in Cellular 
Neuroscience. 2013;7:274. DOI: 10.3389/
fncel.2013.00274
[87] Trias E, Ibarburu S, Barreto-
Núñez R, Babdor J, Maciel TT, Guillo 
M, et al. Post-paralysis tyrosine 
kinase inhibition with masitinib 
abrogates neuroinflammation and 
slows disease progression in inherited 
amyotrophic lateral sclerosis. Journal 
of Neuroinflammation. 2016;13(1):177. 
DOI: 10.1186/s12974-016-0620-9
[88] Lamp J, Keyser B, Koeller DM, 
Ullrich K, Braulke T, Mühlhausen 
C. Glutaric aciduria type 1 metabolites 
impair the succinate transport from 
astrocytic to neuronal cells. The 
Journal of Biological Chemistry. 
2011;286(20):17777-17784. DOI: 
10.1074/jbc.M111.232744
[89] Miquel E, Cassina A, Martínez-
Palma L, Souza JM, Bolatto 
C, Rodríguez-Bottero S, et al. 
Neuroprotective effects of the 
mitochondria-targeted antioxidant 
MitoQ in a model of inherited 
amyotrophic lateral sclerosis. 
Free Radical Biology & Medicine. 
2014;70:204-213. DOI: 10.1016/j.
freeradbiomed.2014.02.019
[90] Díaz-Amarilla P, Miquel E, 
Trostchansky A, Trias E, Ferreira AM,  
Freeman BA, et al. Electrophilic 
nitro-fatty acids prevent astrocyte-
mediated toxicity to motor neurons in 
a cell model of familial amyotrophic 
lateral sclerosis via nuclear factor 
erythroid 2-related factor activation. 
Free Radical Biology & Medicine. 
2016;95:112-120. DOI: 10.1016/j.
freeradbiomed.2016.03.013
[91] Martínez-Palma L, Miquel E, 
Lagos-Rodríguez V, Barbeito L, Cassina 
A, Cassina P. Mitochondrial modulation 
by dichloroacetate reduces toxicity of 
aberrant glial cells and gliosis in the 
SOD1G93A rat model of amyotrophic 
lateral sclerosis. Neurotherapeutics. 
2018;16(1):203-215. DOI: 10.1007/
s13311-018-0659-7
[92] Miller RG, Mitchell JD, Moore DH. 
Riluzole for amyotrophic lateral  
sclerosis (ALS)/motor neuron 
disease (MND). Cochrane 
Database of Systematic Reviews. 
2012;14(3):CD001447. DOI: 
10.1002/14651858.CD001447.pub3
[93] Writing Group. Edaravone (MCI-
186) ALS 19 Study Group. Safety and 
efficacy of edaravone in well defined 
patients with amyotrophic lateral 
sclerosis: A randomised, double-
blind, placebo-controlled trial. Lancet 
25
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat…
DOI: http://dx.doi.org/10.5772/intechopen.84695
Neurology. 2017;16(7):505-512. DOI: 
10.1016/S1474-4422(17)30115-1
[94] Scott A. On the treatment trail for 
ALS. Nature. 2017;550(7676):S120-S121. 
DOI: 10.1038/550S120a
[95] Burns SA, Lee Archer R, Chavis JA,  
Tull CA, Hensley LL, Drew 
PD. Mitoxantrone repression of 
astrocyte activation: Relevance to 
multiple sclerosis. Brain Research. 
2012;1473:236-241. DOI: 10.1016/j.
brainres.2012.07.054
[96] Kocic I, Kowianski P, Rusiecka I, 
Lietzau G, Mansfield C, Moussy A, et al. 
Neuroprotective effect of masitinib 
in rats with postischemic stroke. 
Naunyn-Schmiedeberg’s Archives of 
Pharmacology. 2015;388(1):79-86. DOI: 
10.1007/s00210-014-1061-6
[97] Rojas F, Gonzalez D, Cortes N, 
Ampuero E, Hernandez DE, Fritz E, 
et al. Reactive oxygen species trigger 
motoneuron death in non-cell-
autonomous models of ALS through 
activation of c-Abl signaling. Frontiers 
in Cellular Neuroscience. 2015;9:203. 
DOI: 10.3389/fncel.2015.00203
[98] Martínez-Muriana A, Mancuso R, 
Francos-Quijorna I, Olmos-Alonso A, 
Osta R, Perry VH, et al. CSF1R blockade 
slows the progression of amyotrophic 
lateral sclerosis by reducing microgliosis 
and invasion of macrophages into 
peripheral nerves. Scientific Reports. 
2016;6:25663. DOI: 10.1038/srep25663
Chapter 3
Stem Cell Therapy in Motor
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Abstract
Motor neuron disease (MND) is an insidious, fatal disorder that progresses with
the selective loss of anterior horn cells of the spinal column. Over 150 years since it
was first described, various therapeutic approaches have been tested in the quest of
a cure but with little success. Current standard therapy only improves lifespan by a
few months; palliative care is the only option available for patients. Stem cell
therapy is a potent approach for the treatment of this devastating disease. A multi-
tude of vitalizing effects, both paracrine and somatic, a robust safety profile, as well
as ease of availability make a strong case for using these cells for therapeutic
purposes. Coupled with rigorous rehabilitation, this powerful treatment modality
has been shown to slow disease progression, improve quality of life, and increase
survival, along with being well tolerated by amyotrophic lateral sclerosis (ALS)/
MND patients. Compelling preclinical as well as clinical evidence abounds that stem
cells hold great potential as a therapy for ALS/MND. Although not a definitive
solution yet, stem cells have been verified to have slowed and/or halted disease
progression in a subset of ALS/MND patients.
Keywords: motor neuron disease (MND), amyotrophic lateral sclerosis (ALS),
stem cells, stem cell therapy, neurorehabilitation, neuro-regenerative rehabilitation
therapy (NRRT), bone marrow-derived stem cells (BMSCs), bone marrow-derived
mononuclear cells (BMMNCs)
1. Introduction
Motor neuron disease (MND) is a set of heterogeneous, idiopathic neurodegen-
erative syndromes characterized by progressive degeneration of anterior horn cells
of the spinal cord, clinically characterized by weak and wasting musculature, which
is eventually fatal [1]. Diagnosis is confirmed via thorough neuro-electrophysiological
investigations [2]. Crude incidence of ALS/MND is 1.75 (1.55–1.96)/100,000
person-years of follow-up [3]. The male/female ratio is reported to be between
1 and 3 but varies with population and age [4]. The pathophysiology is multifarious
(see Section 3.1), causing poor prognosis to be the major hurdle faced by clinicians
worldwide [5]. Multidisciplinary symptomatic management is the sole option
that can be availed by patients [6]. Pharmacological treatment includes riluzole
(glutamate inhibition) [7], edaravone (effective only in the early stages) [8], and
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Nuedexta (for treating pseudobulbar affect) [9]. Multidisciplinary rehabilitation is
a key in managing secondary complications of the disease [10–12].
Studies worldwide endorse the safety and efficacy of stem cells as a therapeutic
intervention, for a variety of neurological disorders [13–15], including ALS/MND
[16–22]. Stem cells are a potent weapon in the fight against neurodegeneration.
These cells hold the unique capacity to self-renew indefinitely while also giving rise
to differentiated progeny under defined physiological conditions, thus repopulating
damaged tissue [23]. Exercise has also been shown to enhance the mobilization and
recruitment of these cells [24]. Given these properties, harnessing the potential of
stem cells as a therapy to attenuate disease progression for neurodegenerative
disorders, along with customized rehabilitative regimes, has gained traction in
recent years.
2. Stem cells
The defining characteristics [25] of a stem cell are the unique capabilities of the
following:
2.1 Clonogenicity
Stem cells self-renew throughout life, i.e., the cells undergo symmetric division
under defined physiological conditions to produce identical daughter cells and
thereby maintain the stem cell pool in the organism.
2.2 Multilineage differentiation
Under certain physiological conditions, stem cells may differentiate and divide
asymmetrically to yield an identical daughter cell and a nonidentical, specialized
daughter cell that acquires the properties of a cell type specific to a tissue.
2.3 Tissue regeneration
Stem cells have the capacity to renew the tissues that they populate. The body
contains stem cell “niches,” i.e., specific regulatory microenvironments conducive
to the maintenance, proliferation, and differentiation of stem cells [26].
Depending on the source, stem cells are classified as embryonic stem cells
(ESCs), fetal stem cells (FSCs), adult stem cells (ASCs), and induced pluripotent
stem cells (iPSCs). ASCs are further classified into bone marrow stem cells
(BMSCs), umbilical cord stem cells (UCSCs), and adipose tissue-derived stem cells
(ADSCs). ESCs are pluripotent, self-renewing cells derived from the inner mass of
the preimplantation blastocyst [27]. Their most obvious benefit is their
pluripotency. However, ESCs tend to be highly tumorigenic, require considerable
manipulation, and are in the hotbed of ethical debates [28]. FSCs are multipotent
cells obtained from fetal tissues of natural, spontaneous abortuses that undergo in
utero death within a specific gestational age range [29]. Limited supply, high degree
of heterogeneity in the cell viability and cellular composition, and ethical issues
hamper their clinical application [30].
Among ASCs, BMSCs take the lead in stem cell therapy in a wide variety of
neurological disorders owing to their robust safety profile and efficient integration
into host parenchyma [31–33]. Because these are adult cells, these are easily avail-
able and are not tumorigenic. The distinctive advantage of the BMSCs over other
cell types is the lack of ethical issues for acquisition and administration. Currently,
28
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these comprise the most widely employed therapeutic strategy [19, 22, 31, 34–36].
UCSCs overcome the ethical concerns faced by the ESCs due to the ease of collec-
tion postpartum and minimal processing while posing no risk for the mother or the
child. These cells, however, lose their advantage due to slow engraftment, limited
single-dose availability, and long-term storage issues. Hereditary disorders further
limit the benefits of UCSCs [37]. A minimally invasive subcutaneous accessibility
and isolation procedure and a robust, long-term proliferation capacity outline the
ADSCs’superiority [38, 39]. However, these cells find their limits in the presence of
a highly heterogeneous population [40]. Pluripotent stem cells generated from
cultured adult skin fibroblast cells by “inducing” dedifferentiation of unipotent,
differentiated adult tissue cells by the addition of only a few defined factors are
known as induced pluripotent stem cells [41]. iPSCs circumvent ethical concerns
over the use of human embryos for the generation of cells of a desired tissue.
However, oncogenic factors are used for induction of iPSCs’ phenotype and may
risk spontaneous induction of cancerous phenotypes and genomic instability [42].
3. Stem cells and motor neuron degeneration
3.1 Neuropathology of ALS/MND
Grossly, ALS/MND patients exhibit spinal cord atrophy and, in some cases,
atrophy of cerebral white and gray matter (Figure 1). Some patients who have
concomitant frontotemporal dementia show presence of cortical atrophy in frontal
and temporal cortex. Microscopically, this is characterized by demyelination and
axonal loss (Figure 2) [43–51].
3.2 Mechanism of action of stem cells
The clinical outcomes observed in ALS/MND are currently postulated to be due
to various paracrine and somatic mechanisms that render a neurotrophic effect in
various neurodegenerative diseases (Figure 3).
3.2.1 Paracrine effects
Stem cells confer neuroprotection through various paracrine mechanisms.
Depending on the cellular microenvironment, these cells secrete and regulate a
plethora of neurotrophic factors that are essential for the nervous system, like nerve
growth factor-β (NGF-β, critical for the development and maintenance of the ner-
vous system [52]), ciliary neurotrophic factor (CNTF, promotes neurogenesis [53]),
Figure 1.
The anterior horn of the spinal cord and the precentral gyrus are selectively affected and atrophy in ALS/MND.
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brain-derived neurotrophic factor (BDNF, major role player in neuronal develop-
ment as well as synaptic plasticity [53]), glial cell-derived neurotrophic factor
(GDNF, plays an important role in striatal dopaminergic transport [54]), and
angiopoietin 1 (ANG-1, promotes angiogenesis [55]).
3.2.2 Somatic effects
They also migrate to various tissues by homing strategies and have been shown
to integrate into cells of target tissue.
Figure 2.
Pathophysiology of motor neuron disease is multifaceted. Neuronal and nonneuronal cells like glial cell
dysfunction have been postulated to contribute to the pathophysiology. Oxidative stress and subsequent rise in
intracellular peroxidation, upregulation of astrocytic glutamate, mitochondrial abnormality, immune
dysfunction, excitotoxicity, generalized neuroinflammation due secretion of pro-inflammatory cytokines by
microglia, axonal transport system dysfunction, and synaptic failure are some of the mechanisms that have been
identified. Apart from these mechanisms, abnormal cytoplasmic protein inclusions in patients with ALS have
highlighted genetic causality.
Figure 3.
Stem cells play multifarious roles in mitigating ALS/MND pathology.
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3.2.3 Immunomodulation
These cells exude various beneficial immunomodulatory effects and are capable
of homing onto injured sites, as guided by various chemoattractant pathways [55].
Modification of the exaggerated microglial response by immunomodulatory effects
is also observed. Various secreted neurotrophic factors like connective tissue
growth factor (CTGF), fibroblast growth factor (FGF) 2 and 7, and various inter-
leukins (ILs) are responsible for cell proliferation and cytoprotection. Stem cells
regulate innate and adaptive immune cells through release of soluble factors such as
tumor growth factor (TGF)-β and elevation of regulatory T cells (Tregs) and T-
helper-2 cells (Th2 cells) [56]. Reduced levels of TNF-α, IL-1β, IL-1α, and IL-6 and
increased levels of IL-10 lead to an anti-inflammatory effect on the neural micro-
environment [56–58], enhancing neuronal repair. Soluble factors from stem cells
have been shown to significantly upregulate the expression of glutamate trans-
porters in ALS astrocytes, resulting in enhanced glutamate uptake function. Stem
cells also produce vascular endothelial growth factor (VEGF), hepatic growth factor
(HGF), and insulin growth factor (IGF)-1, which are reported to have
neuroprotective effects [57].
3.2.4 Neurogenesis
Mezey et al. have also shown that in a strain of mice incapable of developing cells
of the myeloid and lymphoid lineages, transplanted adult bone marrow cells
migrated into the brain and differentiated into cells that expressed neuron-specific
antigens [58].
3.2.5 Oligodendrogenesis
Using cell fate tracking techniques, Sasaki and colleagues show that stem cells
can differentiate into an oligodendroglial myelinating phenotype in vivo and repair
demyelinated CNS [59].
3.2.6 Astrogliogenesis
Eglitis and Mezey have demonstrated the ability of hematopoietic stem cells
(HSCs) to differentiate into both astrocytes and microglia in wild-type adult mice
using in situ hybridization [60]. Wislet-Gendebien et al. show that nestin-positive
(but not nestin-negative) mesenchymal stem cells are able to favor the astroglial
lineage in certain stem cell progenitors. They also demonstrate that mesenchymal
stem cells express leukemia inhibitory factor (LIF), CNTF, and BMP2 and BMP4
(bone morphogenic protein) mRNAs-cytokines known to play a role in astroglial
fate decision [61].
3.2.7 Neoangiogenesis
Further secretion of growth factors like vascular endothelial growth factor
(VEGF), fibroblast growth factor (FGF), and brain fibroblast growth factor (bFGF)
leads to neoangiogenesis and upregulation of hormones like erythropoietin [62].
The cascade of events triggered due to these leads to formation of new vessels as
well as improved blood circulation, thus retrieving lost tissue functions. Stem cells
may thus be instrumental in arresting the disease progression through the
abovementioned mechanisms.
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Figure 3.
Stem cells play multifarious roles in mitigating ALS/MND pathology.
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A wide variety of preclinical studies show that stem cells migrate to and restore
lost function of damaged tissue in ALS/MND. Rodent studies have investigated
different cell types such as mouse ES cells differentiated to neurons expressing
green fluorescent protein (GFP) under the promoter of the motor neuron (MN)-
specific gene hb9, mesenchymal stem cells (MSCs), human bone marrow mesen-
chymal stem cells (hMSCs) obtained from an ALS patient (ALS-hMSCs), human
neural stem cells (hNSCs), human cord blood stem cells (HuCB-MNCs), human
embryonic stem cell-derived motor neuron progenitors (hMNPs), bone marrow
cells (BMCs), mesenchymal stromal (stem) cells (MSCs), human umbilical cord
blood (MNC-hUCB), human fetal spinal neural stem cells (hNSCs), human iPSC-
derived neural progenitors (hiPSNPs), HB1.F3.Olig2 cell (stable immortalized
hNSCs encoding the OLIG2 gene)-derived motor neurons, human amniotic mesen-
chymal stem cells (hAMSCs), glial-rich neural progenitors derived from human
iPSCs, enriched population of embryonic stem cell-derived astrocytes (hES-AS),
and neural progenitor cells secreting GDNF (hNPCGDNF) [63–79].
Primarily, stem cells have been shown to have a vast repertoire of paracrine
effects, including release of neurotrophic factors such as GDNF, BDNF, vascular
endothelial growth factor (VEGF), insulin-like growth factor (IGF)-1, NGF, and
neurotrophin (NT)-3. Stem cells also confer neuroprotection by migrating, effi-
ciently engrafting into target tissue, reducing astrogliosis, and differentiating into
neuroglial cell types. Further, they improve motor performance as measured on
rotarod (test measuring rodent balance, grip strength, endurance, and motor coor-
dination), delay disease pathology, and safely extend survival in ALS rodent models
(see Appendix) [20, 63–79].
A limitation of preclinical models of ALS, however, is the inherent inability to
replicate the sporadic onset of ALS/MND, which constitutes majority of patients in
clinical scenario [79]. Additionally, an obvious drawback is the underrepresentation
of the genomic, anatomical, and physiological complexity of humans by the disease
models, which may preclude the translation of results obtained in preclinical set-
tings to the treatment of ALS patients.
4.2 Clinical studies
4.2.1 Worldwide published data
A systematic review and meta-analysis of clinical studies by Moura et al. [80]
have suggested that stem cell therapy is a promising therapy and highlighted the
need for studies with rigorous methodologies to better understand the efficacy of
these therapies. Table 7 (see Appendix) summarizes the studies reviewed by Moura
et al. and other studies that were published using stem cells as therapy in the past
decade. Nineteen clinical studies are summarized; a variety of cells have been
investigated in clinical settings, such as:
1. Autologous mesenchymal stem cells (intraspinal) [81]
2. Bone marrow-derived hematopoietic progenitor stem cells (intraspinal) [18]
3. Autologous peripheral blood stem (intracerebral) [82]
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4. Autologous bone marrow stem cells (intrathecal) [83]
5. Autologous mesenchymal stem cells (intrathecal and intravenous) [31]
6. Olfactory ensheathing cells (intracerebral) and autologous mesenchymal
stromal cells (intrathecal and intravenous or only intrathecal) [84]
7. Neural stem cells derived from a fetal spinal cord (intrathecal) [85]
8. Mesenchymal stem cells induced to secrete neurotrophic factors
(intramuscular, intrathecal, or both) [86]
9. Autologous bone marrow stem cells (intraspinal) [34]
10. Autologous mesenchymal stem cells (intraspinal) [21]
11. Fetal olfactory ensheathing cells (intracerebral) [19]
12. Fetal-derived neural stem cells (intraspinal) [22]
13. NSI-566RSC (Neuralstem, Inc.), a human neural stem cell (intrathecal) [87]
14. Autologous bone marrow mononuclear cells (intrathecal) [16]
15. Mesenchymal stem cells (intrathecal) [35]
16. Autologous mesenchymal stem cells (intravenous, intrathecal) [88]
17. Autologous bone marrow stem cells (intramedullary) [89]
18. Autologous mesenchymal stem cells (intrathecal) [36]
Overwhelmingly, results point toward a robust safety profile for stem cell treat-
ment in ALS/MND. Stem cell therapy has also proven to be efficacious in mitigating
the hostility of a degenerating prognosis in all these studies (see Appendix). These
data collectively advocate for the safety and efficacy of various types of stem cells
for the treatment of this disease, although small scale; larger clinical trials with
sufficient power are required for clearing the turbid field of ALS/MND therapy.
4.2.2 Our published results
4.2.2.1 Our published protocol for stem cell therapy in ALS/MND
4.2.2.1.1 Pre-intervention procedures
We use intrathecal autologous bone marrow mononuclear cell (BMMNC) trans-
plantation for the treatment of ALS/MND, chosen according to the World Medical
Association Declaration of Helsinki—Ethical Principles for Medical Research
Involving Human Subjects. The ethical approval for the intervention is obtained
from Institutional Ethics Committee (IEC). Our exclusion criteria include the pres-
ence of respiratory distress; thus, the effect of stem cell therapy on such patients
cannot be assessed. Our inclusion criteria involve patients diagnosed as definite or
probable ALS according to revised El Escorial criteria [90]. The procedure is
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explained to the patients in detail, and a written informed consent is obtained.
Patients are thoroughly examined by an experienced team of doctors and therapists.
Pre-surgical routine blood tests, urinalysis, and chest X-ray are carried out for
assessing anesthetic and surgical fitness. About 300 μg of granulocyte colony-
stimulating factor (G-CSF) injections are administrated subcutaneously 48 and
24 hours prior to BMMNC transplantation, as they enhance the mobility of
BMMNCs, stimulates CD34+ cells, and increases their survival as well as multipli-
cation rate [91]. The transplant is then carried out in three steps (Figure 4).
4.2.2.1.2 Bone marrow aspiration
Performed in the operation theater under aseptic conditions, 100–120 ml of bone
marrow is aspirated under local anesthesia from the region of anterior superior iliac
spine and collected in the heparinized tubes.
4.2.2.1.3 Cell separation
Using density gradient centrifugation, stem cells are separated. The cell pellet is
analyzed under a microscope using trypan blue to check for the viability of the cells.
Cell number is counted using Tali cell counter. FACS analysis using CD34 PE
antibody is used for identification of CD34+ cells.
4.2.2.1.4 Cell transplantation
In the operation theater under aseptic conditions, the cells are transplanted intra-
thecally into the cerebrospinal fluid through lumbar puncture between the level of
fourth and fifth lumbar vertebra, using an 18G Touhy needle.
4.2.2.1.5 Posttransplantation
Cell transplantation is followed by standard multidisciplinary rehabilitation includ-
ing physiotherapy, occupational therapy, speech therapy, psychological interven-
tion, aquatic therapy, and dietary advice. This approach is termed as neuro-
regenerative rehabilitative therapy (NRRT). Standard medical treatment was con-
tinued with Rilutor. Tablet lithium was prescribed for 6 weeks for its
neuroprotective properties. Lithium levels were monitored.
Figure 4.
Stem cell therapy protocol at NeuroGen Brain and Spine Institute.
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4.2.2.2 Case series
We have published a retrospective controlled cohort study with a total of 57 ALS
patients that investigates the effects of stem cell therapy, in addition to standard
rehabilitation, lithium, and riluzole [79]. Out of these, 37 patients underwent autol-
ogous BMMNC transplantation, while the remaining 20 did not; these served as
controls. We saw that there was a clinically significant difference of 30.38 months
between the average survival duration of intervention and control groups. Inter-
vention group survived for 87.76 (10.45) months, while controls survived for 57.38
(5.31) months. Patients with the onset of the disease below 50 years of age survived
significantly longer (p = 0.039), while limb symptom onset and co-administration
of lithium improved survival duration in a clinically significant manner [16]. Lith-
ium increases the survival, potency, and target tissue integration of BMSCs [92]. It
has been shown to confer neuroprotection in vitro by enhancing cellular BDNF
[93]. In vivo, lithium has been shown to activate autophagy, normalize mitochon-
drial aberration, and suppress reactive astrogliosis. It also reduces ubiquitinated
protein aggregates and increases the number of spared motor neurons in transgenic
ALS mice [94]. Further, lithium is well tolerated by ALS patients who are on
riluzole, even though it may not be effective by itself for treating ALS. This was
confirmed by two trials: a phase III multicenter, randomized, double-blind,
placebo-controlled trial (LiCALS) by Al-Chalabi et al. [95] and a phase IIb random-
ized, double-blind, placebo-controlled, sequential trial by Verstraete et al. [96].
Taken together, these results suggest that a combination strategy of stem cells and
lithium may have played a pronounced role in the outcomes of this study, summa-
rizes the prognostic factors that influence survival in the intervention group. Youn-
ger age at symptom onset and spinal symptom onset favors longer survival
durations according to our findings. Post intervention, lithium prescription com-
bined with standard riluzole treatment and comprehensive rehabilitation enhances
the effect of cellular therapy (Figure 5 and Table 1).
4.2.2.3 Case reports
A 40-year-old female suffering from ALS for 3 years was given intrathecal
autologous BMMNC transplantation along with riluzole, lithium, and intensive
rehabilitation. The disease progression slowed over 17 months along with improve-
ments in neurological symptoms. de Carvalho et al. have previously reported that
the ALSFRS-R score deteriorates about 17% every 6 months [97]; here, the ALSFRS-
R score dropped only by 8% over 17 months after cell transplantation (Figure 6 and
Table 2) [98].
A 41-year-old female suffering from ALS for 3 years was given intrathecal
autologous BMMNC therapy combined with riluzole, neuro-rehabilitation, and
6 weeks of lithium. Her ALSFRS-R score increased from 29 to 32, and FIM score
increased from 48 to 64. The highlight of this case is halting of disease progression
with symptomatic improvements over a period of 12 months after intervention
(Table 3 and Figure 7).
A 63-year-old man who underwent autologous intrathecal BMMNC transplan-
tation as a therapy in a clinical case of MND followed by multidisciplinary
neurorehabilitation showed improvements in muscle strength, fine motor activities,
fasciculation, cramps, and walking (Table 4). ALSFRS-R score improved from 33 to
37; Berg’s balance score improved from 43 to 50, and 6-minute walk test improved
from 283.8 to 303.6 m. His FIM score remained unchanged at 113. These improve-
ments may be attributed to cellular therapy along with standard treatment and
neurorehabilitation [99].
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Figure 5.
(a) Kaplan-Meier survival analysis comparing the mean survival duration of the intervention (n = 37) and
control group (n = 20) from Sharma et al. [16]. Mean survival duration of patients in the intervention group
was higher than the control group by a clinically significant difference of 30.38 months. (b) Subgroup analysis
of the effect of age of symptom onset on survival duration within the intervention group, from Sharma et al. [16]
shows significantly higher survival of those with an onset of symptoms above 50 years of age (p = 0.039).
(c) Subgroup analysis of the effect of the type of symptom onset (limb vs. bulbar) on survival duration in the
intervention group shows higher survival of patients with limb onset of symptoms by 12.23 months.
(d) Subgroup analysis of the effect of lithium prescription on survival duration within the intervention group
shows a clinically higher survival of 106.73 months of the group prescribed with lithium. This is a clinically
significant difference of 30.90 months as compared to controls, whose average survival was 66.83 months.
Prognostic factor Median survival since symptom onset p-Value
Lithium Given 106.73 (15.69) 0.121
Not given 66.83 (7.52)
Age at symptom onset Below 50 years 113.34 (15.45) 0.039*
Above 50 years 63.02 (7.7)
Type of symptom onset Limb 78.01 (14.23) 0.902
Bulbar 90.24 (13.27)
*Statistically significant (p < 0.05).
Table 1.
Summary of prognostic factors affecting patient survival in the intervention group, from Sharma et al. [16].
Standard deviation is indicated in parentheses.
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Figure 6.
Maintenance of a 40-year-old female ALS patient’s condition over the period of 17 months. Disease progression
in patient (red) was compared using ALSFRS-R with average values obtained from de Carvalho et al. (blue) at






At 5 months after the first








ALSFRS-R 36 36 36 33
FIM 113 113 113 113
Table 2.
ALSFRS-R and FIM instrument scores of the patient remain stable as compared to assessment, when followed


















ALSFRS-R 29 33 34 33 32
FIM 48 72 73 71 64
Table 3.
ALSFRS-R and FIM scores of a 41-year-old female ALS patient measured at assessment and after intervention
(at 2, 6, 9, and 12 months post autologous BMMNC transplantation) depict stark improvement.
Figure 7.
ALSFRS-R and FIM scores were marked at 2, 4, 6, 9, and 12 months for this patient. ALSFRS-R score was
measured across survival duration (in months) to compare the disease progression of this patient with natural
disease progression in ALS, as measured by de Carvalho et al. [97]. The patient’s condition was maintained
over a period of 12 months.
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A 29-year-old female patient with anterior horn cell involvement suffering from
MND for 5 years presented with complaints of sudden onset of weakness in bilateral
lower limbs post pregnancy. Her progressive condition was followed by gradual
involvement of upper limbs also; EMG studies were also suggestive of MND. Her
features were suggestive of pure motor system involvement affecting lower motor
neurons. Post NRRT, she immediately showed clinical and functional
improvements [17].
4.2.2.4 Unpublished data
4.2.2.4.1 Female hormones enhance the neuroprotective benefits of cellular
transplantation in patients with amyotrophic lateral sclerosis (ALS)
The male/female ratio in ALS/MND worldwide points toward a lower incidence in
females as compared to males. We hypothesized that this was due to a
neuroprotective effect conferred by female hormones. In order to investigate this
hypothesis, we designed a cohort study with 40 sequentially recruited ALS patients
(28 males and 12 females) who were treated with stem cell therapy. To study the
effect of reproductive hormones, patients were divided into pre- and postmeno-
pausal women and men below and above 50 years of age.
We saw that percentage survival was highest in the premenopausal women
(100%) followed by men below the age of 50 years (75%), postmenopausal women
(60%), and men above the age of 50 years (45%). The disease progression was also
slowest in the premenopausal women, followed by postmenopausal women, and
men below 50 years of age; it was fastest in men above the age of 50 years
(Table 5).
Outcome measures Pre-first SCT At 6 months post the first SCT
ALSFRS-R 33 37
FIM 113 113
6-minute walk test 283.8 m 303.6 m
Berg’s balance score 43 50
Table 4.
Improvements in outcome measures over a period of 6 months in a 63-year-old male ALS patient. ALSFRS-R,












26 23 3 20 0
Postmenopausal
females (5)
21 14 7 14 40
Males below
50 years of age (16)
25 20 5 10 25
Males above
50 years of age (12)
32 25 7 13 55
Table 5.
Percentage mortalities across the four subgroups in a cohort study.
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4.2.2.4.2 Correlation of testosterone levels with progression of amyotrophic lateral
sclerosis: a cross-sectional study
We conducted an open-label nonrandomized cross-sectional study to interrogate
the relationship of testosterone (TT) with disease progression. We found that 39 of
the total 50 (78%) ALS patients had plasma TT levels lower than the mean levels in
healthy, age-matched control males. We also found a decline in TT levels as the
disease progressed on King’s staging as well as ALSFRS-R (Figure 8). There was a
statistically significant moderate monotonic correlation between ALSFRS-R scores
and King’s staging of patients with plasma testosterone levels (ALSFRS-R: r = +0.33;
Figure 8.
Relationship of testosterone with (a) King’s staging and (b) ALSFRS-R.
Figure 9.
Kaplan-Meier survival curves for control vs. intervention groups in our open-label study with a total of 157
subjects (intervention = 116; control = 41). On an average, the treated group survived for 32 months longer
than the control group (p = 0.026).
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King’s staging: r = 0.35; p = 0.01). Taken together, these results suggest that
reduced testosterone may exacerbate motor neuron loss or cause other
etiopathological dysfunctions that remain to be elucidated.
4.2.2.4.3 Effect of intrathecal application of autologous bone marrow mononuclear cells
on survival duration in ALS
We performed a large, open-label cohort study, which included 157 patients diag-
nosed with ALS from September 2013 to May 2017. About 116 patients who
received cell transplantation (autologous BMMNCs) together with standard treat-
ment formed the treatment group, and 41 patients who received only the standard
treatment formed the control group (Figure 9 and Table 6). We observed that on
an average, the treated group survived for 32 months longer than the control group
(p = 0.026).
Collectively, these findings were indicative of possible neuroprotective benefits
of female reproductive hormones. Prognostic factors that predict improved survival
and retarded disease progression include lithium co-administration, limb onset of
symptoms, younger age of symptom onset, and, most importantly, presence of
female hormones (Figure 10).
Characteristics Intervention Control
Total number of patients 157 116 41
Gender Males 81 30
Females 35 11
Mean age at symptom onset (years) 51  11 53  9
Type of symptom onset Bulbar 26 6
Limb 90 21
Table 6.
Demographic data for an open-label study with 157 participants.
Figure 10.
(a) Subgroup analysis: survival duration was 46 months more in patients with limb onset as compared to
bulbar onset (p = 0.001). Bulbar onset n = 26 patients and limb onset n = 90. (b) Survival duration was
41 months more in patients with age of symptom onset <50 years as compared to symptom onset at/above
50 years (p < 0.000).
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5. Conclusion and future directions
Stem cell therapy is a novel, promising modality for the treatment of ALS/MND.
Robust safety profiles, low risk-to-benefit ratio, and ease of access make this
approach a strong contender in the race against ALS/MND. Consistently, autolo-
gous BMMNC therapy has been proven to mitigate disease progression; however,
this response may be dependent on various factors, like age of symptom onset,
gender, hormones, type of onset (limb vs. bulbar), and genetic makeup of the
patient, to name a few. Younger patients—especially premenopausal females—may
respond better to autologous BMMNC therapy. Stem cells combat tissue degenera-
tion via a host of somatic and paracrine mechanisms, including neurogenesis,
astrogliogenesis, neoangiogenesis, and immunomodulation. Multidisciplinary
neurorehabilitation enhances the response to cellular therapy.
Although not a cure yet, a combinatorial approach integrating stem cell therapy,
intensive neurorehabilitation, and current pharmacotherapeutic agents (e.g.,
riluzole, lithium, etc.) may be the best way forward. Studies that interrogate the
genetics of patients and their family are the need of the hour, to enhance response
to treatment and develop diagnostics and biomarkers. Also, the role of reproductive
hormones such as progesterone, estradiol, and testosterone needs to be further
explored. Larger clinical studies with stringent criteria are required to understand
the efficacy of these combined methods in the treatment of ALS/MND. The current
scenario suggests that autologous stem cell therapy can be considered along with
standard treatment in carefully selected patients of ALS/MND.
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9/13 (69.23%) patients improved as
compared with their preoperative
status, as confirmed by EMG
Martinez et al. [82], Mexico
(controlled clinical trial, 10)
Autologous peripheral blood
stem (intracerebral)
The survival of treated patients was
statistically higher (p = 0.01) than
untreated control patients
Prabhakar et al. [83], India
(clinical trial—pilot study, 10)
Autologous bone marrow stem
cells (intrathecal)
There was no significant
deterioration in ALSFRS-R
composite score from baseline at a
1-year follow-up (p = 0.090). The
median survival post procedure was
18.0 months and median time to 4-
point deterioration was 16.7 months
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Karussis et al. [31], Israel
(phase I/phase II clinical
trial, 19)
Autologous mesenchymal
stem cells (intrathecal and
intravenous)
The mean ALSFRS-R score
remained stable during the first
6 months of observation. In 80%
of the patients, FVC values
remained stable or above 70% for a
time of 9 months and remained in
60% of patients at 12 months after
application. Signs of disease
stabilization in some patients during
the first 6 months after the
intervention





(intrathecal + intravenous or
only intrathecal)
No changes in the decline of FVC
and ALSFRS-R compared with the
disease’s natural history were
observed
Riley et al. [85], USA (phase I
safety trial, 12)
Neural stem cells derived from
a fetal spinal cord (intrathecal)
Procedural safety of unilateral and
bilateral intraspinal lumbar
microinjections has been suggested
by the results of this trial
Petrou et al. [86], Israel (open-
label proof-of-concept study,





intrathecal (IT) or (IT+IM))
Progression rate of the ALSFRS-R
score in the IT (or IT+IM)-treated
patients was reduced from 1.2 to
0.6 ALSFRS-R points/month
(p = 0.052), and the progression rate
of the forced vital capacity reduced
from 5.1% to 1.2%/month during
the 6 months follow-up vs.
pretreatment period
Blanquer et al. [34], Spain
(clinical trial, pilot safety
study, 11)
Autologous bone marrow stem
cells (intraspinal)
7/11 (63.63%) patients remained
stable post procedure
Mazzini et al. [21], Italy




Brain MRI revealed no structural
changes relative to baseline
throughout follow-up. No
deterioration noted in the
psychosocial status as well
Huang et al. [19], China
(controlled pilot study, 35)
Fetal olfactory ensheathing
cells (intracerebral)
7/14 improved; 2/14 remained stable
compared to the entry in the treated
group, while only 1/17 of the
patients remained stable within
control
Glass et al. [22], USA (phase I
clinical trial, 12)
Fetal neural stem cells
(intraspinal)
Patients remained stable and
tolerated the therapy well, as seen in
clinical assessments at 6–18 months




Cellular delivery to the cervical or
thoracolumbar spinal cord was well
tolerated by the patients






Mean survival duration of
intervention was 87.76 months,
which was higher than the control
(57.38 months) or previous
epidemiological studies. Survival
duration was significantly
(p = 0.039) higher in people with
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the onset of the disease below
50 years of age. Limb onset and
lithium also showed positive
influence on the survival duration
Oh et al. [35], South Korea




Decline in the ALSFRS-R score was
slow during the 6-month follow-up
period
Rushkevich et al. [88], Belarus




Evaluation of the 12-month follow-
up revealed slowing down of the
disease progression in 10 patients
Ruiz-López et al. [89], Spain
(phase I clinical trial, 11)
Autologous bone marrow stem
cells (intramedullary)
All 11 patients were 100% stable
Syková et al. [36], Czech
Republic (phase I/phase IIa
prospective, nonrandomized,




was found in ALSFRS-R decline at 3,
6, 9, and 12 months after treatment
All studies demonstrate safety of stem cells, except Glass et al. [22]. Safety in this table does not describe events
unrelated to stem cell therapy.
Table 7.
Significant clinical studies employing stem cell therapy for treatment of ALS/MND, primarily from March
2009 to February 2019.
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Chapter 4
Introduction to Novel Motor 
Neuron Disease
Humberto Foyaca Sibat and Lourdes de Fátima Ibañez Valdés
Abstract
Motor neuron disease (MND) is a progressive and fatal neuromuscular disease; 
the most common and severe form of MND presentation is amyotrophic lateral 
sclerosis (ALS), commonly known as Lou Gehrig’s disease. The majority of ALS 
patients die within 2–5 years of receiving a diagnosis. Familial ALS is a hereditary 
form of the disease and accounts for 5–10% of cases, whereas the remaining cases 
have no clearly defined etiology. ALS affects persons of all ethnicities and races; 
currently, no curative treatment for ALS is available worldwide. ALS is also the 
major adult-onset MND and is clinically, pathologically, and genetically associated 
with fronto-temporal dementia in some cases, which is the second cause of demen-
tia in elderly people. However, MND does not affect sphincter, sexual function, 
or eye movements. MND is the most common degenerative disorder affecting the 
upper and lower motor neurons at the same time. Most of the patients presenting 
MND in our series complained of muscle weakness, muscle wasting, fasciculation, 
and spasticity plus lower cranial nerve disturbances. According to our bibliographic 
studies, apart from nusinersen, it seems to be that riluzole and edaravone also 
improve motor neuron function by acting on SK channels.
Keywords: motor neuron disease, amyotrophic lateral sclerosis, spinal muscular 
atrophy, riluzole, edaravone
1. Introduction
Motor neuron disease is composed of a group of rare neurodegenerative disor-
ders, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), 
hereditary spastic paraplegia, primary lateral sclerosis, progressive muscular 
atrophy, pseudobulbar palsy, O’Sullivan-McLeod syndrome, and Madras motor 
neuron disease, which are fatal in 50% of affected people within 15–20 months after 
diagnosis. MND is a progressive neuromuscular disease with a fatal outcome; the 
commonest clinical presentation of MND presentation is ALS, commonly known 
as Lou Gehrig’s disease. Most of ALS patients pass away within 2–5 years of con-
firmed a diagnosis. Familial ALS (ALSf) is a hereditary presentation of the disease 
and accounts for 5–10% of affected people. ALS affects persons of all ethnicities 
worldwide; no cure for ALS has yet been available at any country. Sometimes, 
ALS is clinically, pathologically, and genetically associated with fronto-temporal 
dementia, which is the second cause of dementia in elderly people. In our first book, 
we reviewed all previous chapters published by INTECH, and in the Introductory 
Chapter, readers could find summarized information about all publications on ALS 
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1. Introduction
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ders, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), 
hereditary spastic paraplegia, primary lateral sclerosis, progressive muscular 
atrophy, pseudobulbar palsy, O’Sullivan-McLeod syndrome, and Madras motor 
neuron disease, which are fatal in 50% of affected people within 15–20 months after 
diagnosis. MND is a progressive neuromuscular disease with a fatal outcome; the 
commonest clinical presentation of MND presentation is ALS, commonly known 
as Lou Gehrig’s disease. Most of ALS patients pass away within 2–5 years of con-
firmed a diagnosis. Familial ALS (ALSf) is a hereditary presentation of the disease 
and accounts for 5–10% of affected people. ALS affects persons of all ethnicities 
worldwide; no cure for ALS has yet been available at any country. Sometimes, 
ALS is clinically, pathologically, and genetically associated with fronto-temporal 
dementia, which is the second cause of dementia in elderly people. In our first book, 
we reviewed all previous chapters published by INTECH, and in the Introductory 
Chapter, readers could find summarized information about all publications on ALS 
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made by INTECH. Trying to illustrate the reached progress, we displayed this infor-
mation grouped by topics and countries in two graphics. As we saw on that book, 
the number of publications written about ALS increased remarkably for the past 4 
years. To have some idea of this phenomenon, be informed that INTECH published 
more than 40 chapters on ALS in this period of time, and these books “Amyotrophic 
Lateral Sclerosis,” “Current Advances on Amyotrophic Lateral Sclerosis,” and others 
are fully available on line, for free. Therefore, why we are going to publish another 
chapter? All novel information about MND were not published. Therefore, some 
aspects published in 2012 need to be update because new ideas, proposals, findings, 
experiences, and many other’s knowledge have been arising despite of this short 
period of time. Therefore, for the benefit of the readership community, we included 
update information not reported before, mainly new contribution of aberrant 
astrocytes to MND damage and death in the SOD1G93A rat experimental model of 
ALS; novel genetics studies on ALS; an update of the structural and functional con-
sequences of the spinal muscular atrophy-linked mutations of the survival motor 
neuron protein; stem cell therapy for MND; and the novel treatment for SMA and 
ALS in the introductory chapter of this book. Compromises have been inevitable to 
accommodate our visual and factual updated information in a book of his charac-
teristic on top of many chapters about the same issue published recently.
MND does not affect sphincter, sexual function, or eye movements [1]. 
Although ALS is not associated with thermoregulatory dysfunction, its progression 
can affect intensively important cerebral regions that control body temperature and 
affect multiple functions of this homeostatic activity. Nevertheless, experimental 
ALS animals can display altered thermoregulation as a consequence of affected 
energy homeostasis. Indirect evidence suggests, performing studies on the body 
temperature regulatory system, both as a possible modifier of disease progression in 
ALS and as a potential biomarker [2].
Although edaravone and riluzole do not cure MND/ALS, it seems to be that both 
medications can slow its progression. The prevalence of ALS in America was 5.2 
per 100,000 populations with a total of 16,583 cases identified from January 1 to 
December 31, 2015 [3].
MND is the most common degenerative disorder, which affects the upper and 
lower motor neurons at the same time. There are different clinical modalities of 
MND being ALS the commonest one, and its incidence is around 1–3 patients every 
100,000 people [4, 5].
The higher incidence of ALS is in patients with 60 and 70 years of age, but some 
younger cases (20–30 years of age) have been reported as well [4]. Between 5 and 
10% of the patients have a familiar origin due to Mendelian autosomal dominant 
transmission.
Most of the patients presenting MND in our series complain of muscle weak-
ness, muscle wasting, fasciculation, and spasticity plus cranial nerve disturbances 
from the lower brainstem.
The most frequent mutation seen in the familial form of ALS (ALSf) occurs on 
the gene of superoxide dismutase 1 (SOD1) and on the chromosome 9, among oth-
ers. The decreased endovascular factor and the hereditary hemochromatosis protein 
are also genetic mutations. Some variations in the number of copies of Genes 1 and 
2 that codify the motor neuron survival factors have been reported [6]. No correla-
tion investigations have been done. However, some genome-wide studies in patients 
presenting ALS show a series of loci confirming a greater susceptibility to develop 
the disease such as kinase carbohydrate (FGGY), dipeptidyl-peptidase 6 (DPP6), 
and Type 2 inositol triphosphate receptor [7–9]. Most of these findings were not 
able to be replicated in further investigations done. At present, there is not specific 
cure for this deadly disorder as was mentioned before.
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Long time ago, a nitrogenic expansion on the gene C9ORF72 was observed in a 
number of patients presenting ALS associated with Chromosome 9, which brought 
more clarity in the ethiopathogenesis of ALS [10, 11], but these findings are also 
seen in patients presenting fronto-temporal dementia (FTD) and ALS-FTD  
[10, 11]. Below, we will deliver more comments about this topic.
Future genetic investigations should be focused on non-European populations in 
order to bring more clarity on new pathogenic loci.
In the forthcoming years, the exome study that is an emerging field will bring 
novel information about some implicated genes in ALSf.
In 2018, Thompson et al. [12] used a high-throughput proteomic process to dis-
tinguish new biomarkers in patient’s cerebrospinal fluid (CSF), and they found that 
three macrophage-derived chitinases had increased concentration in ALS: chitin-
ase-3-like protein 1, chitotriosidase, and chitinase-3-like protein 2. Elevated CHI3L1 
was commonly seen in ALS, while CHI3L2 and CHIT1 levels did not. Their results 
confirmed the important role of macrophage activity in pathogenesis of ALS.
Decreased cough capacity is almost always present in respiratory tract infec-
tion and is the most important cause of respiratory failure in ALS patients. Other 
authors determined whether the lung function measurement could identify the 
cough function in ALS patients with respiratory tract infection. After screening 
48 patients presenting ALS, they found only four presenting a remarkable cough 
with no assistance. The data that identified unassisted cough effectiveness are peak 
cough flow. These investigators highlighted that the effectiveness of assisted and 
unassisted cough function depends on the peak cough flow reached [13].
It is well known that MND does not affect the motor neurons at the oculomotor 
nucleus in the midbrain. Because it could be remarkably advantageous if neurons 
of motor system resilience can be modeled in vitro, some authors reached elevated 
quantities of oculomotor neurons from embryonic stem cells in mouse through 
transient over expression of PHOX2A in nerve cell progenitors, and they con-
firmed, using immunocytochemistry techniques, electrophysiology studies, and 
RNA sequencing, that in vitro-generated neurons are bona fide oculomotor neuron 
cells based on their neuron properties and similarity to their counterpart in rodent 
(in vivo) and human beings [14].
Increased cortical excitability, thought to reflect pathological changes in the 
balance of local excitatory and inhibitory neuronal influences that are commonly 
seen in patients presenting ALS and non-invasive brain stimulation (NIBS), has 
been shown to modulate cortical activity, with some protocols showing effects that 
outlast the stimulation by months. Therefore, NIBS has been proposed as a probable 
candidate to approach therapeutically these disorders associated with pathological 
neurophysiology activity, such as ALS, among others [15].
ALS type 8 (ALS8) is a familial presentation of MND, with an important 
anterior horn cell degeneration, due to mutation of the vesicle-associated mem-
brane protein-associated protein B. Some authors compare the cognitive function 
of patients with ALS8 and a control group composed by healthy people in order 
to screen behavioral features in ALS8 patients. These authors found that ALS8 
patients showed minimal deficits in executive functions. The total amount of ALS8 
patients and the control group have the same scores of facial emotion recognition. 
They also determined an important clinical expression of psychiatric disorder such 
as anxiety and depression in 36 and 27% of patients, respectively. However, behav-
ioral disturbances were present in around 30% of participants. They concluded 
that these patients had mild executive problems and behavioral problems such as 
apathy, mood disorder, and stereotypic behavior, which suggest that ALS8 is not 
a motor disorder only, and it is associated with minor cognitive and behavioral 
changes [16].
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Lateral Sclerosis,” “Current Advances on Amyotrophic Lateral Sclerosis,” and others 
are fully available on line, for free. Therefore, why we are going to publish another 
chapter? All novel information about MND were not published. Therefore, some 
aspects published in 2012 need to be update because new ideas, proposals, findings, 
experiences, and many other’s knowledge have been arising despite of this short 
period of time. Therefore, for the benefit of the readership community, we included 
update information not reported before, mainly new contribution of aberrant 
astrocytes to MND damage and death in the SOD1G93A rat experimental model of 
ALS; novel genetics studies on ALS; an update of the structural and functional con-
sequences of the spinal muscular atrophy-linked mutations of the survival motor 
neuron protein; stem cell therapy for MND; and the novel treatment for SMA and 
ALS in the introductory chapter of this book. Compromises have been inevitable to 
accommodate our visual and factual updated information in a book of his charac-
teristic on top of many chapters about the same issue published recently.
MND does not affect sphincter, sexual function, or eye movements [1]. 
Although ALS is not associated with thermoregulatory dysfunction, its progression 
can affect intensively important cerebral regions that control body temperature and 
affect multiple functions of this homeostatic activity. Nevertheless, experimental 
ALS animals can display altered thermoregulation as a consequence of affected 
energy homeostasis. Indirect evidence suggests, performing studies on the body 
temperature regulatory system, both as a possible modifier of disease progression in 
ALS and as a potential biomarker [2].
Although edaravone and riluzole do not cure MND/ALS, it seems to be that both 
medications can slow its progression. The prevalence of ALS in America was 5.2 
per 100,000 populations with a total of 16,583 cases identified from January 1 to 
December 31, 2015 [3].
MND is the most common degenerative disorder, which affects the upper and 
lower motor neurons at the same time. There are different clinical modalities of 
MND being ALS the commonest one, and its incidence is around 1–3 patients every 
100,000 people [4, 5].
The higher incidence of ALS is in patients with 60 and 70 years of age, but some 
younger cases (20–30 years of age) have been reported as well [4]. Between 5 and 
10% of the patients have a familiar origin due to Mendelian autosomal dominant 
transmission.
Most of the patients presenting MND in our series complain of muscle weak-
ness, muscle wasting, fasciculation, and spasticity plus cranial nerve disturbances 
from the lower brainstem.
The most frequent mutation seen in the familial form of ALS (ALSf) occurs on 
the gene of superoxide dismutase 1 (SOD1) and on the chromosome 9, among oth-
ers. The decreased endovascular factor and the hereditary hemochromatosis protein 
are also genetic mutations. Some variations in the number of copies of Genes 1 and 
2 that codify the motor neuron survival factors have been reported [6]. No correla-
tion investigations have been done. However, some genome-wide studies in patients 
presenting ALS show a series of loci confirming a greater susceptibility to develop 
the disease such as kinase carbohydrate (FGGY), dipeptidyl-peptidase 6 (DPP6), 
and Type 2 inositol triphosphate receptor [7–9]. Most of these findings were not 
able to be replicated in further investigations done. At present, there is not specific 
cure for this deadly disorder as was mentioned before.
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Long time ago, a nitrogenic expansion on the gene C9ORF72 was observed in a 
number of patients presenting ALS associated with Chromosome 9, which brought 
more clarity in the ethiopathogenesis of ALS [10, 11], but these findings are also 
seen in patients presenting fronto-temporal dementia (FTD) and ALS-FTD  
[10, 11]. Below, we will deliver more comments about this topic.
Future genetic investigations should be focused on non-European populations in 
order to bring more clarity on new pathogenic loci.
In the forthcoming years, the exome study that is an emerging field will bring 
novel information about some implicated genes in ALSf.
In 2018, Thompson et al. [12] used a high-throughput proteomic process to dis-
tinguish new biomarkers in patient’s cerebrospinal fluid (CSF), and they found that 
three macrophage-derived chitinases had increased concentration in ALS: chitin-
ase-3-like protein 1, chitotriosidase, and chitinase-3-like protein 2. Elevated CHI3L1 
was commonly seen in ALS, while CHI3L2 and CHIT1 levels did not. Their results 
confirmed the important role of macrophage activity in pathogenesis of ALS.
Decreased cough capacity is almost always present in respiratory tract infec-
tion and is the most important cause of respiratory failure in ALS patients. Other 
authors determined whether the lung function measurement could identify the 
cough function in ALS patients with respiratory tract infection. After screening 
48 patients presenting ALS, they found only four presenting a remarkable cough 
with no assistance. The data that identified unassisted cough effectiveness are peak 
cough flow. These investigators highlighted that the effectiveness of assisted and 
unassisted cough function depends on the peak cough flow reached [13].
It is well known that MND does not affect the motor neurons at the oculomotor 
nucleus in the midbrain. Because it could be remarkably advantageous if neurons 
of motor system resilience can be modeled in vitro, some authors reached elevated 
quantities of oculomotor neurons from embryonic stem cells in mouse through 
transient over expression of PHOX2A in nerve cell progenitors, and they con-
firmed, using immunocytochemistry techniques, electrophysiology studies, and 
RNA sequencing, that in vitro-generated neurons are bona fide oculomotor neuron 
cells based on their neuron properties and similarity to their counterpart in rodent 
(in vivo) and human beings [14].
Increased cortical excitability, thought to reflect pathological changes in the 
balance of local excitatory and inhibitory neuronal influences that are commonly 
seen in patients presenting ALS and non-invasive brain stimulation (NIBS), has 
been shown to modulate cortical activity, with some protocols showing effects that 
outlast the stimulation by months. Therefore, NIBS has been proposed as a probable 
candidate to approach therapeutically these disorders associated with pathological 
neurophysiology activity, such as ALS, among others [15].
ALS type 8 (ALS8) is a familial presentation of MND, with an important 
anterior horn cell degeneration, due to mutation of the vesicle-associated mem-
brane protein-associated protein B. Some authors compare the cognitive function 
of patients with ALS8 and a control group composed by healthy people in order 
to screen behavioral features in ALS8 patients. These authors found that ALS8 
patients showed minimal deficits in executive functions. The total amount of ALS8 
patients and the control group have the same scores of facial emotion recognition. 
They also determined an important clinical expression of psychiatric disorder such 
as anxiety and depression in 36 and 27% of patients, respectively. However, behav-
ioral disturbances were present in around 30% of participants. They concluded 
that these patients had mild executive problems and behavioral problems such as 
apathy, mood disorder, and stereotypic behavior, which suggest that ALS8 is not 
a motor disorder only, and it is associated with minor cognitive and behavioral 
changes [16].
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Because one of the most effective clinical strategies for SMA is to protect the 
anterior horn cell, apart from nusinersen (that is a very expensive medication), one 
anti-epileptic medication levetiracetam has been used as well.
Kepra (levetiracetam) provoked neurite elongation in SMA-iPSCs-MNs. 
TUNEL-positive anterior horn cell was significantly decreased by kepra in SMA-
iPSCs-MNs. On the other hand, the expression level of cleaved-caspase 3 was 
diminished by levetiracetam in SMA-iPSCs-MNs. Furthermore, kepra improved 
impaired mitochondrial function in SMA-iPSCs-MNs. On the other hand, kepra did 
not modify the expression level of SMN protein in SMA-iPSCs-MNs. These results 
suggest that kepra has a neuroprotective effect for SMA [17].
For patients presenting SMA (most common reason of inherited infant mortal-
ity), the gene therapy seems to be the most effective strategy [18].
Another therapeutic modality to treat ALS is the noninvasive brain stimulation 
(NIBS), which has been shown to modulate cortical activity, with some protocols 
leading effects that outlast the stimulation by months. NIBS have been suggested 
as a potential treatment choice in those processes with associated changes in the 
cortical neurophysiology [15].
A total of 25 genes associated with ALSf and ALS (sporadic form), mutations in 
fused-in-sarcoma (FUS) and superoxide dismutase 1 (SOD1) have been intensively 
studied in the past, focusing on modified excitability of motor neurons. Based on 
their personal experience, Peikkert et al. [19] proposed that the 4-aminopyridine 
(4-AP), which is a potassium channel blocker, can be utilized as a probable therapy 
for ALS patients due to its demonstrated hypo excitability and high frequency of 
apoptosis in a FUS/SOD1-ALS-induced multi-potent stem cell from selected motor 
neuron; they also found that this process is partly reversible by 4-AP.
One of the clinical presentations of MND is SMA, which encompasses a group 
of autosomal recessively inherited degenerative neuromuscular diseases. SMA is an 
inherited disorder that causes progressive lesions on the anterior horn cell leading 
to weakness or paralysis of the affected limbs, and it is caused by elimination or 
mutation of survival motor neuron (SMN) 1 gene. It is well known that homozy-
gous damage and loss of functional mutations in the survival motor neuron 1 gene 
(SMN1) at the chromosome 5q13 are the main cause of SMA, which affect 1 in 
11,000 newborn infants.
SMA usually has a very poor prognosis after rapidly progressive weakness and 
early mortality. However, a new medication named Nusinersen has been released 
for the treatment of all forms of SMA (not on mechanical ventilation) with very 
good results. In December 2016, this medication was approved in the United States. 
Nusinersen, an antisense oligonucleotide (ASO), is administered directly into CSF. It 
alters SMN2 pre-RNA splicing, so exon 7 is included, increasing expression of func-
tional SMN protein. Efficacy assessments for patients receiving nusinersen are based on 
serial assessments of performance on age-appropriate standardized motor scales. Treatment 
requires complex financial and logistics because of the very high drug cost, intrathecal 
administration, and medical fragility of the patients. Treatment implementation also 
engenders ethical considerations related to cost, insurance coverage, limited clinical data on 
groups of patients not in clinical trials, and questions of duration of treatment [20].
One in 50 asymptomatic people carries this autosomal recessive neuromuscular 
code causing SMA in one over 10,000 live births [21].
Based on age at onset, the highest milestone reached, and phenotypic severity: 
SMA has been separated into four different subgroups such as “Nonsitters” (Type I), 
“sitters” (Type II), “walkers” (Type III), and “adult onset” (Type IV) [22].
At the present moment, many patients got confirmation of diagnose very late, or 
the treatment is administered in advance stages. Therefore, poor response is often 
obtained.
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Fortunately, some screening programs are available and accurately and then to 
identify children in pre-symptomatic stages is possible [23]. However, because some 
children develop their clinical manifestation far from birth then to decide when to 
initiate the treatment and whom qualify for therapy is a dilemma.
The majority of SMN2 pre-mRNA transcripts undergo alternative splicing due to 
a nucleotide substitution leading to exclusion of exon 7. Degradation of the result-
ing truncated SMN protein is very fast, and the overall lack of full-length SMN 
protein causes permanent damage on anterior horn cell of the spinal cord [23].
In patients with onset of the disease beyond six months of age, large phase 3 
trials confirmed improvement in motor activities, very high event-free and remark-
able survival in infantile-onset SMA3, also significant improvement in Expanded 
version of the Hammersmith Functional Motor Scale scores has been recorded 
[24, 25].
The copy number of the homologous SMN2 gene is inversely correlated with 
SMA severity and encoded by SMN1 (except for lack of exon 7), which is identical 
to the cDNA encoded by SMN2.
Currently, for the therapy of SMA, there are pipelines developed by antisense 
oligonucleotide (ASO), also available for Huntington disease, ALS, spinocerebellar 
ataxias, Parkinson disease, and Alzheimer disease, among other options, and the 
pharmaceutical industry on ASO development has been delivering a promising 
therapeutic approach. The key care concern to MND patients has been developed, 
and expert consensus guidelines delivered, and best management for lung diseases, 
nutritional problems, and palliative care has also been reached. However, in this 
chapter, we will discuss novel aspects related to treatment and other therapeutic 
procedures later on.
In pre-symptomatic SMA patient’s Types I–III released interim results of a phase 
2 trial evaluating the effects of Nusinersen have been done [23].
Some investigators have been working on stage of improvement after the treat-
ment of SMA and confirmed that the first published data supported important 
good results on the motor function and quality of life from animal models with 
early restoration of SMN levels for those studied within the first 3 postnatal days. 
However, for those treated beyond 5 postnatal days, the level of recovery was low, 
while delivered treatment after 10 postnatal days, it showed no improvement and 
died [26].
One of the problems found in our preliminary review is the big number of SMA 
patients diagnosed at late stage. We found Type I patient with 4 months after onset 
and Type III with 10 months or more after onset [27, 28].
However, newborn screening programs have been a successful process for 
identifying affected children at an asymptomatic stage, leading to pre-symptomatic 
initiation of treatment before irreversible anterior horn cell lesion appears. To per-
form screening methods before birth are certain, and they available and willing to 
deliver the possibility of distinguish patients at the beginning of pregnancy, giving 
a chance to perform a prenatal therapeutic management.
Taiwan and Belgium, also have screening programs for SMA, but in America, 
the leader and an important number of states, further clinical trials have been 
implemented to evaluate the applicability and economic advantages. Unfortunately, 
around 5% of mutations in the SMN1 cannot de identified [23].
Chorionic villus sampling or amniocentesis to identify children with higher risk 
for SMA with an elevated percentage of accuracy can be done, if it is performed 
during the 10–14 or 15–20 weeks of pregnancy. These procedures can be dangerous 
for the mother and the baby to be done in high-risk pregnancies with proven carrier 
status of the parents recommended [23]. Nevertheless, isolating circulating fetal tro-
phoblastic cells by noninvasive prenatal diagnosis techniques is also possible [29] or 
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Because one of the most effective clinical strategies for SMA is to protect the 
anterior horn cell, apart from nusinersen (that is a very expensive medication), one 
anti-epileptic medication levetiracetam has been used as well.
Kepra (levetiracetam) provoked neurite elongation in SMA-iPSCs-MNs. 
TUNEL-positive anterior horn cell was significantly decreased by kepra in SMA-
iPSCs-MNs. On the other hand, the expression level of cleaved-caspase 3 was 
diminished by levetiracetam in SMA-iPSCs-MNs. Furthermore, kepra improved 
impaired mitochondrial function in SMA-iPSCs-MNs. On the other hand, kepra did 
not modify the expression level of SMN protein in SMA-iPSCs-MNs. These results 
suggest that kepra has a neuroprotective effect for SMA [17].
For patients presenting SMA (most common reason of inherited infant mortal-
ity), the gene therapy seems to be the most effective strategy [18].
Another therapeutic modality to treat ALS is the noninvasive brain stimulation 
(NIBS), which has been shown to modulate cortical activity, with some protocols 
leading effects that outlast the stimulation by months. NIBS have been suggested 
as a potential treatment choice in those processes with associated changes in the 
cortical neurophysiology [15].
A total of 25 genes associated with ALSf and ALS (sporadic form), mutations in 
fused-in-sarcoma (FUS) and superoxide dismutase 1 (SOD1) have been intensively 
studied in the past, focusing on modified excitability of motor neurons. Based on 
their personal experience, Peikkert et al. [19] proposed that the 4-aminopyridine 
(4-AP), which is a potassium channel blocker, can be utilized as a probable therapy 
for ALS patients due to its demonstrated hypo excitability and high frequency of 
apoptosis in a FUS/SOD1-ALS-induced multi-potent stem cell from selected motor 
neuron; they also found that this process is partly reversible by 4-AP.
One of the clinical presentations of MND is SMA, which encompasses a group 
of autosomal recessively inherited degenerative neuromuscular diseases. SMA is an 
inherited disorder that causes progressive lesions on the anterior horn cell leading 
to weakness or paralysis of the affected limbs, and it is caused by elimination or 
mutation of survival motor neuron (SMN) 1 gene. It is well known that homozy-
gous damage and loss of functional mutations in the survival motor neuron 1 gene 
(SMN1) at the chromosome 5q13 are the main cause of SMA, which affect 1 in 
11,000 newborn infants.
SMA usually has a very poor prognosis after rapidly progressive weakness and 
early mortality. However, a new medication named Nusinersen has been released 
for the treatment of all forms of SMA (not on mechanical ventilation) with very 
good results. In December 2016, this medication was approved in the United States. 
Nusinersen, an antisense oligonucleotide (ASO), is administered directly into CSF. It 
alters SMN2 pre-RNA splicing, so exon 7 is included, increasing expression of func-
tional SMN protein. Efficacy assessments for patients receiving nusinersen are based on 
serial assessments of performance on age-appropriate standardized motor scales. Treatment 
requires complex financial and logistics because of the very high drug cost, intrathecal 
administration, and medical fragility of the patients. Treatment implementation also 
engenders ethical considerations related to cost, insurance coverage, limited clinical data on 
groups of patients not in clinical trials, and questions of duration of treatment [20].
One in 50 asymptomatic people carries this autosomal recessive neuromuscular 
code causing SMA in one over 10,000 live births [21].
Based on age at onset, the highest milestone reached, and phenotypic severity: 
SMA has been separated into four different subgroups such as “Nonsitters” (Type I), 
“sitters” (Type II), “walkers” (Type III), and “adult onset” (Type IV) [22].
At the present moment, many patients got confirmation of diagnose very late, or 
the treatment is administered in advance stages. Therefore, poor response is often 
obtained.
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Fortunately, some screening programs are available and accurately and then to 
identify children in pre-symptomatic stages is possible [23]. However, because some 
children develop their clinical manifestation far from birth then to decide when to 
initiate the treatment and whom qualify for therapy is a dilemma.
The majority of SMN2 pre-mRNA transcripts undergo alternative splicing due to 
a nucleotide substitution leading to exclusion of exon 7. Degradation of the result-
ing truncated SMN protein is very fast, and the overall lack of full-length SMN 
protein causes permanent damage on anterior horn cell of the spinal cord [23].
In patients with onset of the disease beyond six months of age, large phase 3 
trials confirmed improvement in motor activities, very high event-free and remark-
able survival in infantile-onset SMA3, also significant improvement in Expanded 
version of the Hammersmith Functional Motor Scale scores has been recorded 
[24, 25].
The copy number of the homologous SMN2 gene is inversely correlated with 
SMA severity and encoded by SMN1 (except for lack of exon 7), which is identical 
to the cDNA encoded by SMN2.
Currently, for the therapy of SMA, there are pipelines developed by antisense 
oligonucleotide (ASO), also available for Huntington disease, ALS, spinocerebellar 
ataxias, Parkinson disease, and Alzheimer disease, among other options, and the 
pharmaceutical industry on ASO development has been delivering a promising 
therapeutic approach. The key care concern to MND patients has been developed, 
and expert consensus guidelines delivered, and best management for lung diseases, 
nutritional problems, and palliative care has also been reached. However, in this 
chapter, we will discuss novel aspects related to treatment and other therapeutic 
procedures later on.
In pre-symptomatic SMA patient’s Types I–III released interim results of a phase 
2 trial evaluating the effects of Nusinersen have been done [23].
Some investigators have been working on stage of improvement after the treat-
ment of SMA and confirmed that the first published data supported important 
good results on the motor function and quality of life from animal models with 
early restoration of SMN levels for those studied within the first 3 postnatal days. 
However, for those treated beyond 5 postnatal days, the level of recovery was low, 
while delivered treatment after 10 postnatal days, it showed no improvement and 
died [26].
One of the problems found in our preliminary review is the big number of SMA 
patients diagnosed at late stage. We found Type I patient with 4 months after onset 
and Type III with 10 months or more after onset [27, 28].
However, newborn screening programs have been a successful process for 
identifying affected children at an asymptomatic stage, leading to pre-symptomatic 
initiation of treatment before irreversible anterior horn cell lesion appears. To per-
form screening methods before birth are certain, and they available and willing to 
deliver the possibility of distinguish patients at the beginning of pregnancy, giving 
a chance to perform a prenatal therapeutic management.
Taiwan and Belgium, also have screening programs for SMA, but in America, 
the leader and an important number of states, further clinical trials have been 
implemented to evaluate the applicability and economic advantages. Unfortunately, 
around 5% of mutations in the SMN1 cannot de identified [23].
Chorionic villus sampling or amniocentesis to identify children with higher risk 
for SMA with an elevated percentage of accuracy can be done, if it is performed 
during the 10–14 or 15–20 weeks of pregnancy. These procedures can be dangerous 
for the mother and the baby to be done in high-risk pregnancies with proven carrier 
status of the parents recommended [23]. Nevertheless, isolating circulating fetal tro-
phoblastic cells by noninvasive prenatal diagnosis techniques is also possible [29] or 
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even getting from maternal blood cell-free fetal DNA [30]. These above-mentioned 
techniques allow to identify SMA in unborn children with 100% accuracy, promis-
ing a better future for SMA patients [23].
At this stage, it is also important to mention that significant ethical issues are 
involved in this genetic screening methodology and its need to be considered by 
the medical community before making these procedures fully available [31]. At the 
present moment, we are not quite sure how to predict disease severity accurately 
or even its presence because not all patients present clinical manifestation birth 
or because only few minimal sings are detectable. Treatment algorithm for SMA 
patients confirmed by newborn screening based on SMN1 deletion analysis in 
dried blood spots is available since 2005 [28]. Indications of treatment are based on 
the clinical phenotype of the patients and correlation of SMN2 copy numbers. All 
patients presenting 2–3 copies should be treated with the immediate effect accord-
ing to NBS Multidisciplinary Working Group recommendations even if the child is 
asymptomatic with only one copy, but when four or more copies are present due to 
milder course of the disease, the treatment must be delayed [28].
In 2017, some authors studied a big number of SMA patients (n = 3500) trying to 
compare SMN2 copy number with their clinical information and found that patients 
with 1–4 copies have mild to severe phenotype, respectively, while there was an 
important overlap among patients with 2–3, confirming any possible phenotype 
[32], but more than 80% of patients in this group cohort carried two to three 
SMN2 copies, suggesting the similar problem in medical practice. In these cases, 
presenting two or three SMN2 copies to predict the severity of the disorder is not 
certain [23].
It is important to take into account that those SMA patients (families and 
siblings) presenting the same amount of SMN2 copies have another phenotype 
[33]; in the context, SMN1 (homozygous) mutations, SMN2 copies in people free 
of symptoms and signs, and even in SMA Type I have been found [34]. SMN2 
transcripts and the SMN2 copy number do not show any correlation in a series of 
investigations done between 2001 and 2017 [35–38].
Following some recommendations delivered by the Phase 1 trial and studies on 
its pharmacological process, the investigators found that the half-life of nusinersen 
in the CFS is 163 days, and the ideal way for administration should be intrathecal 
(at the dosage of 12 mg) every 4 months. After that period of time, patients should 
receive five intrathecal injections within the first 6 months of treatment. These 
authors also confirmed that no correlation exits between concentrations of the CSF, 
age of the patients, and body weight [39, 40].
Based on results published by Luu et al., the doses of nusinersen according to 
the age of the patients produce more median exposures in the CSF, which suggest 
that prescribing fixed dosage programs through all age groups is the best choice 
[40]. For the other hand, Finkel et al. [41] conducted a Phase 2 dose-escalation 
investigation confirming that a single dose of 12 mg is better than 6 mg. The best 
way to assess the outcome for these patients is to measure the advantage of motor 
milestone, depending on ventilator machine, achievement of motor activities, clini-
cal electrophysiological studies, and overall survival. Twenty patients younger than 
1 year of age and less than 10 kg of body weight were screened, and these results 
confirmed the previous postulate [41]. The results from the small group studied in 
phase 2 clinical trials and the pharmacological studies done can accurately reflect 
clinical practice, is an interrogation still no responded.
Taking into account the great variability among SMA patients related to the age 
at disease onset, residual motor function, body weight, and fixed dose at the same 
intervals for patients, it seems to be remarkably inaccurate [23]. Reliable biomark-
ers and screening procedures for proper diagnosis at early stage of the disease are 
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need more than ever if we are looking for longer survival and positive modifications 
of the patient outcome. If reliable biomarkers are not available, then determining 
the SMN protein level and epigenetic modifiers to provide confident information 
about the intensity of the process is mandatory. When more than three SMN2 copies 
are detectable, chance for life-saving treatment is not certain. In summary, novel 
screening techniques, procedures to predict the intensity of the disease, and reliable 
biomarkers, which support monitoring of the treatment, have been discovered 
and recently developed, but unfortunately, none of them provide an unequivocal 
explanation of the pathophysiology of SMA [23].
To develop more accurate diagnostic procedures including confident biomark-
ers, better therapeutic approaches, and novel predictors to determine the ideal 
dosing recommendation, more investigations are required. This is the only way to 
guarantee a reliable long-term treatment and successful outcome [23].
Two years ago, the European Medicines Agency finally approved nusinersen an 
antisense oligonucleotide (ASO) as the treatment of choice for SMA, and later, this 
medication has been considered as part of the treatment for patients with Type 2 
SMA as well [23]. In patients with SMA presenting spinal bone deformities, severe 
contractures, scoliosis, spine fusion surgeries, and respiratory distress, the adminis-
tration intrathecal of nusinersen could be a great challenge.
Recently, with the intention of assess, the accuracy, and feasibility of nusinersen 
administrated by lumbar puncture (LP) in young patients, Wurster et al. [42] 
studied in 93 patients in whom the LP is done, highlighting the amount of attempts 
performed, site of injection, length of the spinal needle, duration of the procedure, 
medications used for sedative purposes, local anesthesia, level of O2 saturation in 
blood, appearance of the CFS, and adverse effects. These results confirm that LP 
is the best way to administer this medication in adolescent and young adults with 
later-onset SMA even in candidates with spinal bone deformities and respiratory 
failure mainly if the patient is managed under a multidisciplinary team.
Nusinersen is not available in Africa as yet but can be found in many European 
countries for all SMA types.
A few weeks ago, Sansone et al. [43] reported their experience and good results 
after studied 50 SMA patients treated with intrathecal nusinersen. They concluded 
that in spite of the severity of the disease and the age of patients, this treatment 
is feasible, safe, and suitable for SMA patients if they are managed by a good 
skilled team.
According to the information provided by Gidaro et al., a few weeks ago, in 
Australia, the commercial availability of the medication from the transition of 
expanded access programmed its right in corner. While in New Zealand, a broad 
access to this program is available, and in Canada, negotiators are discussing about 
the most convenient price at the present moment. However, some problems such as 
advanced age, patients with respiratory failure depending ventilator machine, and 
patients presenting spinal fusion still need to be solved [44].
As was mentioned before, the traditional LP for intrathecal administration of 
nusinersen can be impeded due to deformities of the spinal bone and orthopedic 
surgical procedures among other impediments commonly seen in SMA patients. 
However, the accumulated experiences from cervical myelograms serve to recom-
mend this procedure as an ideal approach for cervical intrathecal administration of 
nusinersen, especially if it can be guided by ultrasound [45]. The same investigators 
studied 14 patients after the administration of nusinersen by cervical punctured 
guide by ultrasound with local anesthesia and found that all patients presented 
no major complications. One of the advantages of this technique is that general 
anesthesia is no required, and patients can be managed in real-time ultrasound 
guidance.
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even getting from maternal blood cell-free fetal DNA [30]. These above-mentioned 
techniques allow to identify SMA in unborn children with 100% accuracy, promis-
ing a better future for SMA patients [23].
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the medical community before making these procedures fully available [31]. At the 
present moment, we are not quite sure how to predict disease severity accurately 
or even its presence because not all patients present clinical manifestation birth 
or because only few minimal sings are detectable. Treatment algorithm for SMA 
patients confirmed by newborn screening based on SMN1 deletion analysis in 
dried blood spots is available since 2005 [28]. Indications of treatment are based on 
the clinical phenotype of the patients and correlation of SMN2 copy numbers. All 
patients presenting 2–3 copies should be treated with the immediate effect accord-
ing to NBS Multidisciplinary Working Group recommendations even if the child is 
asymptomatic with only one copy, but when four or more copies are present due to 
milder course of the disease, the treatment must be delayed [28].
In 2017, some authors studied a big number of SMA patients (n = 3500) trying to 
compare SMN2 copy number with their clinical information and found that patients 
with 1–4 copies have mild to severe phenotype, respectively, while there was an 
important overlap among patients with 2–3, confirming any possible phenotype 
[32], but more than 80% of patients in this group cohort carried two to three 
SMN2 copies, suggesting the similar problem in medical practice. In these cases, 
presenting two or three SMN2 copies to predict the severity of the disorder is not 
certain [23].
It is important to take into account that those SMA patients (families and 
siblings) presenting the same amount of SMN2 copies have another phenotype 
[33]; in the context, SMN1 (homozygous) mutations, SMN2 copies in people free 
of symptoms and signs, and even in SMA Type I have been found [34]. SMN2 
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need more than ever if we are looking for longer survival and positive modifications 
of the patient outcome. If reliable biomarkers are not available, then determining 
the SMN protein level and epigenetic modifiers to provide confident information 
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The most significant advantage to antisense oligonucleotide (ASO) therapeutics 
over other small molecule approaches is that acquisition of the target sequence 
provides immediate knowledge of putative complementary oligonucleotide 
therapeutics.
In 2019, Scoles et al. [46] described several therapeutic modalities with ASO 
and how they can be indicated for medical treatment of SMA, apart from the work 
done to develop novel ASO therapies looking for better results in the management 
of neurodegenerative disorders [46]. Novel advances of the genetic studies will 
allow distinguishing different genetic information for many neurological disorders. 
The mutated protein found and its chance to be placing into the cellular pathway 
will support a faster development of way for treatment. For the other hands, new 
opportunities for reliable treatment have been arising from the new capacities 
of targeting the disorder gene and RNAs. Among other procedures, to target the 
expression of RNA, some authors highlighted the utilization of ASOs to treat 
neurological problems. Treatment based on ASOs varies from 18 to 30 base pairs in 
length. These investigators changed expression of a target mRNA modifying splic-
ing or by recruiting RNase H (cellular enzyme) that recognizes DNA: RNA hybrids 
causing target degradation [46].
Apart from nursinersen, other ASO therapeutics approved by FDA are eteplirsen 
to treat Duchene muscular dystrophy 2 and inotersen for managing patients pre-
senting familial amyloid polyneuropathy. For treatment of Huntington disease, 
ASOs targeting HTT have been used [47]. As we and other authors reported in other 
publications, the treatment of choices for ALS is SOD1 and C9ORF72 [48, 49] and 
MAPT (TAU) in cases affected by Alzheimer disease [50]. Because most of the 
treatment with ASO does not cross the blood-brain barrier (BBB), it is necessary to 
administer it by injection into the intraventricular system in mouse and by intrathe-
cal administration in humans.
Some investigators have mentioned that nucleic acids are prompt to nuclease 
degradation, and its protein binding is weak, leading to inefficient tissue uptake and 
unreliable use as drugs [26, 51].
Most of these changes modify the pharmacokinetic, pharmacodynamic, or 
endocytic uptake that controls the specific function of the proteins (cell surface) 
[51, 52].
Oligonucleotide chemistry, methoxyethyl oligonucleotide, constrained nucleic 
acids, Stereopure PS ASOs, Peptide nucleic acid, 5′-methylcytosine modification, 
target fate, mixed chemistry, and gapmers are aspects that are not discussed in this 
chapter and should be considered by interested readers on this matter. In order to 
get most complete information about it, we recommend checking the article of 
Scoles et al. [46].
ASOs are being used for some genetic etiology of ALS. Obviously, these biologi-
cal pathways affecting the recognized mechanism of production of the disorder also 
modify the results when ASO is used [53].
2. Therapy with riluzole and edaravone
In 1994, the idea about the role of the excitatory amino acid neurotransmit-
ter glutamate in the mechanism of production of ALS was prevalent. At that 
time, some investigators evaluated the safety and accuracy of the antiglutamate 
agent riluzole, at the dose of 100 mg daily, in patients presenting ALS. They 
studied 155 outpatients, and after 12 months of treatment, they found that 74% 
of the patients were still alive (P = 0.014), and the decrease of muscle power 
was remarkable in patients consuming riluzole compared with the control group 
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(placebo). Therefore, they concluded that riluzole decreases the speed of progres-
sion in ALS patients, and it can prolong the survival period in patients presenting 
bulbar palsy [54].
Without doubt, nusinersen improves motor neuron function, but riluzole by 
acting on SK channels also causes similar results [55].
Since 1996, it is well known that one of the etiological pathogenesis of ALS is 
caused by neural damage due to glutamate excite-toxicity. Riluzole is a synthetic 
benzothiazole drug with glutamine antagonist activity [56, 57].
The first analyses, and at posteriori meta-analyses done on results obtained 
from controlled trials by randomization, confirm that riluzole extends survival by 
2–3 months and augment the possibilities of an additional 12 months of survival by 
~9%. Same authors reported improvements in media survival times over 76 weeks 
for an important number of ALS patients [58].
In 1995, oral riluzole was approved by FDA as part of the treatment of 
ALS. Riluzole is a well-known presynaptic glutamate release inhibitor, which can 
provide neural injury and prevent muscle-power worsening. Currently, this medi-
cation has been licensed to be prescribed in many places including the European 
Union [59].
The dose of 50 mg twice, to be taken 1 hour before meal or 2 hours after it, has 
been approved by the Institute for Health and Care Excellence since 2001 with good 
results [60].
One good news is that riluzole is now available in oral suspension (Teglutik®) 
which presentation (5 mg/ml) and has been shown its beneficial for patients 
presenting bulbar palsy with functional dysphagia allowing longer therapy [61, 62].
Not randomized controlled trials (RCTs) with riluzole for ALS patients have 
been performed.
However, other RCTs have been done for patients with cervical myelopathy, 
chronic psychosis, and autistic spectrum disorder [63–65].
Real-world evidence confirmed that an important prolongation of median 
survival times in ALS patients treated with riluzole is certain. Based on retrospec-
tive/prospective investigations done on large database, these authors concluded that 
patients under riluzole therapy had better prognosis than those without treatment, 
mainly at the first stage of the pathological process [58].
Brooks et al. studied two series of ALS patients: one group of 51 patients under 
riluzole treatment and another group of 241 patients without riluzole (before 1996) 
and a second series of 112 ALS patients’ riluzole-treated and 65 nontreated patients 
(after 1996). These authors found that Cox analysis concluded that patients on 
treatment got an extension of survival (P < 0.0001) and even remarkable improve-
ments in elderly people and patients in advanced stage. Therapy with riluzole pro-
vides a median extension of survival in affected patients between 40 and 72 weeks 
[66]. Survival benefit would be 36 weeks if patients are managed like prospective 
RCTs according to other researchers [67]. Based on Cox model technique, Mitchell 
et al. found that survival times are bigger in riluzole-treated ALS patients than 
nontreated cases (HR 0.20, P < 0.001) [68]. While other authors communicated 
that Cox multivariate analysis of therapy was related to a prolongation of survival at 
48 weeks (HR 0.51, P = 0.06) [69].
Retrospective population-based studies on the effect of riluzole on survival 
of ALS patients done between 1999 and 2008 and made by Lee et al. concluded 
that Cox multivariate analysis (n = 1149) that riluzole provide a longer survival 
on treated-patients; unadjusted HR 0.32 (P < 0.001) and adjusted HR 0.34 
(P < 0.001) [70].
Georgoulopoulou et al. and Knibb et al. conducted a prospective population-
based study on the survival of 193 patients (between 2000 and 2009) and 575 cases 
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(between 1990 and 2013) consuming riluzole, respectively. According to the Cox 
multivariate model used during the first series of participants riluzole-treated, they 
reached a prolonged survival and remarkable delay of pulmonary complications 
including patients with bulbar palsy and even those with affected four limbs, and 
the second series of cases riluzole-treated showed a slower progression to pulmo-
nary involvement [71, 72].
Chen et al. also studied a group of ALS patients using the same methodol-
ogy and concluded that the median survival time in cases riluzole-treated was 
268 weeks compared to 256 weeks in nontreated cases (log-rank P = 0.780); HR 
0.855 (P = 0.167) [73].
Based on meta-analysis of RCTs recently done and all data obtained up to date, 
riluzole prolonged survival in ALS cases by 8–12 weeks and augmented the chance 
of additional 52 weeks of survival by ~9%.
Other authors reported that riluzole-treated cases can increase their median 
survival by up to 76 weeks, after reviewing 10 clinical ALS databases with around 
~6000 cases [58].
In a series of patients studied by Inoue-Shibui et al., riluzole therapy was inter-
rupted in 20 cases among 92 patients [74]. The most common cause of discontinu-
ation of riluzole was abnormal of liver enzymes (5.4%), followed by interstitial 
pneumonia, among other causes.
All adverse events happened within 24 weeks of the beginning of riluzole 
therapy, with 50% of the adverse events occurring within 2 weeks. In almost all 
patients, adverse events disappeared after stopping the treatment. In the real-
world setting, riluzole has been well assimilated for long periods of up to 7 years or 
more [75].
Recently, two patients presenting recurrent pancreatitis were communicated 
to the medical literature. In both cases, the diagnosis was done within the first 3 
months after initiated the treatment with riluzole [76], being another strong reason 
to highlight our recommendation about a careful observation of adverse events in 
the first 6 months of riluzole administration.
A few weeks ago, Jaiswal et al. also confirmed that riluzole delay progres-
sion of ALS in animal model based on their experiences and many experimental 
drug trials done over the past decades, but riluzole did not show similar results 
in human beings or results are still nonconcluded under Phase I–III trials, which 
are quite true, and riluzole is the only available medication with some benefits on 
survival [77]. Nevertheless, an antioxidant drug (edaravone) has been produced by 
Mitsubishi Tanabe Pharma, and its effectiveness in halting ALS progression during 
early stages has been found.
In 2015, edaravone (Ridicut) was launched for the management of patients 
with ischemic stroke at first and later for the treatment of ALS patients [78]. 
Edaravone is a drug with a free radical scavenger with no remarkable benefits in 
ALS patients according to Phase III clinical trial, but edaravone is also a strong 
antioxidant able to prevent oxidative stress leading to motor neuron fatal damage 
in ALS. These investigators found another study, which confirmed good therapeu-
tic response to edaravone in diagnosed patients by revised diagnostic criteria (El 
Escorial) of MND/ALS. Other authors investigated the effect of intraperitoneal 
administration of edaravone in wobbler’s mice and demonstrated that elevated 
dose (10 mg/kg) of edaravone therapy remarkable attenuated paresis and muscle 
contracture on the extremities and stopped denervation atrophy in the proximal 
muscles and degeneration in the cervical anterior horn cell neurons compared 
to control group. After large waiting period of 22 years, the Mitsubishi Tanabe 
Pharma America acquired an US FDA approval for edaravone (Radicava) in May 
2017 for the therapeutic approach of ALS.
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To low progression of MND/ALS, edaravone is a good indication according to 
the previous reports delivered to the medical literature. Recent phase three studies 
done on ALS patients treated with this medication did not confirm remarkable 
advantage in the Revised ALS Functional Rating score over the control group 
[79]. Between November 28, 2011 and September 3, 2014, the Writing Group 
[80] studied 213 cases and selected 192 candidates. Of these, 137 cases completed 
the first period for close observation: 69 were selected to be edaravone-treated 
(randomly), and 68 were assigned to control group to be treated with placebo 
also randomly, both series were included in the primary efficacy analysis. The 
results observed from the primary outcome demonstrated that the control group 
change −7.50 (0.66) in ALSFRS-R score compare with −5.01 (SE 0.64) in the group 
edaravone-treated. In favor of edaravone, the least-square mean confirmed a 
difference among two series of 2.49 (SE 0.76, 95% CI 0.99–33: P = 0.0013). These 
researchers concluded that edaravone works in a small subset of ALS patients 
who met criteria identified in post-hoc analysis of most recent Phase 3 studies, 
showing a remarkable diminish ALSFRS-R score compared with control group 
who received placebo. They also highlighted that there is no proof that edaravone 
might be efficient in a bigger series of ALS cases who do not meet the criteria [80]. 
The best way to administer edaravone (60 mg) is by slow IV infusion (2 hours 
duration) every 28 days. Edaravone has demonstrated its capacity to slow down 
the process of loss of motor function by 33% of ALS cases compared with control 
group. Being a powerful free radical scavenger, edaravone is able to inhibit nitration 
of tyrosine in the CSF and to improve the motor neuron cell activity in ALS mouse 
[81]. Unfortunately, there is no unanimous agreement about the positive effect of 
riluzole in patients presenting degenerative disorders. At the present moment, most 
of the neurology community agrees that riluzole is not a remarkable strong effect on 
the progression of ALS. Because the oxidative stress is considered to be involved in 
the pathology of ALS, almost all consider that the free radical scavenger edaravone 
may play a better relevant role for the treatment of cases presenting ALS. Without 
doubt, the first medication able to provide an efficient inhibition of motor neuron 
function deterioration in MND/ALS cases is edaravone if it is taken at early stage 
of this pathological disorder, but the lung function must be well assessed when a 
deterioration in the respiratory capacity is confirmed [82]. Most reports published 
in the medical literature show controversial benefits and safety about the edaravone 
treatment of ALS. Recently, Luo et al. [83] made a meta-analysis research to evalu-
ate the accuracy and safety of edaravone as a therapy of choice for ALS, by search-
ing PubMed, the Cochrane Library, and Embase from the inception of electronic 
data (April 2018), including randomized, double-blind, placebo-controlled trials 
reporting ALS cases receiving 60-mg IV edaravone or IV saline solution as placebo 
for 24 weeks. The study included 367 patients from three randomized controlled 
trials (183 patients on IV edaravone; 184 receiving IV saline solution). They arrived 
to the following conclusion: edaravone IV is a good treatment for ALS cases, with no 
remarkable side effects [83].
3. Other medications for MND
Although there is no available medicine to cure any clinical presentation of 
MND, during the first semester of this year (2019), a number of medications have 
been used to treat affected patients. Unfortunately, no remarkable results have been 
obtained, but some of them still show good action over this disease. In this chapter, 
we will deliver some comments about the results reached by some authors accord-
ing to their report to the medical literature. The most common used medications 
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of tyrosine in the CSF and to improve the motor neuron cell activity in ALS mouse 
[81]. Unfortunately, there is no unanimous agreement about the positive effect of 
riluzole in patients presenting degenerative disorders. At the present moment, most 
of the neurology community agrees that riluzole is not a remarkable strong effect on 
the progression of ALS. Because the oxidative stress is considered to be involved in 
the pathology of ALS, almost all consider that the free radical scavenger edaravone 
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doubt, the first medication able to provide an efficient inhibition of motor neuron 
function deterioration in MND/ALS cases is edaravone if it is taken at early stage 
of this pathological disorder, but the lung function must be well assessed when a 
deterioration in the respiratory capacity is confirmed [82]. Most reports published 
in the medical literature show controversial benefits and safety about the edaravone 
treatment of ALS. Recently, Luo et al. [83] made a meta-analysis research to evalu-
ate the accuracy and safety of edaravone as a therapy of choice for ALS, by search-
ing PubMed, the Cochrane Library, and Embase from the inception of electronic 
data (April 2018), including randomized, double-blind, placebo-controlled trials 
reporting ALS cases receiving 60-mg IV edaravone or IV saline solution as placebo 
for 24 weeks. The study included 367 patients from three randomized controlled 
trials (183 patients on IV edaravone; 184 receiving IV saline solution). They arrived 
to the following conclusion: edaravone IV is a good treatment for ALS cases, with no 
remarkable side effects [83].
3. Other medications for MND
Although there is no available medicine to cure any clinical presentation of 
MND, during the first semester of this year (2019), a number of medications have 
been used to treat affected patients. Unfortunately, no remarkable results have been 
obtained, but some of them still show good action over this disease. In this chapter, 
we will deliver some comments about the results reached by some authors accord-
ing to their report to the medical literature. The most common used medications 
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are EH301, 5Fluoroucil, Tryptophan, RNS60, Rasagiline, Tirasemtiv, Aquaporin, 
Fasudil, and Lunasil.
de la Rubia et al. [84] evaluated the accuracy and feasibility of Elysium Health’s 
candidate drug EH301 in ALS cases by a single-center, prospective, double-blind, 
randomized, placebo-controlled pilot study. Thirty-two ALS patients studied 
underwent for assessment during 4 months. Differences between EH301 and con-
trol group were evaluated based on their findings, and EH301 confirmed a remark-
able slow progression of ALS compared with nontreated cases and even confirmed 
clinical benefits in many key outcome measures relative to their baseline.
Searching for drug candidates for ALS, Rando et al. investigated the action of 
anti-metabolite 5-fluorouracil (5-FU) administered by a single intraperitoneal 
injection at 150 mg/kg in SOD1G93A model of ALS. Un expectedly, the authors 
found that 5-FU (anti-cancer drug) increases survival delays of the disorder onset 
and improves motor function in ALS mice, but they were not able to demonstrate 
the mechanism of the beneficial 5-FU action in ALS mice. Despite of 5-FU did not 
improve the modulate motor neuron survival remarkably and did not improve 
reactive gliosis or change the muscle morphology, their findings recommended that 
a low dose of 5-FU or its analogs may have good effects on MND/ALS [85].
Other authors postulate that toxic gain of function, spread, and SOD1 misfold-
ing is suggested as part of pathological mechanism of MND/ALS, but the nature of 
SOD1 toxicity has been hard to describe [86]. Only in SOD1 proteins from humans 
and other primates, and rarely in other species, a tryptophan residue at position 32 
(W32) is predicted to be solvent exposed and to participate in SOD1 misfolding. 
DuVal et al. considered that W32 is influential in SOD1 acquiring toxicity, as it is 
known to be important in template-directed misfolding [86].
DuVal et al. highlighted the relevant influence of W32 on cases SOD1 toxicity to 
upper and lower motor neuron cells morphology and its activities. They assessed 
pharmaceutical targeting of the W32 residue for rescuing SOD1 toxicity [86]. 
When RNS60 is administered by IV infusion every 7 days and daily nebulization, it 
acts as a novel immune-modulator agent able to provide neuroprotective action in 
MND/ALS preclinical models. Paganoni et al. [87] studied 16 ALS patients during 
23 weeks for safety and tolerability. Some investigations were done such as PBR28 
positron emission tomography imaging and plasma biomarkers of inflammation. 
These authors did not find serious reactions, and no participants were removed 
from the study due to drug-related complications. At the present moment, a large, 
multicenter, Phase II trial of RNS60 is currently including cases to test the effects of 
RNS60 on MND/ALS biomarkers and disease deterioration based on the previous 
findings. They concluded that long-term RNS60 administered by IV infusion (as 
indicated) is well assimilated by patients and is also accurate [87]. In ALS, the pro-
long use of immune-modulating therapies has been showing not good results and 
did not help to understand how the immune system modifies disease outcome [88].
Rasagiline (monoamine oxidase B inhibitor) administered at 2 mg/day has 
a neuroprotective effect in MNS/ALS cases. In order to verify this postulate, 
Fernandez et al. performed a trial of 80 ALS patients from 10 hospitals in America. 
They did not identify any difference between Rasagiline-treated cases and the 
control group. Therefore, they assumed that Rasagiline did not change disease 
output compared with control group during 12 months of therapy. Rasagiline was 
well assimilated, and no serious adverse events were report.
Shefner et al. conducted a multinational clinical trial to study the accuracy of 
tirasemtiv (125 mg twice daily) using an escalating dosage protocol during 4 weeks 
[89]. Comparisons between two series of cases with ALS were performed. One 
group constituted by fast skeletal muscle troponin activator and a second control 
group by placebo. Of 744 candidates, 565 participants assimilated open-label 
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tirasemtiv and were treated randomly. As a side effect of tirasemtiv, nausea, weight 
loss, dizziness, fatigue, and insomnia were more often seen. The frequency of 
severe side effects was seen equally on both series of cases. Obviously, tirasemtiv 
did not change the decline of slow vital capacity or remarkable impact secondary 
outcome assessment and weak tolerability of tirasemtiv may lead to poor effect on 
MND/ALS.
Aquaporin 4 (AQP4) is present in astrocytes in the nervous system as primary 
water channel and has been postulated to participate in a myriad of acute, chronic 
brain disorders and the incidence of MND/ALS. Depolarization of AQP4 causes 
degeneration of the upper and lower motor neurons via GLT-1, and suppressions 
increase recovery of motor activity in MND/ALS cases probable due to NGF. No 
clinical trial targeting AQP4 has been done up to date [90].
Studies made with Fasudil (30 mg for IV application) have shown good results 
in cell culture and animal research of MND/ALS. This medication is a Rho kinase 
(ROCK) inhibitor, which has been used in Japan (1995) for the management of 
Reynaud’s syndrome, pulmonary hypertension, and vasospasm secondary to 
subarachnoid hemorrhage, angina pectoris, and also to treat complications from 
high blood pressure. Currently, some authors are looking for efficacy, safety and 
tolerability of a ROCK-ALS of fasudil in MND/ALS cases that started patient 
recruitment in 2019 [91]. ROCK (serine/threonine kinase) is a novel medication 
to target for neurodegenerative brain disorders, and it has two isoforms: ROCK1 is 
mainly for the peripheral nervous system, and ROCK2 is expressed preferentially in 
nervous central system [92]. Levels of ROCK augment according to age and tissue 
of MND/ALS cases. Some authors also confirmed increased levels of ROCK2 and 
downstream targets LIMK1 and coiling [93]. Fasudil also modifies microglia activity 
[91]. Main side effect of fasudil is intraparenchymal hemorrhage. Nevertheless, in 
studied population of cases with subarachnoid hemorrhage, the incidence of bleed-
ing did not differ remarkably from the control group. Therefore, hemorrhage is 
not an expected complication, and it will not put in risk the life in selected patient. 
Cases with past medical history of intraparenchymal bleeding, congenital or acquire 
aneurysms or Moyamoya disease should not be included in the therapeutic group.
Lingor et al. confirmed that ROCK-MND/ALS clinical trial provides a well-
tolerated, safe, and accurate way of treatment. The biomarker collection associated 
with this study will deliver additional data as indicators of progression. Finally, 
we comment about Lunasin a soy peptide that modify histone acetylation in vitro 
joined to single MND/ALS effect but no remarkable activity on histone acetylation or 
disorder deterioration in 50 participants treated during 5.5 months by Bedlack et al. 
[94]. Excellent retention and adherence have been found but not better results than 
riluzole or edaravone.
As a result of the great interest showed by investigators and participants on 
different studies done during the first half of this year (2019), today we can see an 
important number of other therapeutic procedures also looking for the best man-
agement of ALS patients. This modality ranges from physical exercises to acupunc-
ture including other choices such as stem cell therapy, treatment for sialorrhea, and 
spasticity, among others.
In our times, many healthy people do physical exercises on regular basis; some 
do exercise for slimming purposes, others for prophylactic treatment, rehabilita-
tion, and so forth.
Unfortunately, due to lack of space, these topics will not be included in this 
chapter.
After reviewing the most recent studies published in the medical literature, we 
concluded that we still have no curative treatment for MND patients, but a promis-
ing future is forthcoming.
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At present, with the advanced affordable genetic testing, the rate of discover-
ing amyotrophic lateral sclerosis (ALS)-related genes rapidly increases. These 
genetic findings provide new insights into therapies that target genetic subset of 
ALS. However, the research on the genetic and environmental causes of ALS is still in 
the early stage. In this chapter, we review the current understanding of ALS-related 
genes and summarize the worldwide ALS distribution feature by the frequency of 
occurrence in different regions. We summarize the advances in genetic testing and 
counseling for ALS. Based on the increase in genetic testing, we believe that the ALS 
patients and families would be benefited from our studies in the near future.
Keywords: ALS, genetic frequency features, GWAS, genetic testing, genetic counseling, 
genetic therapy
1. Introduction
Amyotrophic lateral sclerosis (ALS) is an adult onset and generally fatal 
neurodegenerative disease characterized by progressive weakness and atrophy of 
voluntary skeletal muscles due to dysfunction and death of upper and lower motor 
neurons. Onset typically occurs between 60 and 69 years of age, with wide-range 
severity. About 90% of cases are sporadic amyotrophic lateral sclerosis (SALS), 
while familial amyotrophic lateral sclerosis (FALS) accounts for the remaining 10% 
cases [1]. The pathogenesis of ALS remains obscure, but genetic mutations have 
been accounted for several impaired cellular and molecular mechanisms and, thus, 
provide clues for potential therapeutic strategies.
The superoxide dismutase 1 (SOD1), identified in 1993, was the first gene 
discovered to be associated with ALS. Subsequently, several gene mutations that 
have been identified to cause ALS. Till 2018, more than 180 genes have been identi-
fied as causative genes or related genes of ALS. Many of these genes are related to 
metabolism, trafficking of RNA, and chromatin, including C9orf 72, TDP43, FUS, 
TAF15, ELP3, ANG, hnRNPA1, and hnRNPA2B1 [2]. Some genes are involved in 
conformational instability and aggregation of proteins, such as SOD1, VCP, OPTN, 
and UBQLN2; others are related to axonal and cytoskeletal biology, such as PFN1, 
DCTN1, TUBA4A, and EPHA4 [2].
In most cases, FALS is inherited in the dominant pattern and the penetrance is 
associated with age. It has been observed that the differences of age onset and disease 
progression within and between ALS families are significant. In addition, some ALS 
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is recessive inherited, such as OPTN, SPG11, FUS, and SOD1 (definite, Asp90Ala 
homozygous mutation), and UBQLN2 associated ALS is X-linked dominant inher-
ited. Besides causative genes, multiple genetic variants interact simultaneously to 
increase ALS susceptibility. Considering oligogenic manner of ALS described by 
some researchers, many ALS patients may not appear to be familial in a conventional 
Mendelian manner. Therefore, the oligogenic manner may underlie the apparently 
sporadic form of the disease [3].
Some ALS caused by specific genetic mutations exhibit unique clinical charac-
teristics. For example, ALS associated with SPG11 and ALS3 has clinical features 
of early onset and slow progression. SPG11 mutations were identified in autosomal 
recessive juvenile ALS [4], and the patients with ALS3 mutations have an early 
onset of approximately 45 years and the average disease duration about 5 years.
Recently, progress in gene discovery and technology has both complicated and 
empowered the process of genetic testing options, which may help neurological 
clinicians and ALS patients to understand the pathogenesis of ALS, and then 
provide genetic counseling for family members, allow accurate risk assessment, 
and open the door for genotype-specific treatments. As the genetic basis of the 
remainder of FALS, and potentially SALS, is unraveled, genetic testing and coun-
seling will become increasingly vital and should be incorporated into the routine 
management of ALS [4–6].
2. Recent advances in ALS gene map
2.1 SOD1
The superoxide dismutase 1 (SOD1), located in 21q22, was discovered in 1993. 
Up to date, more than 180 mutations have been described to be associated with ALS, 
while most of these mutations are missense mutations. Its mutation probability 
accounts for 20% of FALS cases and 1–2% of SALS cases [1, 2, 7, 8].
2.2 C9orf 72
The C9orf 72, located in 9p21.2, was discovered in 2011. The protein encoded by 
C9orf 72 is mainly related to autophagy, endosomal transport, and immune func-
tion. According to statistics, about 40–50% of FALS and 10% of SALS carried the 
C9orf 72 expanded alleles. The pathogenic alleles of C9orf 72 may have hundreds or 
even thousands of the GGGGCC hexanucleotide repeats. A large number of clinical 
investigations have shown that about 700–1600 GGGGCC hexanucleotide repeats 
are inserted into the intron located between the two untranslated optional exons 1a 
and 1b of the C9orf 72 gene [1–3, 9, 10].
2.3 FUS
The FUS RNA-binding protein (FUS) gene, discovered in 2009, was mapped in 
16p11.2.
Mutations in FUS are observed in 4% of FALS and 1% of SALS. At present, more 
than 79 mutations have been described, predominantly in the 3′ region encoding an 
arginine/glycine-rich region and a NLS domain (nuclear localization signal). FUS 
protein, essentially localized in the nucleus, regulates RNA processing, splicing, 
and mRNA trafficking. Mutant FUS localized to cytoplasmic stress granules (SGs) 
and interacted with the stress granule protein PABP in an RNA-dependent manner 
resulting in mislocalization of the wildtype protein to stress granules [7–9, 11].
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2.4 CCNF
CCNF, located in 16p13.3, encoding the cyclin F, was first reported in 2016. The 
mutation of CCNF accounts for approximately 4% of FALS and 2% of SALS [7].
CCNF protein is a kind of kithe cell cyclin, involved in the regular of cell cycle 
transitions by activating cyclin-dependent protein kinases. Furthermore, it is the 
substrate recognition component of the Skp1-cullin-F-box E3 ubiquitin ligase 
complex. The neurons of the over-expressed mutant CCNF showed an increase in 
protein-labeled proteins, including TDP43. It indicates that mutated-CCNF protein 
interfere the proteasome degradation pathway by using traversing protein abnor-
malities to mark all proteins or inhibiting transferring transprotein-labeled proteins 
to proteasome complexes. This finding suggests that the CCNF mutation may cause 
abnormal protein homeostasis, which may be exacerbated by TDP43 protein disease.
Therefore, enhancing protein removal or reducing ubiquitin may be a feasible 
treatment [1, 3].
2.5 TIA1
The TIA1 gene, located in 2p13.3, encodes an RNA-binding protein involved 
in splicing regulation and translational repression. The mutations in TIA1 were 
identified in 2.2% of FALS and 0.4% of SALS [7]. TIA1 protein is a key component 
of SGs, cytoplasmic foci sequester untranslated mRNAs upon different types of 
cellular stress, and the low complexity domain (LCD) region of TIA1 plays a central 
role in promoting SGs assembly. A heterozygous founder mutation (E384K) in 
the LCD was first reported in Swedish/Finnish patients as the cause of Welander 
distal myopathy (WDM). Recently, a mutation (p.P362L) in TIA1 affecting a highly 
conserved residue in the LCD was identified as one cause of ALS/ALS-FTD [12].
2.6 TBK1
The TANK-binding kinase 1 (TBK1) gene, located in 12q14.2, was discovered 
in 2015 [7]. The protein encoded by this gene is similar to the IκB kinase and can 
mediate NFκb activation in response to certain growth factors. The TBK1 mutations 
were found in approximately 1% of FALS and 1% of SALS. The clinical phenotypes 
associated with the TBK1 mutation are heterogeneous, with different ages at onset, 
different progressions, and irregular survival times.
Some patients also reported with extrapyramidal, ataxia, or psychosis. 
Neuropathological examination of central nervous system (CNS) tissues from 
patients with TBK1 mutations revealed that SQSTM1/p62- and TDP-43-positive 
inclusion bodies which can indicate abnormalities in TDP-43 protein aggregation 
and protein clearance pathways [1, 2, 4, 5].
2.7 TARDBP
The TARDBP (trans-activation element DNA-binding protein), located in 
1p36.22, was discovered in 2008 [5].
The TARDBP gene mutation was found in 5% of FALS cases and 1% in SALS 
cases. Till now, more than 50 different mutations have been identified [9]. Except 
for D169G, a majority of these mutations are located in the 3′ region encoding a 
glycine-rich domain in its product, TDP-43. ALS patients carrying TARDBP gene 
mutations normally exhibit a classical ALS phenotype and rare dementia, they also 
have earlier disease onset, with upper limb onset being more common and compat-
ible with a longer life. Most of TDP-43 is expressed in nucleus, involved in RNA 
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metabolism in many ways—transcriptional regulation, splicing, mRNA stabiliza-
tion (including its own transcripts), and microRNA processing. TDP43 also regu-
lates axonal transport and neuronal plasticity. In ALS, TDP-43 is often observed in 
cytoplasm. The pathogenesis of TDP-43 mainly includes cytoplasm construction of 
high phosphorylation TDP-43 and clearance of nuclear TDP-43 [1, 2, 7, 8].
2.8 Pathogenesis of ALS-related genes
The cellular processes, including RNA processing, protein degradation path-
ways, ubiquitin-proteasome system (UPS), autophagy, and so on, are all reported 
related to ALS pathogenesis [1–3, 7–22]. Sorted by the various processes, we sum-
marize the causative genes and genes might increase susceptibility of ALS which 
impact physiological activities mentioned above (Figure 1).
Figure 2. 
The worldwide frequency of ALS-related genes. The x-axis is the time when genes discovered. The y-axis is 
the logarithms of the mutation frequency of genes in ALS. The mutation frequency of C9orf 72, CHCHD10, 
CCNF, KIF5A, and ANXA11 are only within FALS. Where gene frequency was not available (ALS2, SETX, 
SIGMAR1, and PDIA1), one “circle size” equivalent to 1% is given for illustrative purposes.
Figure 1. 
Dysfunction cellular processes and related genes contributed to the pathogenesis of ALS.
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2.9 Advances on gene discovery and frequency
We describe the worldwide ALS distribution feature by frequency of occurrence 
in different regions (Figure 2) [1–3, 7–9, 11, 14, 23, 24]. We summarize ALS muta-
tion genes frequency according to the researches in Mainland China (Figure 3).
3. GWAS on ALS
Recently, the studies on ALS have shown the development trend of the blowout 
with the technology improving, however, no longer limited by technical condition, 
the number of newly discovered ALS-related gene did not meet expectation. It 
indicates a shift in the genetic pathway that multiple genetic variants and environ-
mental factors may interact simultaneously to increase ALS susceptibility. On the 
basis of the fact that sporadic form apparently accounts for high rate of ALS and 
the hypothesis that ALS may not appear to be familial in a conventional Mendelian 
manner, a new research method, genome-wide association study (GWAS), is 
applied to the research of ALS.
Since GWAS was applied to complex diseases, remarkable achievements have 
been made in certain fields. It is also hoped that in this way, we will be able to find 
the risk factors of ALS [25–27].
3.1 SNPs and GWAS
The International HapMap Project, which began in 2002, mapped the single-
nucleotide polymorphisms (SNPs) haplotypes of the human genome from four major 
populations in the world and promoted the development of GWAS. At the same time, 
the rapid development of high-density and high-throughput genotyping technology, 
which can detect hundreds of thousands of SNPs in a single reaction, makes it pos-
sible to systematically screen mutations associated with complex diseases throughout 
the genome. Unlike previous candidate gene studies, GWAS does not need to build 
any assumptions based on disease pathophysiology prior to the study and can rela-
tively be an unbiased screen for almost all common mutations in the genome. At pres-
ent, some risk factors of complex diseases, such as age-related macular degeneration, 
diabetes mellitus, breast cancer, and so on, have been initially identified by GWAS.
Figure 3. 
ALS mutation genes frequency among FALS and SALS in Mainland China. The y-axis means the percentage 
of different mutation genes.
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3.2 ALS GWAS boot
Schymiek et al. firstly reported GWAS in SALS in February 2007 [28]. A total 
of 276 patients and 271 controls with white American ancestry were recruited in 
this research. They used a chip to detect 555,352 SNPs and found 34 of the most 
relevant SNPs by association analysis. For negative results, they elucidated that 
SALS might contain a group of diseases with similar clinical manifestations like 
FALS, each of which is determined by different mutation sites, and that different 
diseases and mutation sites may interfere with GWAS’s shooting out of susceptible 
genes. Among the 34 SNPs, there was an overexpression of genes associated with 
cytoskeletal actin regulation. For example, the KIAAl721 gene of rs11099864 and 
the FMN2 gene of rs1037666 had a homologous region that played an important 
role in the regulation of cytoskeletal actin. The most closely related rs4363506 of 
34 SNPs was located in the DOCKl gene, which plays an important role in nerve 
growth. Although no disease-susceptible gene was found, the study identified 
possible SNPs and published all the results, which facilitated subsequent large-
scale SALS GWAS studies.
Recently, a series of ALS GWAS studies have been published and found several 
potential risk genes [29–32]. However, the results of these studies are different with 
the same ideas and methods. The biological process of some candidate genes is 
unclear, and the evidence needs to be supplemented.
4. Genetic testing
Gene testing helps ALS patients and families enhance their understanding 
on the condition and information requested in genotype-specific treatments. 
Although ALS patients desire access to genetic testing, genetic advances have been 
slow to reach the clinical care of the ALS patient. In recent years, the landscape of 
genetic testing and genetic counseling for ALS has been rapidly transformed with 
the identification of novel genes and the advent of next-generation sequencing 
technology.
4.1 Genetic testing options
As with all clinical testing, genetic risk assessment, including family history and 
pedigree analysis, and pretest counseling, helping patients anticipate the possible 
impact of genetic testing on themselves and their family members, are necessary for 
patients before genetic testing.
Currently available genetic testing options for ALS include Sanger sequenc-
ing for traditional simple mutations, assays for the C9orf 72 repeat expansion, 
next-generation sequencing panels, whole-exome sequencing, and whole-genome 
sequencing.
4.2 Post-test counseling
Regarding the positive result, specific mutation, genotype-phenotype cor-
relations, family history, and inheritance pattern should be thoroughly analyzed. 
Meanwhile, implications and risks for family members, including offspring and 
siblings, and theories about why the disease occurs also should be reviewed and 
addressed. For the reported definite pathogenic mutations, clinicians should 
provide information and hope about the potential genetic therapies in the future.
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4.3 Presymptomatic testing
To increase certainty, make health or lifestyle choices, and make decisions about 
family planning, the presymptomatic testing could be conducted. According to the 
guidelines for presymptomatic genetic testing in other neurodegenerative diseases 
such as Huntington disease and Alzheimer disease, ALS should be tailored as fol-
lowing: pretest genetic counseling, baseline neurologic and cognitive assessment, 
psychological evaluation, in-person disclosure, presence of support person, and 
posttest genetic counseling. Most of important, presymptomatic testing should be 
offered to adult first-degree relatives of ALS patients with established mutations 
after written informed consent obtained [4].
5. Gene therapy
With the exception of riluzole, an anti-glutamatergic agent which was shown to 
prolong survival for 2–3 months by blocking the presynaptic release of glutamate, 
and edaravone, an antioxidant which was shown to decrease the rate of patient 
immobility, no effective treatment is currently available for ALS that can stop or 
reverse the disease progression.
Gene therapy is a promising therapeutic approach for ALS since it can be used to 
deliver “gene drugs,” encoding for blocking the novel gene expression, antiapoptotic 
proteins, and for neurotrophic factors, to the motor neurons crossing the blood-
brain barrier specifically to prevent further motor neuron degeneration and to 
preserve the function of remaining motor neurons.
Here, we are to illustrate some examples of each therapeutic strategy for describ-
ing the present status and advance of gene therapy treatment.
5.1 SOD1
The neurotoxicity of mutant SOD1 is related to the dose of the toxic protein 
through multiple pathological mechanisms. A potential therapeutic approach to SOD1-
related ALS is to block the expression of the toxic SOD1 that could cause motor neuron 
degeneration [33]. This therapy option which is more worthy of attention is that it pos-
sibly avoids and decreases potential influence in downstream pathological cascades. 
Recently, the studies mostly focus on antisense oligonucleotides and RNA interference 
which are both to block gene expression through enhancing the degradation of RNA.
5.1.1 Antisense oligonucleotides in models and human
In animal models of SOD1-associated ALS, antisense oligonucleotide treatment 
significantly delayed disease onset, improved neuromuscular function, and pro-
longed survival.
The first clinical trial of antisense oligonucleotide treatment in human beings 
had favorable safety outcomes, and now the clinical trial to assess the safety, toler-
ability, and pharmacokinetics of a second generation SOD1 antisense oligonucle-
otide is in progress (Clinical Trials.Gov, NCT02623699) [34].
5.1.2 Short hairpin RNA (shRNA) treatment in mutant SOD1 ALS models
According to literature, in SOD1G93A mice, reduction of human SOD1 expres-
sion can significantly slow ALS progression and extend survival by using a single 
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peripheral injection of an adeno-associated virus serotype 9 (AAV9) encoding 
shRNA [35].
While, in a recent study reported, SOD1 expression in the motor cortex of P70 
SOD1G93A models was selectively silenced by delivery of AAV9-SOD1-shRNA. As 
a result, not only the ALS progression was slowed and the survival was extended 
significantly, but also the survival of spinal motor neurons was significantly 
enhanced [36].
5.1.3  miRNA treatment in mutant SOD1 ALS models and healthy nonhuman primates
In a study, scientists reported a new method that systemically delivered drug 
based on an artificial microRNA. In the SOD1G93A mice, this drug delayed ALS 
onset, prolonged the survival, and significantly preserved muscle strength and 
motor and respiratory functions. Notably, the research of this drug has been con-
ducted in nonhuman primates, and the result showed that SOD1 expression in lower 
motor neurons was safely blocked [37].
5.2 C9orf 72
Similar therapeutic approach targeting C9orf72 for ALS is also in development. 
The toxicity of mutated C9orf72 is imparted by the formation of nucleolar RNA 
foci that sequester important RNA-binding proteins and by the generation of toxic 
dipeptide repeat (DPR) proteins.
The C9orf72 hexanucleotide repeat expansion (HRE) of GGGGCC DNA and 
RNA enables the formation of complex structures including G-quadruplexes. 
Because the Guanosine-rich DNA and RNA sequences are prone to formation of 
G-quadruplexes, a stable four-stranded structure present within ribosomal DNA 
sequences, transcription start sites, the promoter and untranslated regions of 
mRNA, human telomeric DNA sequences. It may play an important role in vari-
ous cellular processes such as telomere maintenance, ribosome biogenesis, gene 
replication, transcription, and translation. Therefore, both C9orf72 HRE DNA and 
RNA may contribute to the pathogenesis of ALS/FTD disease through a mecha-
nism associated with their structure polymorphism. Presently, based on the above 
mechanism, two strategies including antisense-mediated interventions and small-
molecule-based approach have been developed to interfere with neurodegenerative 
diseases associated with G-quadruplexes [38].
5.2.1 Antisense oligonucleotides in mutant C9orf72 ALS models
A recent study reported that the RNA foci and DPR proteins were reduced 
significantly in mutant C9orf72 ALS mice by a single-dose injection of antisense 
oligonucleotides to reduce C9orf72 RNA repeats, and after 6 months of treatment, 
the motor function was also preserved [39].
5.2.2  Small-molecule ligands targeting the G-quadruplex structure in mutant 
C9orf72 cells
The small-molecule ligands, such as porphyrin, acridine, pentacridium, 
telomestatin, naphthalene diamide, and bisquinolium, directly target and bind 
to the G-quadruplex structure and selectively modulated the function of the 
G-quadruplex. For example, TMPyP4, a cationic porphyrin, can bind and disrupt 
the secondary structures of C9orf72 HRE and even damage its interactions with 
hnRNPA1 and ASF/SF2 proteins [40].
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Similarly, some studies also showed that three small-molecule ligands can bind 
G-quadruplex and decreased RNA foci and RNA translation in both cultured cells 
and patient-derived neurons [41].
5.3 Others
TBK1 is a key regulatory molecule upstream of OPTN, SQSTM1/p62, and 
IRF3 in the autophagy and neuroinflammatory pathways that are implicated in 
ALS. Manipulation of TBK1 might potentially compensate for defects caused by 
other ALS-associated proteins in these pathways—for example, VCP and UBQLN2. 
NEK1 and C21orf2 are known to interact at the protein level and, in addition to 
TUBA4A, PFN1, NEFH, and PRPH, they represent the building blocks of the cel-
lular scaffold. Administration of small molecules that enhance cytoskeletal integrity 
could represent a viable therapy for stopping progression or reversing the disease 
course in patients with these mutations [4–6].
6. Conclusion
Nearly a decade ago, the only way to test ALS-related gene was SOD1 sequenc-
ing, whereas clinicians now have a wide availability of testing options already. 
Whole-exome sequencing is current standard in most related searches. However, 
the factors such as high rate of incomplete penetrance in ALS, few large pedigrees, 
and short survival of patients lead to the discovery of ALS-related genes worse than 
expected and the identification of susceptible mutations limited.
Although many known ALS-related genes’ structural characteristics and roles 
have been discovered, which have highlighted critical processes, pathways, and 
intracellular localizations of dysregulation, there are still many reported variants 
with uncertain significance. Further functional studies are needed to clarify the 
pathogenesis of these genes. Till now, more people believe that ALS is the result of 
interaction between multiple genes that each increases the susceptibility of the dis-
ease, but does not initiate the pathogenesis alone. So, we need to do more research 
on oligogenic ALS cases. Most importantly, with the improvement of understanding 
of ALS genetics, we will have more opportunities to develop meaningful therapies.
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ease, but does not initiate the pathogenesis alone. So, we need to do more research 
on oligogenic ALS cases. Most importantly, with the improvement of understanding 
of ALS genetics, we will have more opportunities to develop meaningful therapies.
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Structural and Functional 
Consequences of the 
SMA-Linked Missense Mutations 
of the Survival Motor Neuron 
Protein: A Brief Update
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Abstract
Genetically linked to the survival motor neuron 1 gene SMN1, spinal muscular 
atrophy (SMA) is an autosomal recessive neuromuscular disease with dysfunctional  
α -motor neurons. As the product of the SMN1 gene, the survival motor neuron 
protein (SMN) plays an essential role in the molecular pathogenesis of SMA. On 1 
June 2017, a PLoS ONE article reported a set of computational structural analysis 
to illustrate how do SMA-linked mutations of SMN1 lead to structurally/function-
ally deficient variants of SMN. Following this article, this chapter provides a brief 
update of the structural and functional consequences of the missense mutations of 
this SMA protein.
Keywords: spinal muscular atrophy, survival motor neuron protein, missense 
mutation, structural consequence(s), functional consequence(s)
1. Setting the scene up
On 1 June 2017, PLoS ONE published an original research article (Figure 1) [1] 
with a title ‘How do SMA-linked mutations of SMN1 lead to structural/functional 
deficiency of the SMA protein?’, of which this chapter aims to provide a brief 
update.
1.1 The genetics of SMA: a brief introduction
SMA is an autosomal recessive neuromuscular disease with  α -motor neuron 
(anterior horn of the spinal cord) dysfunction and muscular atrophy [2]. SMA 
is caused by loss ( ∼ 95% of SMA cases) or mutation ( ∼ 5% of SMA cases) of the 
survival motor neuron gene 1 SMN1 (telomeric SMN, telSMN or SMN1, GenBank: 
U18423, the 5q13 region of human chromosome) [3]. In the 5q13 region of the 
human chromosome, there is also a nearly identical survival motor neuron 2 gene 
SMN2 (centromeric SMN, cenSMN or SMN2, GenBank: NM_022875) [3]. The two 
genes (SMN1 and SMN2) have been extensively characterised, and their roles in 
SMA have been reviewed in detail [2–8].
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Genetically linked to the survival motor neuron 1 gene SMN1, spinal muscular 
atrophy (SMA) is an autosomal recessive neuromuscular disease with dysfunctional  
α -motor neurons. As the product of the SMN1 gene, the survival motor neuron 
protein (SMN) plays an essential role in the molecular pathogenesis of SMA. On 1 
June 2017, a PLoS ONE article reported a set of computational structural analysis 
to illustrate how do SMA-linked mutations of SMN1 lead to structurally/function-
ally deficient variants of SMN. Following this article, this chapter provides a brief 
update of the structural and functional consequences of the missense mutations of 
this SMA protein.
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1. Setting the scene up
On 1 June 2017, PLoS ONE published an original research article (Figure 1) [1] 
with a title ‘How do SMA-linked mutations of SMN1 lead to structural/functional 
deficiency of the SMA protein?’, of which this chapter aims to provide a brief 
update.
1.1 The genetics of SMA: a brief introduction
SMA is an autosomal recessive neuromuscular disease with  α -motor neuron 
(anterior horn of the spinal cord) dysfunction and muscular atrophy [2]. SMA 
is caused by loss ( ∼ 95% of SMA cases) or mutation ( ∼ 5% of SMA cases) of the 
survival motor neuron gene 1 SMN1 (telomeric SMN, telSMN or SMN1, GenBank: 
U18423, the 5q13 region of human chromosome) [3]. In the 5q13 region of the 
human chromosome, there is also a nearly identical survival motor neuron 2 gene 
SMN2 (centromeric SMN, cenSMN or SMN2, GenBank: NM_022875) [3]. The two 
genes (SMN1 and SMN2) have been extensively characterised, and their roles in 
SMA have been reviewed in detail [2–8].
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1.2 The survival motor neuron protein and its role in SMA
The survival motor neuron (SMN) protein is the product of SMN1, the SMA-
determining survival motor neuron gene [2, 3]. As a result, SMN is also called the 
SMA protein. In fact, the 38-kD SMN is the actually affected protein in SMA [9–11], 
and is a cytoplasmic protein that also occurs in dot-like nuclear structures called 
gems, which is why SMN is formerly termed Gemin1 [3, 12], too.
In the molecular pathogenesis of SMA, of particular interest is an exon 7-skip-
ping splicing defect identified in the pre-mRNA editing of the SMN2 gene [5]. Due 
to this splicing defect, SMN2 predominantly produces exon 7-skipped transcripts, 
which encode a truncated isoform of the SMN protein (SMN Δ 7 or SMN2 with 282 
residues), in comparison with the full-length SMN protein with 294 residues (SMN1 
or FL-SMN).
In pre-mRNA editing, spliceosome is the major functional unit, and spliceoso-
mal small nuclear ribonucleoproteins (snRNPs) are essential components of the 
nuclear pre-mRNA processing machinery [13–17]. In the pathogenesis of SMA, the 
SMN protein plays a critical role in pre-mRNA processing, because the biogenesis of 
spliceosomal snRNPs is promoted by the SMN complex [14, 18, 19], which consists 
of SMN (Gemin1), Gemin2–8 and UNR-interacting protein (UNRIP) [13, 16, 20]. 
In the formation of the SMN complex, SMN forms oligomers and directly interacts 
via its N-terminus with Gemin2 and via its tudor domain with spliceosomal (Sm) 
proteins [13, 21, 22]. A key component of the SMN complex, SMN first assembles 
the essential SMN/Gemin complex, which in turn mediates the formation of the Sm 
core domain of the spliceosomal snRNPs [13, 21, 22].
2.  Structural and functional consequences of the SMA-linked missense 
mutations of SMN
In general, genetic mutation includes missense, nonsense, insertion and deletion 
mutations. A nonsense mutation is a point mutation in a DNA sequence that results 
in a premature stop codon, or a nonsense codon in the transcribed mRNA, and in a 
truncated, incomplete and usually functionally deficient protein product. In con-
trast, a missense mutation involves substitution of one single amino acid residue, 
and therefore is able to provide unique access to residue-specific structural insights 
Figure 1. 
A flow chart for the computational analysis of structural/functional consequences of clinically identified genetic 
diseases-linked missense mutation(s) of key gene(s) and protein(s). In [1], SMA was shown as an example of 
the computational analysis as illustrated here in this figure (http://biomedical-advances.org/ep-20182-14/).
89
Structural and Functional Consequences of the SMA-Linked Missense Mutations of the Survival…
DOI: http://dx.doi.org/10.5772/intechopen.81887
into the role of the residue in the structure and function of the target protein, 
provided that the three-dimensional structure of the target protein is experimen-
tally determined and deposited in the Protein Data Bank. Thus, this chapter focuses 
on SMA-linked missense mutations of SMN and aims to provide a brief update of 
their structural and functional consequences with a set of computational structural 
analysis as described in [1].
2.1 An update of SMA-linked missense mutations of SMN
A set of point mutations (missense and nonsense mutations) have been previ-
ously summarised in [1], including A2G [23], nonsense mutation Q15X [24], D30N 
[25], D44V [25–27], V94G [28], G95R [25], Y130C [29], nonsense mutation Q157X 
[30], A188S [31], nonsense mutation W190X [32], nonsense mutation L228X [33], 
P245L [34], L260S [28], S262G and S262I [4, 25], M263T [32], S266P [29], Y272C  
[4, 35, 36], H273R [29], T274I [4, 35, 36], G275S [32], G279C and G279V [4, 35, 37, 
38]. As of 25 September 2018, eight more missense mutations of SMN were sum-
marised and reported, including A2V, Y109C, Y130C, Y130H, P221L, S230L, P244L 
and R288S [39].
2.2 An update of experimentally determined SMN-related structures
In [1], 11 SMN-related structures were retrieved from the PDB database [40] 
with 2 search parameters (text search for: survival motor neuron protein and 
molecule: survival motor neuron protein). In a new search of the PDB database 
(accessed 25 September 2018) [40] with the same parameters, 14 PDB entries were 
retrieved, including 1G5V, 1MHN, 2LEH, 4A4E, 4A4G, 4GLI, 4QQ6, 4V98, 
5XJL, 5XJQ, 5XJR, 5XJS, 5XJT and 5XJU. In a comparison with the PDB entries in 
[1], during the past 16 months, six new SMN-related structures were deposited in 
the Protein Data Bank, including 5XJL (to supersede 3S6N [41]), 5XJQ [42], 5XJR 
[42], 5XJS [42], 5XJT [42] and 5XJU [42]. While the six PDB entries do contain a 
set of different yet functionally related protein molecules, including snRNP Sm-D1, 
snRNP Sm-D2, snRNP E, snRNP F and snRNP G, they also contain a fragment of 
the survival motor neuron protein (SMN residues 26–62), according to the fasta 
format data of the six PDB entries [42].
2.3 An update of the structural and functional consequences of the missense 
mutations of SMN
2.3.1 Asp44 in the Gemin2-binding domain of SMN
In light of the six new experimentally determined SMN-related structures 
(Table 1), a new set of computational structural analysis, as previously described 
in detail in [1], is within the reach of this chapter to provide an update of it. Two 
aspartates (Asp 35 and Asp44) of SMN stood out in the structural analysis of both 
intramolecular and intermolecular salt bridges for this SMA protein, as listed in 
Table 2.
Asp44 is in the exon 2a of SMN1 (the Gemin2-binding domain), and involved 
in an SMA-linked Asp44Val (D44V) missense mutation [25], which involves a 
substitution of Asp44’s charged side chain by Val44’s hydrophobic side chain. Of 
extraordinary functional significance is that SMN’s Gemin2-binding activity is 
totally suppressed by the D44V mutation in SMN1 [41]. Moreover, the D44V SMN 
(SMND44V) mutant’s snRNP assembly activity is lower than that of the wild-type 
SMN (FL-SMN or SMN1) [27].
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1.2 The survival motor neuron protein and its role in SMA
The survival motor neuron (SMN) protein is the product of SMN1, the SMA-
determining survival motor neuron gene [2, 3]. As a result, SMN is also called the 
SMA protein. In fact, the 38-kD SMN is the actually affected protein in SMA [9–11], 
and is a cytoplasmic protein that also occurs in dot-like nuclear structures called 
gems, which is why SMN is formerly termed Gemin1 [3, 12], too.
In the molecular pathogenesis of SMA, of particular interest is an exon 7-skip-
ping splicing defect identified in the pre-mRNA editing of the SMN2 gene [5]. Due 
to this splicing defect, SMN2 predominantly produces exon 7-skipped transcripts, 
which encode a truncated isoform of the SMN protein (SMN Δ 7 or SMN2 with 282 
residues), in comparison with the full-length SMN protein with 294 residues (SMN1 
or FL-SMN).
In pre-mRNA editing, spliceosome is the major functional unit, and spliceoso-
mal small nuclear ribonucleoproteins (snRNPs) are essential components of the 
nuclear pre-mRNA processing machinery [13–17]. In the pathogenesis of SMA, the 
SMN protein plays a critical role in pre-mRNA processing, because the biogenesis of 
spliceosomal snRNPs is promoted by the SMN complex [14, 18, 19], which consists 
of SMN (Gemin1), Gemin2–8 and UNR-interacting protein (UNRIP) [13, 16, 20]. 
In the formation of the SMN complex, SMN forms oligomers and directly interacts 
via its N-terminus with Gemin2 and via its tudor domain with spliceosomal (Sm) 
proteins [13, 21, 22]. A key component of the SMN complex, SMN first assembles 
the essential SMN/Gemin complex, which in turn mediates the formation of the Sm 
core domain of the spliceosomal snRNPs [13, 21, 22].
2.  Structural and functional consequences of the SMA-linked missense 
mutations of SMN
In general, genetic mutation includes missense, nonsense, insertion and deletion 
mutations. A nonsense mutation is a point mutation in a DNA sequence that results 
in a premature stop codon, or a nonsense codon in the transcribed mRNA, and in a 
truncated, incomplete and usually functionally deficient protein product. In con-
trast, a missense mutation involves substitution of one single amino acid residue, 
and therefore is able to provide unique access to residue-specific structural insights 
Figure 1. 
A flow chart for the computational analysis of structural/functional consequences of clinically identified genetic 
diseases-linked missense mutation(s) of key gene(s) and protein(s). In [1], SMA was shown as an example of 
the computational analysis as illustrated here in this figure (http://biomedical-advances.org/ep-20182-14/).
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into the role of the residue in the structure and function of the target protein, 
provided that the three-dimensional structure of the target protein is experimen-
tally determined and deposited in the Protein Data Bank. Thus, this chapter focuses 
on SMA-linked missense mutations of SMN and aims to provide a brief update of 
their structural and functional consequences with a set of computational structural 
analysis as described in [1].
2.1 An update of SMA-linked missense mutations of SMN
A set of point mutations (missense and nonsense mutations) have been previ-
ously summarised in [1], including A2G [23], nonsense mutation Q15X [24], D30N 
[25], D44V [25–27], V94G [28], G95R [25], Y130C [29], nonsense mutation Q157X 
[30], A188S [31], nonsense mutation W190X [32], nonsense mutation L228X [33], 
P245L [34], L260S [28], S262G and S262I [4, 25], M263T [32], S266P [29], Y272C  
[4, 35, 36], H273R [29], T274I [4, 35, 36], G275S [32], G279C and G279V [4, 35, 37, 
38]. As of 25 September 2018, eight more missense mutations of SMN were sum-
marised and reported, including A2V, Y109C, Y130C, Y130H, P221L, S230L, P244L 
and R288S [39].
2.2 An update of experimentally determined SMN-related structures
In [1], 11 SMN-related structures were retrieved from the PDB database [40] 
with 2 search parameters (text search for: survival motor neuron protein and 
molecule: survival motor neuron protein). In a new search of the PDB database 
(accessed 25 September 2018) [40] with the same parameters, 14 PDB entries were 
retrieved, including 1G5V, 1MHN, 2LEH, 4A4E, 4A4G, 4GLI, 4QQ6, 4V98, 
5XJL, 5XJQ, 5XJR, 5XJS, 5XJT and 5XJU. In a comparison with the PDB entries in 
[1], during the past 16 months, six new SMN-related structures were deposited in 
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[42], 5XJS [42], 5XJT [42] and 5XJU [42]. While the six PDB entries do contain a 
set of different yet functionally related protein molecules, including snRNP Sm-D1, 
snRNP Sm-D2, snRNP E, snRNP F and snRNP G, they also contain a fragment of 
the survival motor neuron protein (SMN residues 26–62), according to the fasta 
format data of the six PDB entries [42].
2.3 An update of the structural and functional consequences of the missense 
mutations of SMN
2.3.1 Asp44 in the Gemin2-binding domain of SMN
In light of the six new experimentally determined SMN-related structures 
(Table 1), a new set of computational structural analysis, as previously described 
in detail in [1], is within the reach of this chapter to provide an update of it. Two 
aspartates (Asp 35 and Asp44) of SMN stood out in the structural analysis of both 
intramolecular and intermolecular salt bridges for this SMA protein, as listed in 
Table 2.
Asp44 is in the exon 2a of SMN1 (the Gemin2-binding domain), and involved 
in an SMA-linked Asp44Val (D44V) missense mutation [25], which involves a 
substitution of Asp44’s charged side chain by Val44’s hydrophobic side chain. Of 
extraordinary functional significance is that SMN’s Gemin2-binding activity is 
totally suppressed by the D44V mutation in SMN1 [41]. Moreover, the D44V SMN 
(SMND44V) mutant’s snRNP assembly activity is lower than that of the wild-type 
SMN (FL-SMN or SMN1) [27].
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In a solid alignment with the computational analysis in [1], a set of salt bridges 
were structurally identified between SMN’s Asp44 (M_Asp_44) and Gemin2’s 
Arg213 (2_Arg_213), as shown in Table 2. In particular, four intermolecular salt 
bridges were identified between the buried side chains (Table 3) of these two 
charged residues, i.e. according to the coordinates data in the PDB entry 5XJL [42], 
as shown in Figure 2.
Taken together, it is conceivable that the buried side chains of SMN’s Asp44 and 
Gemin2’s Arg213 form a salt bridge, which constitutes a favourable electrostatic 
energy contribution to the SMN-Gemin2 complex structural stability [41], and 
highlights the functionally indispensable roles of the two residues’ charged side 
chains, considering the experimental observation that the SMN-Gemin2 binding is 
abrogated by the D44V mutation [41], resulting in a functionally deficient SMA-
linked D44V SMN mutant.
In addition to the intermolecular salt bridges formed between SMN’s Asp44 and 
Gemin2’s Arg213, a set of intramolecular salt bridges were also identified between 
side chains of SMN’s Asp35 and Lys41 (Table 2), which was reported in [1], too, 
where 15 salt bridges were identified between the side chains of SMN’s Asp35 and 
Lys41 in the salt bridge analysis of the NMR-determined SMN-Gemin2 complex 
ensemble (PDB ID: 2LEH) [22, 41]. In SMN, Lys41 is a positively charged residue 
and also a neighbouring residue of Asp44. Functionally different to the SMA-linked 
D44V mutation, a Lys41Ala (K41A) mutation (not SMA-linked) does not affect 
SMN-Gemin2 binding [41]. Thus, in another solid agreement with the structural 
analysis in [1], the structural analysis highlights that the salt bridges between SMN’s 
Asp35 and Lys41 are intramolecular, i.e. within the apo SMN protein, instead of 
intermolecular, i.e. at the SMN-Gemin2 complex structure interface, which help to 
explain why the Lys41Ala (K41A) mutation is not SMA-linked [41].
Overall, there is a solid agreement between the old [1] and the new (this chap-
ter) sets of computational structural analysis for both NMR and X-ray SMN-related 
structures, reflecting the technical maturity of the two main biophysical tools 
for biomolecular structure determination, particularly in light of the booming 
number of cryo-electron microscopy (cryo-EM) images uploaded to the Electron 
PDB ID Structure title Method Release 
date
5XJL Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1/D2/F/E/G from human
X-ray 2 May 
2018
5XJQ Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1(1–82)/D2/F/E/G from human
X-ray 4 July 
2018
5XJR Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2dN39 in complex with SmD1(1-82)/D2/F/E/G from human
X-ray 4 July 
2018
5XJS Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2dN39 in complex with SmD1(1-82)/D2/F/E from human
X-ray 4 July 
2018
5XJT Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1(1-82)/D2.R61A/F/E/G from 
human
X-ray 4 July 
2018
5XJU Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2dN39 in complex with SmD1(1-82)/D2.R61A/F/E/G from 
human
X-ray 4 July 
2018
In this table, X-ray represents X-ray crystallography as a biophysical tool for biomolecular structure determination.
Table 1. 
A list of new (compared with those summarised in [1]) experimentally determined SMN-related structures as 
of 25 September 2018 [40].
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Microscopy Data Bank (EMDB), where a long way is there to go still for cryo-EM to 
match NMR spectroscopy and X-ray crystallography in terms of technical maturity 
and the urgent need of tools for structural model quality validation [45].
2.3.2 Gly95 in the SMN tudor domain
Although not located in the structurally determined region of the six new struc-
tures (Table 1), Gly95 is a residue in the SMN tudor domain, and it is involved in a 
Gly95Arg (G95R) mutation [25]. This G95R mutation significantly reduces SMN’s 
ability to bind Sm proteins, such as Sm-B and Sm-D1 [25], confirming that tudor 
domain is the essential binding site of SMN to Sm proteins.
In a further inspection of the computational analysis as reported in [1], no salt 
bridge or hydrogen bond was identified for Gly95. Nonetheless, in the SMN tudor 
domain NMR ensemble [46], between the side chains of Asp96 and Lys93, 1 salt 
bridge was found for PDB ID 1G5V [46] with 10 structure models, 18 salt bridges 
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
5XJL 4 M_ASP_44 OD1 2_ARG_213 NH1 2.946 (Yellow)
5XJL 4 M_ASP_44 OD1 2_ARG_213 NH2 3.579 (Red)
5XJL 4 M_ASP_44 OD2 2_ARG_213 NH1 3.236 (Brown)
5XJL 4 M_ASP_44 OD2 2_ARG_213 NH2 3.848 (Blue)
5XJQ 3 M_ASP_44 OD1 2_ARG_213 NH1 2.760
5XJQ 3 M_ASP_44 OD1 2_ARG_213 NH2 3.593
5XJQ 3 M_ASP_44 OD2 2_ARG_213 NH1 2.968
5XJR 2 M_ASP_44 OD1 2_ARG_213 NH1 2.385
5XJR 2 M_ASP_44 OD2 2_ARG_213 NH1 2.871
5XJS 3 M_ASP_44 OD1 2_ARG_213 NH1 3.078
5XJS 3 M_ASP_44 OD1 2_ARG_213 NH2 3.670
5XJS 3 M_ASP_44 OD2 2_ARG_213 NH1 2.631
5XJT 3 M_ASP_44 OD1 2_ARG_213 NH1 2.335
5XJT 3 M_ASP_44 OD1 2_ARG_213 NH2 3.386
5XJT 3 M_ASP_44 OD2 2_ARG_213 NH1 3.067
5XJU 2 M_ASP_44 OD1 2_ARG_213 NH1 2.302
5XJU 2 M_ASP_44 OD2 2_ARG_213 NH1 2.989
5XJQ 1 M_ASP_35 OD1 M_LYS_41 NZ 3.921
5XJS 2 M_ASP_35 OD1 M_LYS_41 NZ 3.670
5XJS 2 M_ASP_35 OD2 M_LYS_41 NZ 3.803
5XJT 2 M_ASP_35 OD1 M_LYS_41 NZ 2.416
XJT 2 M_ASP_35 OD2 M_LYS_41 NZ 2.931
5XJU 1 M_ASP_35 OD1 M_LYS_41 NZ 3.274
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified from the PDB entries listed in this table. In the top four rows for PDB entry 
5XJL, Yellow, Red, Brown and Blue represent the colouring scheme for Figure 2. Distance represents the distance 
between two oppositely charged groups/atoms in Å.
Table 2. 
A summary of salt bridge analysis of the six new SMN-related structures as of 25 September 2018 [40].
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In a solid alignment with the computational analysis in [1], a set of salt bridges 
were structurally identified between SMN’s Asp44 (M_Asp_44) and Gemin2’s 
Arg213 (2_Arg_213), as shown in Table 2. In particular, four intermolecular salt 
bridges were identified between the buried side chains (Table 3) of these two 
charged residues, i.e. according to the coordinates data in the PDB entry 5XJL [42], 
as shown in Figure 2.
Taken together, it is conceivable that the buried side chains of SMN’s Asp44 and 
Gemin2’s Arg213 form a salt bridge, which constitutes a favourable electrostatic 
energy contribution to the SMN-Gemin2 complex structural stability [41], and 
highlights the functionally indispensable roles of the two residues’ charged side 
chains, considering the experimental observation that the SMN-Gemin2 binding is 
abrogated by the D44V mutation [41], resulting in a functionally deficient SMA-
linked D44V SMN mutant.
In addition to the intermolecular salt bridges formed between SMN’s Asp44 and 
Gemin2’s Arg213, a set of intramolecular salt bridges were also identified between 
side chains of SMN’s Asp35 and Lys41 (Table 2), which was reported in [1], too, 
where 15 salt bridges were identified between the side chains of SMN’s Asp35 and 
Lys41 in the salt bridge analysis of the NMR-determined SMN-Gemin2 complex 
ensemble (PDB ID: 2LEH) [22, 41]. In SMN, Lys41 is a positively charged residue 
and also a neighbouring residue of Asp44. Functionally different to the SMA-linked 
D44V mutation, a Lys41Ala (K41A) mutation (not SMA-linked) does not affect 
SMN-Gemin2 binding [41]. Thus, in another solid agreement with the structural 
analysis in [1], the structural analysis highlights that the salt bridges between SMN’s 
Asp35 and Lys41 are intramolecular, i.e. within the apo SMN protein, instead of 
intermolecular, i.e. at the SMN-Gemin2 complex structure interface, which help to 
explain why the Lys41Ala (K41A) mutation is not SMA-linked [41].
Overall, there is a solid agreement between the old [1] and the new (this chap-
ter) sets of computational structural analysis for both NMR and X-ray SMN-related 
structures, reflecting the technical maturity of the two main biophysical tools 
for biomolecular structure determination, particularly in light of the booming 
number of cryo-electron microscopy (cryo-EM) images uploaded to the Electron 
PDB ID Structure title Method Release 
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5XJL Crystal structure of the Gemin2-binding domain of SMN, 
Gemin2 in complex with SmD1/D2/F/E/G from human
X-ray 2 May 
2018
5XJQ Crystal structure of the Gemin2-binding domain of SMN, 
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In this table, X-ray represents X-ray crystallography as a biophysical tool for biomolecular structure determination.
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of 25 September 2018 [40].
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Microscopy Data Bank (EMDB), where a long way is there to go still for cryo-EM to 
match NMR spectroscopy and X-ray crystallography in terms of technical maturity 
and the urgent need of tools for structural model quality validation [45].
2.3.2 Gly95 in the SMN tudor domain
Although not located in the structurally determined region of the six new struc-
tures (Table 1), Gly95 is a residue in the SMN tudor domain, and it is involved in a 
Gly95Arg (G95R) mutation [25]. This G95R mutation significantly reduces SMN’s 
ability to bind Sm proteins, such as Sm-B and Sm-D1 [25], confirming that tudor 
domain is the essential binding site of SMN to Sm proteins.
In a further inspection of the computational analysis as reported in [1], no salt 
bridge or hydrogen bond was identified for Gly95. Nonetheless, in the SMN tudor 
domain NMR ensemble [46], between the side chains of Asp96 and Lys93, 1 salt 
bridge was found for PDB ID 1G5V [46] with 10 structure models, 18 salt bridges 
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5XJT 3 M_ASP_44 OD2 2_ARG_213 NH1 3.067
5XJU 2 M_ASP_44 OD1 2_ARG_213 NH1 2.302
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In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified from the PDB entries listed in this table. In the top four rows for PDB entry 
5XJL, Yellow, Red, Brown and Blue represent the colouring scheme for Figure 2. Distance represents the distance 
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A summary of salt bridge analysis of the six new SMN-related structures as of 25 September 2018 [40].
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Figure 3. 
Two salt bridges formed between the side chains of SMN’s Asp96 and Lys93 (shown as sticks here) according to 
a salt bridge analysis of the third structural model of the NMR ensemble (PDB ID 4A4E) [47]. In this figure, 
Asp96’s side chain oxygens are coloured red, and Lys93’s side chain nitrogen is coloured blue, while all hydrogen 
atoms are coloured in white.
were found for PDB ID 4A4E [47] with 20 structure models (Figure 3) and 16 salt 
bridges were found for PDB ID 4A4G [47] with 20 structure models. Similarly, 15 
salt bridges were also identified between the side chains of Glu147 and Lys97 of 
SMN (PDB ID: 4A4G [47], with 20 structure models), with the distance between 2 
oppositely charged groups being 2.93  ± 0.39 Å.
Quite interestingly, Gly95 sits right between the two oppositely charged neigh-
bouring residues (Asp96 and Lys93), which are the only two charged residues in the 
Figure 2. 
Four salt bridges formed between the buried side chains of SMN’s Asp44 (M_Asp_44 in red text) and Gemin2’s 
Arg213 (2_Arg_213 in white text). In this figure, the residue naming scheme is Chain ID_residue name_residue 
number. In this figure, Asp44’s side chain oxygens are coloured red, and Arg213’s nitrogen atoms are coloured blue, 
while all hydrogen atoms are coloured in white, the four dotted lines in four colours represent the four side chain salt 
bridges formed between the two oppositely charged residues, where the colouring scheme is described in Table 2.
Residue SASA (Å2) SASA-intrinsic (Å2) SASA-Ratio
2_Arg_213 57 238.76 0.238
M_Asp_44 67 140.39 0.477
In this table, SASA, SASA-intrinsic and SASA-ratio represent for SMN’s Asp44 and Gemin2’s Arg213 the average 
SASA value calculated by DSSP [43], the intrinsic SASA value [44] and the ratio of SASA divided by SASA-intrinsic, 
respectively. In this table, the residue naming scheme is Chain ID_residue name_residue number.
Table 3. 
Solvent accessible surface area (SASA) values of SMN’s Asp44 and Gemin2’s Arg213 (PDB ID: 5XJL) [42].
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tudor domain that are in the spatial proximity of Gly95. Thus, it is conceivable that 
a G95R mutation disrupts the Asp96-Lys93 salt bridge and/or builds another one 
(possibly even stronger) between the side chains of Lys95 and Asp96, which either 
perturbs the structure-stabilising activity of the Asp96-Lys93 salt bridge, and/or 
makes it energetically more unfavourable for Asp96’s side chain to orient towards 
positively charged side chains in Sm proteins and thereby affect the binding of 
SMN to Sm proteins. While the potential local electrostatic interaction disruption 
mechanism here for this SMA-linked G95R mutation is similar to that of the E134K 
and the Q136E mutations of SMN [1], the former mechanism is dependent on 
the occurrence of energetically unfavourable electrostatic interaction(s), but the 
latter mechanism is dependent on the loss of energetically favourable electrostatic 
interaction(s) for local structural stability of the SMN tudor domain, the essential 
part of SMN for the Sm protein-binding, which can help explain the reduced Sm 
core assembly activity of the two SMA-linked SMNE134K and SMNQ136E mutants.
2.3.3 Y109C, Y130C and Y130H in the SMN tudor domain
Among the eight SMN residues with SMA-linked missense mutations [39], 
only Y109 and Y130 are located in the structurally determined region of SMN [1], 
according to the updated list of SMN-related structures as of 25 September 2018. 
Although Y109C, Y130C and Y130H are not located in the structurally determined 
region of the six new structures, the three missense mutations are located in the 
structurally determined region of the experimentally determined structures [1].
Tyr130 is a tudor domain hydrophobic residue with a Tyr130Cys (Y130C) 
mutation [29]. In the computational analysis in [1], no salt bridge or hydrogen bond 
was identified for Tyr130. Nonetheless, Tyr130 is  ∼ 50% buried, with an  SASA value 
of 111.1  ± 4.18 Å2 compared with its standard  SASA value at 212.7 Å2, while Tyr109 
is deeply buried, with an  SASA value of 61.1  ± 8.43 Å2 compared with its standard  
SASA value at 212.7 Å2. Taken together, the SASA analysis of the three SMA-linked 
mutations highlights the potential significance of the deeply buried hydrophobic 
side chains of Tyr109 and Tyr130 in the SMN tudor domain.




 ∠ADH (∗) 
0.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.73 1.80 13.75
3.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.69 1.77 15.61
4.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.67 1.72 10.96
5.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.77 1.86 17.26
6.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.78 15.09
8.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.78 1.87 16.14
12.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.83 1.95 20.70
14.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.78 13.76
18.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.76 10.91
19.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.63 1.70 13.36
In this table, the names of the PDB files correspond to the single NMR structural model split from the NMR ensemble 
(PDB entry 4A4E) by a tcl script [1], the residue naming scheme is Chain ID_residue name_residue number,  
∠ADH represents the angle formed by acceptor (A), donor (D) and hydrogen (H)  (∠ADH) .
Table 4. 
The hydrogen bonds formed between the residue side chains between SMN’s Tyr109 and Asp105 (PDB entry 
4A4E).
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Figure 3. 
Two salt bridges formed between the side chains of SMN’s Asp96 and Lys93 (shown as sticks here) according to 
a salt bridge analysis of the third structural model of the NMR ensemble (PDB ID 4A4E) [47]. In this figure, 
Asp96’s side chain oxygens are coloured red, and Lys93’s side chain nitrogen is coloured blue, while all hydrogen 
atoms are coloured in white.
were found for PDB ID 4A4E [47] with 20 structure models (Figure 3) and 16 salt 
bridges were found for PDB ID 4A4G [47] with 20 structure models. Similarly, 15 
salt bridges were also identified between the side chains of Glu147 and Lys97 of 
SMN (PDB ID: 4A4G [47], with 20 structure models), with the distance between 2 
oppositely charged groups being 2.93  ± 0.39 Å.
Quite interestingly, Gly95 sits right between the two oppositely charged neigh-
bouring residues (Asp96 and Lys93), which are the only two charged residues in the 
Figure 2. 
Four salt bridges formed between the buried side chains of SMN’s Asp44 (M_Asp_44 in red text) and Gemin2’s 
Arg213 (2_Arg_213 in white text). In this figure, the residue naming scheme is Chain ID_residue name_residue 
number. In this figure, Asp44’s side chain oxygens are coloured red, and Arg213’s nitrogen atoms are coloured blue, 
while all hydrogen atoms are coloured in white, the four dotted lines in four colours represent the four side chain salt 
bridges formed between the two oppositely charged residues, where the colouring scheme is described in Table 2.
Residue SASA (Å2) SASA-intrinsic (Å2) SASA-Ratio
2_Arg_213 57 238.76 0.238
M_Asp_44 67 140.39 0.477
In this table, SASA, SASA-intrinsic and SASA-ratio represent for SMN’s Asp44 and Gemin2’s Arg213 the average 
SASA value calculated by DSSP [43], the intrinsic SASA value [44] and the ratio of SASA divided by SASA-intrinsic, 
respectively. In this table, the residue naming scheme is Chain ID_residue name_residue number.
Table 3. 
Solvent accessible surface area (SASA) values of SMN’s Asp44 and Gemin2’s Arg213 (PDB ID: 5XJL) [42].
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tudor domain that are in the spatial proximity of Gly95. Thus, it is conceivable that 
a G95R mutation disrupts the Asp96-Lys93 salt bridge and/or builds another one 
(possibly even stronger) between the side chains of Lys95 and Asp96, which either 
perturbs the structure-stabilising activity of the Asp96-Lys93 salt bridge, and/or 
makes it energetically more unfavourable for Asp96’s side chain to orient towards 
positively charged side chains in Sm proteins and thereby affect the binding of 
SMN to Sm proteins. While the potential local electrostatic interaction disruption 
mechanism here for this SMA-linked G95R mutation is similar to that of the E134K 
and the Q136E mutations of SMN [1], the former mechanism is dependent on 
the occurrence of energetically unfavourable electrostatic interaction(s), but the 
latter mechanism is dependent on the loss of energetically favourable electrostatic 
interaction(s) for local structural stability of the SMN tudor domain, the essential 
part of SMN for the Sm protein-binding, which can help explain the reduced Sm 
core assembly activity of the two SMA-linked SMNE134K and SMNQ136E mutants.
2.3.3 Y109C, Y130C and Y130H in the SMN tudor domain
Among the eight SMN residues with SMA-linked missense mutations [39], 
only Y109 and Y130 are located in the structurally determined region of SMN [1], 
according to the updated list of SMN-related structures as of 25 September 2018. 
Although Y109C, Y130C and Y130H are not located in the structurally determined 
region of the six new structures, the three missense mutations are located in the 
structurally determined region of the experimentally determined structures [1].
Tyr130 is a tudor domain hydrophobic residue with a Tyr130Cys (Y130C) 
mutation [29]. In the computational analysis in [1], no salt bridge or hydrogen bond 
was identified for Tyr130. Nonetheless, Tyr130 is  ∼ 50% buried, with an  SASA value 
of 111.1  ± 4.18 Å2 compared with its standard  SASA value at 212.7 Å2, while Tyr109 
is deeply buried, with an  SASA value of 61.1  ± 8.43 Å2 compared with its standard  
SASA value at 212.7 Å2. Taken together, the SASA analysis of the three SMA-linked 
mutations highlights the potential significance of the deeply buried hydrophobic 
side chains of Tyr109 and Tyr130 in the SMN tudor domain.




 ∠ADH (∗) 
0.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.73 1.80 13.75
3.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.69 1.77 15.61
4.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.67 1.72 10.96
5.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.77 1.86 17.26
6.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.78 15.09
8.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.78 1.87 16.14
12.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.83 1.95 20.70
14.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.78 13.76
18.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.71 1.76 10.91
19.pdb OD2, A_ASP_105 OH, A_TYR_109 HH, A_TYR_109 2.63 1.70 13.36
In this table, the names of the PDB files correspond to the single NMR structural model split from the NMR ensemble 
(PDB entry 4A4E) by a tcl script [1], the residue naming scheme is Chain ID_residue name_residue number,  
∠ADH represents the angle formed by acceptor (A), donor (D) and hydrogen (H)  (∠ADH) .
Table 4. 
The hydrogen bonds formed between the residue side chains between SMN’s Tyr109 and Asp105 (PDB entry 
4A4E).
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What is more, in the computational analysis in [1], 10 side chain hydrogen bonds 
(Table 4) were identified between SMN’s Tyr109 and Asp105 in the PDB entry 
4A4E [47], with the donor-acceptor distances ( D − A in Table 4) at 2.72  ± 0.06 Å 
and  ∠ADH at 14.75  ± 2.93, no salt bridge was identified for Asp105, and no further 
hydrogen bonds were identified for Tyr109 and Asp105 for all experimentally 
determined SMN-related structures as of 25 September 2018.
Taken together, the computational findings here indicate that SMN’s Tyr109 and 
Asp105 contribute to the structural stability of SMN through hydrogen bonding 
between their side chains, as it is quite clear that if Tyr109 is replaced by Cys109, 
then the side chain hydrogen bond (Figure 4, Table 4) will disappear, and that the 
negatively charged side chain of Asp105 will gain more geometric freedom due to 
the disappearance of the hydrogen bond, which can cause a potential disruption of 
the (either intramolecular and/or intermolecular) electrostatic interaction network, 
not to mention the possibility of a disrupted disulphide bonding network within 
the SMN protein, the SMN complex or even the snRNP assembly, which is critical 
to ensure that pre-mRNA editing of the SMN1 gene does not go wrong and that 
its product is the FL-SMN protein, instead of its truncated functionally deficient 
counterpart.
2.3.4  A structural analysis of the hydrogen bonds formed within the six new 
SMN-related structures
In light of the six new experimentally determined SMN-related structures 
(Table 1), a new set of hydrogen bonding analysis is conducted according to the 
details in [1], the result of which is briefly summarised in Table 5.
Table 5 shows the four hydrogen bonds formed between snRNP Sm-D2’s Asp93 
and Gemin2’s Arg235 and Arg239. Functionally, Gemin2 is closely linked to SMN 
(formerly known as Gemin1), and NMR spectroscopy was used to experimentally 
determine a Gemin1-Gemin2 complex structure (PDB ID: 2LEH) [22, 41], making a 
closer visual inspection worthwhile of the SMN-related structures (PDB IDs: 5XJS, 
5XJT and 5XJU [42], Table 1).
From Figure 5 (PDB ID:5XJS), it is quite clear that the three charged residues 
(snRNP Sm-D2’s Asp93 and Gemin2’s Arg235 and Arg239) sit right at the struc-
tural interface between Sm-D2 (pink) and Gemin2 (green), with their oppositely 
Figure 4. 
The hydrogen bond (Table 4) formed between the side chains of SMN’s Tyr109 and Asp105 in the PDB entry 
4A4E [47]. In this figure, SMN’s Tyr109 and Asp105 are shown in sticks, all side chain oxygens are coloured 
red, and side chain nitrogen is coloured blue, while all hydrogen atoms are coloured in white, and all atoms are 
labelled with their names nearby. The blue dotted line between OD2 of Asp105 and HH of Tyr109 represents 
the hydrogen bond formed between SMN’s Tyr109 and Asp105.
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charged side chains closely facing each other, similar to the situation as reported 
by [1], where the deeply buried side chains of SMN’s Lys45 and Asp36 act as two 
electrostatic clips at the SMN-Gemin2 interface via interactions with both the side 
chains and the backbone of Gemin2’s Gln105, Gln109, His120, His123 and Trp124.
In the subsequent computational salt bridge analysis of the six new SMN-related 
structures, it turned out that the three charged residues did form salt bridges 
between their closely facing oppositely charged side chains, as listed in Table 6 
below and illustrated in Figure 6.
Collectively, snRNP Sm-D2’s Asp93 and Gemin2’s Arg235 and Arg239 are three 
structurally important residues which help stabilise the structural interface through 
intermolecular electrostatic interactions, including both salt bridges and also 
hydrogen bonds, similar to the way SMN’s Asp44, Gemin2’s Arg213 and the two 
SMN residues (Lys45 and Asp36) play stabilising roles in the SMN-Gemin2 complex 
structure formation [1].
Considering the intimate functional relationship between Gemin2 and SMN, a 
further set of structural analysis was conducted for the hydrogen bond and the salt 
bridge for Arg235 and Arg239 of PDB entry 2LEH [22, 41], and it turned out that 




 ∠ADH (∗) 
5XJR OE1, A_GLN_24 NH2, B_ARG_94 HH21, B_ARG_94 3.00 1.99 1.79
5XJR OD2, B_ASP_104 NH1, B_ARG_102 HH12, B_ARG_102 2.98 2.07 20.93
5XJS OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.94 1.96 11.86
5XJS OD1, B_ASP_93 NH2, 2_ARG_239 HH21, 2_ARG_239 2.98 1.98 5.80
5XJS OD2, B_ASP_60 ND2, B_ASN_64 HD22, B_ASN_64 2.99 2.13 25.53
5XJT OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.65 1.75 21.43
5XJU OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.98 2.08 23.00
5XJU OD2, B_ASP_60 ND2, B_ASN_64 HD21, B_ASN_64 2.80 1.99 29.63
In this table, the residue naming scheme is Chain ID_residue name_residue number,  ∠ADH represents the angle 
formed by acceptor (A), donor (D) and hydrogen (H)  (∠ADH) .
Table 5. 
The hydrogen bonds formed between the residue side chains within the six new experimentally determined 
SMN-related structures.
Figure 5. 
Crystal structure of the Gemin2-binding domain of SMN, Gemin2 in complex with SmD1/D2/F/E (PDB ID: 
5XJS [42]). In this figure, the whole structure is shown in cartoon and coloured by chain using PyMol [48], 
where green and pink represent Gemin2 and snRNP Sm-D2, respectively. In this figure, three amino acid 
residues are shown in sticks and labelled with red and blue texts nearby.
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What is more, in the computational analysis in [1], 10 side chain hydrogen bonds 
(Table 4) were identified between SMN’s Tyr109 and Asp105 in the PDB entry 
4A4E [47], with the donor-acceptor distances ( D − A in Table 4) at 2.72  ± 0.06 Å 
and  ∠ADH at 14.75  ± 2.93, no salt bridge was identified for Asp105, and no further 
hydrogen bonds were identified for Tyr109 and Asp105 for all experimentally 
determined SMN-related structures as of 25 September 2018.
Taken together, the computational findings here indicate that SMN’s Tyr109 and 
Asp105 contribute to the structural stability of SMN through hydrogen bonding 
between their side chains, as it is quite clear that if Tyr109 is replaced by Cys109, 
then the side chain hydrogen bond (Figure 4, Table 4) will disappear, and that the 
negatively charged side chain of Asp105 will gain more geometric freedom due to 
the disappearance of the hydrogen bond, which can cause a potential disruption of 
the (either intramolecular and/or intermolecular) electrostatic interaction network, 
not to mention the possibility of a disrupted disulphide bonding network within 
the SMN protein, the SMN complex or even the snRNP assembly, which is critical 
to ensure that pre-mRNA editing of the SMN1 gene does not go wrong and that 
its product is the FL-SMN protein, instead of its truncated functionally deficient 
counterpart.
2.3.4  A structural analysis of the hydrogen bonds formed within the six new 
SMN-related structures
In light of the six new experimentally determined SMN-related structures 
(Table 1), a new set of hydrogen bonding analysis is conducted according to the 
details in [1], the result of which is briefly summarised in Table 5.
Table 5 shows the four hydrogen bonds formed between snRNP Sm-D2’s Asp93 
and Gemin2’s Arg235 and Arg239. Functionally, Gemin2 is closely linked to SMN 
(formerly known as Gemin1), and NMR spectroscopy was used to experimentally 
determine a Gemin1-Gemin2 complex structure (PDB ID: 2LEH) [22, 41], making a 
closer visual inspection worthwhile of the SMN-related structures (PDB IDs: 5XJS, 
5XJT and 5XJU [42], Table 1).
From Figure 5 (PDB ID:5XJS), it is quite clear that the three charged residues 
(snRNP Sm-D2’s Asp93 and Gemin2’s Arg235 and Arg239) sit right at the struc-
tural interface between Sm-D2 (pink) and Gemin2 (green), with their oppositely 
Figure 4. 
The hydrogen bond (Table 4) formed between the side chains of SMN’s Tyr109 and Asp105 in the PDB entry 
4A4E [47]. In this figure, SMN’s Tyr109 and Asp105 are shown in sticks, all side chain oxygens are coloured 
red, and side chain nitrogen is coloured blue, while all hydrogen atoms are coloured in white, and all atoms are 
labelled with their names nearby. The blue dotted line between OD2 of Asp105 and HH of Tyr109 represents 
the hydrogen bond formed between SMN’s Tyr109 and Asp105.
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charged side chains closely facing each other, similar to the situation as reported 
by [1], where the deeply buried side chains of SMN’s Lys45 and Asp36 act as two 
electrostatic clips at the SMN-Gemin2 interface via interactions with both the side 
chains and the backbone of Gemin2’s Gln105, Gln109, His120, His123 and Trp124.
In the subsequent computational salt bridge analysis of the six new SMN-related 
structures, it turned out that the three charged residues did form salt bridges 
between their closely facing oppositely charged side chains, as listed in Table 6 
below and illustrated in Figure 6.
Collectively, snRNP Sm-D2’s Asp93 and Gemin2’s Arg235 and Arg239 are three 
structurally important residues which help stabilise the structural interface through 
intermolecular electrostatic interactions, including both salt bridges and also 
hydrogen bonds, similar to the way SMN’s Asp44, Gemin2’s Arg213 and the two 
SMN residues (Lys45 and Asp36) play stabilising roles in the SMN-Gemin2 complex 
structure formation [1].
Considering the intimate functional relationship between Gemin2 and SMN, a 
further set of structural analysis was conducted for the hydrogen bond and the salt 
bridge for Arg235 and Arg239 of PDB entry 2LEH [22, 41], and it turned out that 




 ∠ADH (∗) 
5XJR OE1, A_GLN_24 NH2, B_ARG_94 HH21, B_ARG_94 3.00 1.99 1.79
5XJR OD2, B_ASP_104 NH1, B_ARG_102 HH12, B_ARG_102 2.98 2.07 20.93
5XJS OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.94 1.96 11.86
5XJS OD1, B_ASP_93 NH2, 2_ARG_239 HH21, 2_ARG_239 2.98 1.98 5.80
5XJS OD2, B_ASP_60 ND2, B_ASN_64 HD22, B_ASN_64 2.99 2.13 25.53
5XJT OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.65 1.75 21.43
5XJU OD1, B_ASP_93 NE, 2_ARG_235 HE, 2_ARG_235 2.98 2.08 23.00
5XJU OD2, B_ASP_60 ND2, B_ASN_64 HD21, B_ASN_64 2.80 1.99 29.63
In this table, the residue naming scheme is Chain ID_residue name_residue number,  ∠ADH represents the angle 
formed by acceptor (A), donor (D) and hydrogen (H)  (∠ADH) .
Table 5. 
The hydrogen bonds formed between the residue side chains within the six new experimentally determined 
SMN-related structures.
Figure 5. 
Crystal structure of the Gemin2-binding domain of SMN, Gemin2 in complex with SmD1/D2/F/E (PDB ID: 
5XJS [42]). In this figure, the whole structure is shown in cartoon and coloured by chain using PyMol [48], 
where green and pink represent Gemin2 and snRNP Sm-D2, respectively. In this figure, three amino acid 
residues are shown in sticks and labelled with red and blue texts nearby.
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the two arginines did not form any intermolecular electrostatic interaction with 
SMN, neither salt bridge nor hydrogen bond. Instead, the 2 arginines of Gemin2 
only formed 2 hydrogen bonds with Gln272 and His231 of Gemin2, and 1 stable 
salt bridge with Asp274 of Gemin2, where 16 salt bridges were identified for the 32 
NMR structural models (Table 7), according to the structural analysis of PDB entry 
2LEH [22, 41].
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
5XJL 3 B_ASP_93 OD1 2_ARG_239 NH1 3.734
5XJL 3 B_ASP_93 OD1 2_ARG_239 NH2 3.052
5XJL 3 B_ASP_93 OD2 2_ARG_239 NH2 3.052
5XJQ 3 B_ASP_93 OD1 2_ARG_239 NH1 3.817
5XJQ 3 B_ASP_93 OD1 2_ARG_239 NH2 3.059
5XJQ 3 B_ASP_93 OD2 2_ARG_239 NH2 3.004
5XJR 3 B_ASP_93 OD1 2_ARG_239 NH1 3.811
5XJR 3 B_ASP_93 OD1 2_ARG_239 NH2 3.022
5XJR 3 B_ASP_93 OD2 2_ARG_239 NH2 2.938
5XJS 3 B_ASP_93 OD1 2_ARG_239 NH1 3.688
5XJS 3 B_ASP_93 OD1 2_ARG_239 NH2 2.983
5XJS 3 B_ASP_93 OD2 2_ARG_239 NH2 3.092
5XJT 2 B_ASP_93 OD1 2_ARG_239 NH2 3.251
5XJT 2 B_ASP_93 OD2 2_ARG_239 NH2 3.163
5XJU 3 B_ASP_93 OD1 2_ARG_239 NH1 3.634
5XJU 3 B_ASP_93 OD1 2_ARG_239 NH2 3.084
5XJU 3 B_ASP_93 OD2 2_ARG_239 NH2 3.089
5XJL 2 B_ASP_93 OD1 2_ARG_235 NH2 3.657
5XJL 2 B_ASP_93 OD2 2_ARG_235 NH2 3.475
5XJQ 2 B_ASP_93 OD1 2_ARG_235 NH2 3.686
5XJQ 2 B_ASP_93 OD2 2_ARG_235 NH2 3.647
5XJR 2 B_ASP_93 OD1 2_ARG_235 NH2 3.847
5XJR 2 B_ASP_93 OD2 2_ARG_235 NH2 3.800
5XJS 2 B_ASP_93 OD1 2_ARG_235 NH2 3.548
5XJS 2 B_ASP_93 OD2 2_ARG_235 NH2 3.379
5XJT 2 B_ASP_93 OD1 2_ARG_235 NH2 3.258
5XJT 2 B_ASP_93 OD2 2_ARG_235 NH2 3.766
5XJU 1 B_ASP_93 OD1 2_ARG_235 NH2 3.996
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified from the PDB entries listed in this table. Distance represents the distance 
between two oppositely charged groups/atoms in Å.
Table 6. 
A summary of salt bridge analysis of the six new SMN-related structures as of 25 September 2018 [40].
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3. Concluding remarks
Given SMN’s critical role in the maturation of snRNP and in the development of 
SMA [2, 6, 11], it is necessary for the structure-activity relationship (SAR) charac-
terisation to continue for the SMA protein. With various biophysical tools available 
for structural determination, for SMN-related proteins and biological complexes, 
Figure 6. 
Crystal structure of the Gemin2-binding domain of SMN, Gemin2 in complex with SmD1/D2/F/E (PDB ID: 
5XJS) [42]. In this figure, the yellow dotted lines represent two examples of the hydrogen bonds formed between 
Asp93 and Arg235, while the blue dotted line represents an example of the salt bridge formed between Asp93 
and Arg239 (Table 6).
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
24.pdb 2 A_ASP_274 OD1 A_ARG_239 NH2 3.797
24.pdb 2 A_ASP_274 OD2 A_ARG_239 NH2 2.738
01.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.577
02.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.164
04.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.195
09.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 2.692
16.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 3.871
17.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 2.868
19.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 3.718
21.pdb 2 A_ASP_274 OD2 A_ARG_235 NH1 3.457
21.pdb 2 A_ASP_274 OD2 A_ARG_235 NH2 3.429
23.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.798
24.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 2.888
26.pdb 3 A_ASP_274 OD1 A_ARG_235 NH2 3.770
26.pdb 3 A_ASP_274 OD2 A_ARG_235 NH1 3.836
26.pdb 3 A_ASP_274 OD2 A_ARG_235 NH2 2.442
31.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.403
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified.
Table 7. 
A summary of salt bridge analysis of PDB entry 2LEH [22, 41].
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the two arginines did not form any intermolecular electrostatic interaction with 
SMN, neither salt bridge nor hydrogen bond. Instead, the 2 arginines of Gemin2 
only formed 2 hydrogen bonds with Gln272 and His231 of Gemin2, and 1 stable 
salt bridge with Asp274 of Gemin2, where 16 salt bridges were identified for the 32 
NMR structural models (Table 7), according to the structural analysis of PDB entry 
2LEH [22, 41].
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5XJT 2 B_ASP_93 OD2 2_ARG_239 NH2 3.163
5XJU 3 B_ASP_93 OD1 2_ARG_239 NH1 3.634
5XJU 3 B_ASP_93 OD1 2_ARG_239 NH2 3.084
5XJU 3 B_ASP_93 OD2 2_ARG_239 NH2 3.089
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5XJL 2 B_ASP_93 OD2 2_ARG_235 NH2 3.475
5XJQ 2 B_ASP_93 OD1 2_ARG_235 NH2 3.686
5XJQ 2 B_ASP_93 OD2 2_ARG_235 NH2 3.647
5XJR 2 B_ASP_93 OD1 2_ARG_235 NH2 3.847
5XJR 2 B_ASP_93 OD2 2_ARG_235 NH2 3.800
5XJS 2 B_ASP_93 OD1 2_ARG_235 NH2 3.548
5XJS 2 B_ASP_93 OD2 2_ARG_235 NH2 3.379
5XJT 2 B_ASP_93 OD1 2_ARG_235 NH2 3.258
5XJT 2 B_ASP_93 OD2 2_ARG_235 NH2 3.766
5XJU 1 B_ASP_93 OD1 2_ARG_235 NH2 3.996
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified from the PDB entries listed in this table. Distance represents the distance 
between two oppositely charged groups/atoms in Å.
Table 6. 
A summary of salt bridge analysis of the six new SMN-related structures as of 25 September 2018 [40].
97
Structural and Functional Consequences of the SMA-Linked Missense Mutations of the Survival…
DOI: http://dx.doi.org/10.5772/intechopen.81887
3. Concluding remarks
Given SMN’s critical role in the maturation of snRNP and in the development of 
SMA [2, 6, 11], it is necessary for the structure-activity relationship (SAR) charac-
terisation to continue for the SMA protein. With various biophysical tools available 
for structural determination, for SMN-related proteins and biological complexes, 
Figure 6. 
Crystal structure of the Gemin2-binding domain of SMN, Gemin2 in complex with SmD1/D2/F/E (PDB ID: 
5XJS) [42]. In this figure, the yellow dotted lines represent two examples of the hydrogen bonds formed between 
Asp93 and Arg235, while the blue dotted line represents an example of the salt bridge formed between Asp93 
and Arg239 (Table 6).
PDB ID SBnum Residue A Atom A Residue B Atom B Distance (Å)
24.pdb 2 A_ASP_274 OD1 A_ARG_239 NH2 3.797
24.pdb 2 A_ASP_274 OD2 A_ARG_239 NH2 2.738
01.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.577
02.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.164
04.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.195
09.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 2.692
16.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 3.871
17.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 2.868
19.pdb 1 A_ASP_274 OD2 A_ARG_235 NH1 3.718
21.pdb 2 A_ASP_274 OD2 A_ARG_235 NH1 3.457
21.pdb 2 A_ASP_274 OD2 A_ARG_235 NH2 3.429
23.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.798
24.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 2.888
26.pdb 3 A_ASP_274 OD1 A_ARG_235 NH2 3.770
26.pdb 3 A_ASP_274 OD2 A_ARG_235 NH1 3.836
26.pdb 3 A_ASP_274 OD2 A_ARG_235 NH2 2.442
31.pdb 1 A_ASP_274 OD2 A_ARG_235 NH2 3.403
In this table, the residue naming scheme is Chain ID_residue name_residue number, SBnum represents the number 
of salt bridges computationally identified.
Table 7. 
A summary of salt bridge analysis of PDB entry 2LEH [22, 41].
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such as the SMN complex and snRNPs, their structure determination and func-
tional characterisation will undoubtedly continue to advance, which will be helpful 
both in further understanding of SMN’s role in SMA from a molecular structural 
point of view. In practice, however, advancements do not come easy. For instance, 
although both full-length structures of FL-SMN (with 294 residues) and SMN Δ 7 
(with 282 residues) were already experimentally determined using X-ray crystal-
lography and deposited in the database (PDB IDs: 4NL6 and 4NL7), they were 
subsequently withdrawn by the author because the sample used for the structure 
determination was wrong. Otherwise, these two full-length SMN structures would 
constitute the very first step towards a comprehensive picture of the structural and 
functional insights into SMN’s role in the molecular pathogenesis SMA.
As of 25 September 2018, there is still no full-length SMN (or the SMN complex 
or the snRNP assembly) structure deposited in the wwPDB website [40], although 
it contains six new experimentally determined SMN-related structures, in addition 
to those reported in [1]. In terms of amino acid sequence, those SMN-related struc-
tures are still only SMN fragments, ranging from Gly26 to Lys51, and from Asn84 to 
Glu147. In between, there is still structurally not-determined-yet regions (referred 
to as structural gaps below) consisting of 204 SMN residues. Sixteen months have 
passed since the publication of [1], the structural gaps still remain, literally zero 
progress has been made to bridge them in spite of the six newly deposited struc-
tures, calling again [1] for further comprehensive structural determination and 
functional research for this SMA protein.
4.  A residue-specific distributional analysis of the structural gaps in the 
Protein Data Bank
As a 38-kD protein, SMN is essentially a small one in terms of molecular weight, in 
comparison with all proteins whose structures have been deposited in the Protein Data 
Bank (PDB), a primary database for experimentally determined structures of biologi-
cal molecules [40]. As discussed above, even for a protein as small as SMN, experimen-
tal structure determination does not seem simple or easy, especially when it has to be 
done in a full-length and gapless manner. Therefore, to test whether any residue-spe-
cific statistical pattern (not known yet before this chapter) exists in the structural gaps 
in the whole Protein Data Bank (accessed 25 September 2018), this chapter presents a 
set of residue-specific distributional analysis of all structural gaps throughout PDB.
While the number of experimentally determined protein structures keeps 
increasing in the PDB, with the number of cryo-EM structures [49] on the rise, 
X-ray crystallography and NMR spectroscopy remain to date the two main (Table 8) 
supplementary biophysical tools in structural biology, both with strengths and 
weaknesses [50, 51].
In PDB-format data, the atomic coordinates presented in ATOM records in a 
PDB file may not exactly match the sequence in the SEQRES records. However, 
these amino acids will often be included in the SEQRES records, since the portion 
of the chain was present during the experiment. In these cases, a ‘REMARK 465’ 
entry will be included in the header of the PDB file to identify each missing residue. 
For X-ray crystallography data, the ends of chains and mobile loops are often not 
observed in crystallographic experiments, and as a result, atomic coordinates are 
not included as ATOM records in the file, leading to the occurrence of gaps for 
structure determined by X-ray crystallography. Among currently available bio-
physical tools, NMR spectroscopy is able to provide unique access to atomic-level 
structural dynamic behaviour of protein molecules in solution under physiological 
conditions (such as temperature, pH, etc.). As a result, this chapter focuses on 
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the structural gaps within protein structures determined by NMR spectroscopy, 
and aims to test whether any residue-specific statistical pattern exists in them. 
Here, structural gaps are defined as protein fragments with residues which exist 
in the originally studied molecule as shown in the SEQRES records, but not in the 
observed structure/atomic coordinates.
As of 20 September 2018, 10,844 NMR-determined protein structures have 
been deposited in the Protein Data Bank, according to a structure search with two 
parameters (molecule type = protein, experimental method = NMR). After the 
10,844 PDB files were downloaded from the PDB website, the numbers of the total 
and the missing amino acid residues were extracted with an in-house python script 
for all proteins, as listed in Table 9.
Experimental method Proteins Nucleic acids Protein/NA complex Other Total
X-ray 121,081 1958 6257 10 129,306
NMR 10,848 1256 250 8 12,362
Electron microscopy 1750 31 623 0 2404
Other 244 4 6 13 267
Multi-method 117 5 2 1 125
Table 8. 
A summary of the number of experimentally determined biomolecular structures in PDB as of 25 September 2018.
Residue Missing no. Total no. Ratio = Missing no./Total no.
A 1782 75,627 0.023
C 152 25,777 0.00589673
E 1811 79,729 0.022
D 1390 59,908 0.023
G 3321 81,347 0.041
F 615 38,993 0.015
I 640 55,070 0.011
H 5146 26,182 0.196
K 1442 75,766 0.019
M 1203 23,652 0.050
L 1439 90,833 0.015
N 831 43,080 0.019
Q 1273 44,594 0.028
P 1518 46,205 0.032
S 3159 73,904 0.042
R 1234 52,761 0.023
T 1112 56,787 0.019
W 138 13,211 0.010
V 980 70,252 0.013
Y 626 32,905 0.019
Sum 29,812 1,066,583 0.027
Table 9. 
The numbers of the total and the missing amino acid residues in NMR-determined protein structures as of 25 
September 2018.
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Figure 7. 
A residue-specific distribution of the missing residues in NMR-determined protein structures as of 25 
September 2018. In this figure, x-axis represents the one-letter codes for amino acid residues, and y-axis 
represents the residue-specific ratio of missing versus total residues in those NMR structures. The red vertical 
line highlights histidine as a particular residue with an outstanding missing ratio.
In total, the 10,844 protein structures contains 1,066,583 amino acid residues,  
 ∼ 2.8% of which (29812) are missing, i.e. the atomic positions of the 29,841 residues 
were not experimentally determined by NMR spectroscopy, although they were 
present in the NMR sample during the structural determination process.
From Figure 7, it can be seen that for 19 residues (excluding histidine), the 
missing ratio is well below or pretty close to 5%, while the missing ratio is 19.6% for 
histidine, as shown by the blue sharp peak on Figure 7. In a statistical one sample 
t-test analysis of the 19 missing ratios, it turned out 100% acceptable ( P=1 ) that the 
average of ratio is 0.0231, and that the fitness between the 19 missing ratios and the 
red horizontal line (Figure 8) is 100% acceptable ( P=1 ), according to a statistical 
Chi-square test, as revealed by Figure 8.
While a missing ratio of 5% might be considered statistically insignificant, a 
missing ratio of 19.6% is clearly not to be ignored here, raising one obvious ques-
tion: what on earth is so special about histidine that makes it so special among the 
20 naturally occurring amino acids in this residue-specific distributional analysis of 
the structural gaps?
Similar to the other 19, histidine is a naturally occurring amino acid that is used 
in the biosynthesis of proteins. Also similar to the other 19, it contains an amino 
group (which is in the protonated ▬NH3+ form under biological conditions) and a 
carboxylic acid group (which is in the deprotonated ▬COO− form under biological 
conditions). In particular, histidine has an imidazole side chain (which is partially 
protonated), classifying it as a positively charged amino acid at physiological 
pH ( ∼ 7.4). That is, among the 20 naturally occurring amino acids, five (Arg, Lys, 
His, Glu and Asp) possess ionisable side chains. Among the five, histidine is the 
only one whose side chain has an ionisable (with an intrinsic pKa at 6.04) [52, 53] 
imidazole ring structure, which can exist in two inter-convertible tautomeric 
states. While at a pH of 7.0, the imidazole ring is mostly deprotonated (proton 
occupancy = 9.88%), at a pH of 6.0, the imidazole ring is largely protonated (proton 
101
Structural and Functional Consequences of the SMA-Linked Missense Mutations of the Survival…
DOI: http://dx.doi.org/10.5772/intechopen.81887
occupancy = 52.30%), as defined by the classical Henderson-Hasselbalch equation 
[50], where the positively charged imidazole ring bears two NH bonds and has a 
positive electric charge, which is equally distributed between both nitrogens. As 
the pH increases, the imidazole ring loses the positive charge, and the remaining 
proton of the neutral imidazole ring can reside on either nitrogen, giving rise to two 
tautomeric states of the histidine side chain [52, 54, 55].
To sum up, it is probable that the missing ratio of histidine is much higher than 
the other 19 because it has a special side chain with special dynamic structural and 
physicochemical properties (such as stacking interaction [56]), and with a special 
imidazole ring in constant protonation-deprotonation equilibrium [57] and two 
tautomeric states [52, 54, 55], making its NMR-observables (chemical shift for 
instance) difficult to be experimentally observed and measured by NMR spectros-
copy and structurally calculated by NMR-related software in the structural deter-
mination of proteins. To address this issue of PDB-wide structural gaps, selective 
isotope labelling of histidine residues (the side chains in particular) can be a useful 
approach in biomolecular structural determination by NMR spectroscopy, not just 
alone, but also in collaboration with other biophysical tools, not just for the special 
histidine, but also for its 19 siblings in the fundamental building block of life.
Figure 8. 
A residue-specific scatter plot of the missing residues in NMR-determined protein structures as of 25 September 
2018. In this figure, x-axis represents the one-letter codes for amino acid residues, and y-axis represents the 
residue-specific ratio of missing versus total residues in those NMR structures. The red horizontal line represents 
the average missing ratio level of the 19 residues.
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